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GENERAL INTRODUCTION 
 
There is a great need to treat cognitive impairments such as age related 
forgetfulness and dementia. Pharmacological treatments have been 
investigated for over 30 years now and results have been far from successful 
[e.g. (Courtney, et al., 2004)]. For example, worldwide there are five drugs 
registered for the treatment of Alzheimer’s disease with cognitive symptoms 
as core target. Neither of these drugs attenuates the progress of the disease, 
indicating that they are not fully successful.  The unsuccessful 
pharmacological treatment also partially indicates that we do not fully 
understand the pathology of the disorders. For example, Alzheimer’s disease 
is associated with decreased activity of the neurotransmitter acetylcholine. 
Theoretically, returning the activity of the neurotransmitter system to a 
normal level should decrease the symptoms characteristic cognitive 
disorders. However, Alzheimer’s disease is characterized by a decline across 
a whole spectrum of cognitive functions (Riedel, 1995) and besides brain 
atrophy functional decline of several neurotransmitter systems are involved 
in symptomatology of the disorder. In order to understand the pathology 
attempts have been made to model these impairments in healthy subjects. 
However, these attempts have been relatively unsuccessful, possibly because 
just one transmitter system is pharmacologically manipulated as opposed to 
multiple. For example, muscarinic receptors in the brain, through which 
acetylcholine functions, can be blocked using the drug scopolamine. As 
scopolamine induces impaired memory functioning, it does not cause the 
large variety of impairments typical for Alzheimer’s disease and is therefore 
not a sufficient model for the disorder. In addition, stimulating the 
muscarinic receptors has little effect on the whole range of cognitive 
complaints seen in Alzheimer’s patients (Kelly, 1999). Therefore, the view 
that only the cholinergic system is affected appears to be to reductionistic 
(Bacciottini, Passani, Mannaioni, & Blandina, 2001). Hence, cognition 
enhancing drugs used in clinical disorders and Alzheimer’s disease in 
particular should be based on more neurotransmitter systems. 
 
Histamine and clinical disorders 
In respect of developing new treatments that can be given additional to or 
that can replace the current treatment the histamine neurotransmitter system 
may be a promising target. This transmitter system has been associated with 
some clinical disorders like Alzheimer’s disease [e.g. (Higuchi, 2000)], 
schizophrenia [e.g. (Nakai, et al., 1991)], Attention Deficit Hyperactivity 
Disorder (Komater, et al., 2005; Peled, Carraso, Globman, & Yehuda, 1997), 
depression (Akhtar, Pillai, & Vohora, 2005; Kano, et al., 2004), Parkinson’s 
disease [e.g.(Anichtchik, Rinne, Kalimo, & Panula, 2000; Rinne, et al., 2002)] 
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and Wernicke-Korsakoff’s syndrome [for review see: (Onodera, Yamatodani, 
Watanabe, & Wada, 1994)]. 
Of these disorders, the relationship between Alzheimer’s disease 
and histamine has been studied the most. Using Positron Emission 
Tomography imaging Higuchi et al. (2000) found a decrease in histamine 
receptors in Alzheimer’s disease patients and a relationship between the 
cognitive impairment and the absence of these histamine receptors. The 
decrease in number of receptors seemed particularly to be the case in areas 
of the brain involved in memory functioning. In addition, Panula et al. (1998) 
found a decrease in histamine concentration in deceased Alzheimer’s disease 
patients in the same areas as Higuchi and colleagues. More so, Airaksinen, 
Paetau, et al. (1991) and Airaksinen, Reinikainen, Riekkinen, & Panula (1991) 
found that the characteristic neurofibrillary tangles to be present in the 
histaminergic cells in Alzheimer’s disease patients brains. Taken together, 
these studies strongly suggest a relationship between histamine and 
Alzheimer’s disease. 
Another example of histamine being involved in clinical disorders 
regards schizophrenia. Nakai et al. (1991) found a decreased number of 
histamine receptors in brains of schizophrenic patients and Prell et al. (1995) 
found increased breakdown products of histamine in the cerebrospinal fluid 
of schizophrenic patients. 
More so, in patients suffering from Parkinson’s disease it has been 
shown that density of histamine nerves to areas of the brain particularly 
deteriorated in Parkinson’s disease and the density of certain histamine 
receptors are altered (Anichtchik, Peitsaro, Rinne, Kalimo, & Panula, 2001; 
Anichtchik, et al., 2000). In addition, these patients exhibit increased 
histamine levels in the brain (Rinne, et al., 2002). These studies show that the 
deficits in the histaminergic system may contribute to the impairment seen 
in these patients. The histamine neurotransmitter system, therefore, might be 
a good candidate to base new drugs on in order to pharmacologically treat 
such clinical disorders. 
 
Histamine system in the brain 
Before embarking on determining how histamine based drugs may 
contribute to the treatment of clinical disorders, some background 
knowledge about the histamine system may be useful. 
Histamine has been known to be a neurotransmitter for little more 
than 30 years. Schwartz in 1975 suggested that histamine is a 
neurotransmitter in the mammalian brain and that it may play a role in sleep 
and wakefulness. Around that time Garbarg, Barbin, Feger, & Schwartz 
(1974) actually showed that histaminergic neurons were present in the 
mammalian brain. Later Watanabe, et al. (1983) and Panula, Yang, & Costa 
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(1984) more specifically showed that histaminergic neurons were located in a 
structure called the tuberomammillary nucleus of the posterior 
hypothalamus in the rat brain. Panula, Airaksinen, Pirvola, & Kotilainen 
(1990) finally showed that such a histamine system is also present in the 
human brain. The histaminergic cells in the tuberomammillary nucleus 
project to all areas of the brain and such a structure resembles that of other 
monoamine systems. This suggests that histamine may play a large role in 
many functions including cognition. 
It is known that histamine exerts its functions in the brain through 
interactions with four types of receptors i.e. the H1, H2, H3 and H4 receptors 
located throughout the brain [for a comprehensive review see: (Haas, 
Sergeeva, & Selbach, 2008)]. As the H4 receptor has only recently been 
discovered little is known about its functional role, but it seems to closely 
resemble the H3 receptor in structure (Gbahou, et al., 2006; Nakamura, 
Itadani, Hidaka, Ohta, & Tanaka, 2000). The other receptors have been 
extensively studied. Activation of the H1 and H2 receptors leads to excitatory 
signal transmission or increased firing of neurons. In contrast, the H3 
receptor functions as an autoreceptor and activation leads to decreased 
histamine release from neurons (Arrang, Garbarg, & Schwartz, 1983). The H3 
receptor also functions as a heteroreceptor whereby it decreases the release 
of other neurotransmitters (e.g. norepinephrine, serotonin and 
acetylcholine). As many clinical disorders coincide with deficits in multiple 
transmitter systems and drug treatments are based on increasing 
neurotransmitter activity (e.g., Alzheimer’s disease, Attention Deficit 
Hyperactivity Disorder, Parkinson’s disease, depression) blocking the H3 
receptor and increasing not only histamine activity, but at the same time also 
that of other neurotransmitters, is a very promising concept for 
pharmacological treatments. 
 
New histamine based drug treatments 
There are now histamine based drugs under development, which show very 
promising preliminary results. Many pharmaceutical companies are 
developing H3-antagonists and these have proven effective in animal models 
for cognitive deficits, which occur in clinical disorders. Blocking the H3 
receptor in animal brains leads to increased performance on many tasks 
assessing cognitive functioning [for reviews see: (Bonaventure, et al., 2007; 
Esbenshade, Fox, & Cowart, 2006; Leurs, Blandina, Tedford, & Timmerman, 
1998; Vohora, 2004; Wijtmans, Leurs, & de Esch, 2007; Witkin & Nelson, 
2004)]. Especially performance on learning and memory tasks was improved 
in animals that otherwise show impaired performance. For example, mice 
that showed early signs of senescence improved their performance on tasks 
assessing memory consolidation after being treated with the H3 antagonist 
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thioperamide (Meguro, et al., 1995). This drug was also able to reverse 
scopolamine induced spatial orientation, working memory and passive 
avoidance impairments in animals (Komater, et al., 2005; Medhurst, et al., 
2007). In addition, H3-antagonists have shown to attenuate deficits in animal 
models for impairments seen in schizophrenia to the same degree as 
antipsychotics (Akhtar, Uma Devi, Ali, Pillai, & Vohora, 2006; Browman, et 
al., 2004; Fox, et al., 2005). This is only a small selection of the evidence 
derived from studies done in animals that suggest that H3-antagonists may 
be effective in cognitive disturbances in clinical disorders in humans. When 
taken all the research done together, the evidence is quite overwhelming. 
 
Aim 
In spite of all the evidence from animal studies direct evidence that 
histamine H3 receptor antagonists are effective as treatments in humans is 
still very scarce, because these drugs are still hardly available for use and 
testing in humans. However, these drugs will be available before long and, 
when suitable to be used in humans, need to be tested. Testing the many 
compounds that will be available in long-term patient studies is very time 
consuming. Alternatively, if cognitive deficits associated with histaminergic 
dysfunction can be modelled in healthy humans, the screening of the new 
treatments can be speeded up significantly. In order to be able to effectively 
test the efficacy of these new drugs knowledge about the role of histamine in 
human cognition is very useful. First, we need to know in which cognitive 
functions histamine is involved to determine which functions can be targeted 
with H3 antagonists. Second, with this knowledge a model of cognitive 
impairments associated with histaminergic dysfunction can be constructed 
in order to rapidly test new H3 drugs. Therefore, the aim of this dissertation 
is to determine what role histamine plays in cognitive functioning i.e. what 
cognitive functions highly depend on histaminergic activity. Second, to 
determine what manipulation of the histamine system can be used to model 
cognitive deficits associated with histamine dysfunction. 
 
Methodology 
There are different approaches that can be taken to evaluate the involvement 
of a neurotransmitter system in human cognition. First, the neurotransmitter 
system can be manipulated in different ways and, second, the subsequent 
functional impairments can be measured using different methods.  
In this dissertation, the histamine neurotransmitter system is 
manipulated in two ways. The first is by blocking the histamine H1 receptor 
in the central nervous system by administering ‘first generation’ 
antihistamines to healthy subjects. The drawback of using the ‘first 
generation’ antihistamine is that they are mostly unselective in their ability 
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to block receptors for neurotransmitters. The later developed ‘second 
generation’ are more selective, but may be less suitable as they penetrate the 
central nervous system to a lesser extent. Both types of substances are 
investigated in this dissertation. 
Another way to manipulate the histamine system is by depleting the 
central nervous system of the histamine precursor L-histidine. Histamine is 
synthesized by decarboxylation of L-histidine by the enzyme histidine-
decarboxylase (Schwartz, Arrang, Garbarg, Pollard, & Ruat, 1991). The 
primary source of L-histidine is every day food. Taking L-histidine out of the 
consumed food leads to decreased levels of L-histidine in the body. It is 
hypothesised that consequently to the decrease in L-histidine histamine 
levels are decreased in the central nervous system, which affect cognitive 
performance. 
To assess the effects of these different treatments on cognitive 
performance several approaches will be taken. The first consists of applying 
a test battery, which can be called the multiple-tasks one-factor approach 
(Riedel, Mehta, & Unema, 2006). The one factor is the treatment of which the 
effects are measured on a variety of neuropsychological and other 
behavioural tests. The result is profile of cognitive impairments as measured 
with these different tasks. 
 The second approach is the multi-factor one-task approach in which 
task manipulations are combined with drug treatments in order to determine 
their interacting effects on specific cognitive processes. The basic logic 
underlying this method has been developed by Sternberg in 1969 who 
showed that if factors interacted with each other they affect at least the same 
cognitive process. The method applying this basic principle was called the 
‘Additive Factor Method’. For example, in studying the effects of drugs a 
choice reaction time task can be used in which the difficulty of recognizing a 
stimulus, the difficulty of response choice and/or the complexity of the 
response itself can be varied. If a treatment interacts with one of these 
factors, it is concluded that the treatment affects the cognitive process that is 
also affected by that particular factor. For instance, it is known that visual 
degradation of a stimulus affects the cognitive process of stimulus 
identification. If a certain treatment enlarges the effect of stimulus 
degradation, it is concluded that the treatment affects stimulus identification. 
 In this dissertation, different outcome measures are used to evaluate 
treatment effects on cognitive functioning. Next to measures like reaction 
time and number of correct answers as outcome measures, 
psychophysiological measures are also used. These psychophysiological 
measures consist of measuring evoked brain potentials using electrodes 
placed on the scalp of a subject. The signals derived following an event e.g. 
stimulus presentation and/or response execution, are called Event Related 
Potentials. The duration between the event and occurrence of such potentials 
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are indicative of the duration of certain cognitive brain processes. For 
instance, a certain potential occurs X ms after the presentation of a visual 
stimulus which is easily recognizable. If this same potential occurs X + Y ms 
after the presentation of a stimulus difficult to recognize, the process of 
recognizing that stimulus is said to take Y ms longer. Using these Event 
Related Potentials and measures of their properties effects of treatments on 
specific cognitive processes will be presented in this dissertation. 
 
Outline of this thesis 
 
Chapter 1 
The main question attempted to be answered in chapter 1 is: What cognitive 
processes and domains are affected by histamine H1 blockade? Therefore, 
papers are reviewed in which the effects of first generation H1 antagonists on 
cognitive performance in healthy volunteers are described. 
 
Chapter 2 
The open questions revealed by the review are attempted to be answered by 
the study described in chapter 2. An experimental study is described that 
assessed the effects of a first generation antihistamine on psychomotor 
performance, memory and attention. 
 
Chapter 3 
It is unclear whether H1 antagonists affect memory performance and 
whether this is secondary to the sedative effects of these drugs. An 
experiment is described which specifically investigates the effects of the first 
generation H1 antagonist dexchlorpheniramine on memory and arousal. The 
effects are contrasted with the effects of the benzodiazepine lorazepam on 
memory and arousal. 
 
Chapter 4 
The second generation antihistamines are more selective for the histamine H1 
receptor than the first generation drugs. It is also claimed in general that the 
2nd generation antihistamine drugs penetrate the brain to a much lesser 
extent. However, this general claim is highly disputed. An example of the 
evidence may be provided by studying the cognitive effects of the 2nd 
generation antihistamine cetirizine. This chapter describes an experimental 
study in which the effects of cetirizine on psychomotor performance, 
memory and attention were investigated. 
 
Chapter 5 
Psychomotor performance seems to be very sensitive to the effects of H1 
antagonists. It is, however, unclear what underlying processes are affected 
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resulting in impaired performance. In chapter 5, a study is reported in which 
behavioural and electrophysiological measures are used to determine the 
effects of a first generation antihistamine on specific cognitive processes. To 
this end task manipulations and the Additive Factor Method are employed. 
 
Chapter 6 
An alternative method to decrease histaminergic activity is by depleting 
subjects from the histamine precursor L-histidine. As opposed to H1 
blockade, L-histidine depletion may affect the histaminergic system 
differently and may be a good method to model histaminergic dysfunction. 
L-histidine depletion has hardly been studied and the effects of L-histidine 
depletion on cognitive performance have never been studied. Chapter 6 
describes an experimental study in which blood-plasma levels of the 
histamine precursor L-histidine and other amino acids and cognitive 
performance after L-histidine depletion are evaluated.  
 
Chapter 7 
The final chapter provides a general discussion of the previous chapters. The 
role histamine plays in cognition is discussed and the attempts to answer 
which manipulations may be used to model histaminergic dysfunction are 
made. 
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COGNITIVE DOMAINS AFFECTED BY 
HISTAMINE H1 ANTAGONISM IN HUMANS: 
A LITERATURE REVIEW 
 
Van Ruitenbeek, P., Vermeeren, A., Riedel, W. J. (submitted). Cognitive 
domains affected by histamine H1 antagonism in humans: a literature 
review. 
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INTRODUCTION 
 
Some 30 years ago Schwartz (Schwartz, 1975, 1977; Schwartz, Pollard, & 
Quach, 1980) suggested that histamine is a neurotransmitter in the 
mammalian central nervous system and that it plays a role in arousal. The 
histaminergic cells in the tuberomammillary nucleus project to all areas of 
the brain. Activation of the H1 and H2 receptors leads to excitatory 
transmission or increased neuronal firing. In contrast, the H3 receptor 
functions as an autoreceptor and activation leads to decreased histamine 
release (Arrang, Garbarg, & Schwartz, 1983). The widespread presence of 
histaminergic projections and receptors suggest a role in various central 
nervous system functions, which may be affected in clinical disorders, 
including cognitive performance. 
The histamine system has been shown to be affected in Parkinson’s 
disease, epilepsy, dementia and schizophrenia (Onodera, Yamatodani, 
Watanabe, & Wada, 1994; Vohora, 2004). For example, Higuchi et al. (2000) 
found decreased H1 receptor binding potential in the frontal and temporal 
cortex in Alzheimer’s disease patients as compared with normal age 
matched subjects. In addition, Panula et al. (1998) found a decrease in 
histamine content in the hypothalamus, hippocampus and temporal cortex 
of post mortem Alzheimer brains. Regarding schizophrenia, Nakai et al. 
(1991) found a decreased number of H1 receptors in brains of schizophrenic 
patients and Prell et al. (1995) found increased histamine metabolites in the 
cerebrospinal fluid of schizophrenic patients. These studies suggest a 
histamine dysfunction in these disorders. 
Development of new treatments that increase histamine activity 
include H3-receptor antagonists. Results from animal studies have already 
shown that administration of H3-antagonists leads to increased histaminergic 
activity and to improved cognitive performance on many cognitive tasks, 
especially learning and memory in impaired animals [e.g. (Bernaerts, 
Lamberty, & Tirelli, 2004; Komater, et al., 2005; Medhurst, et al., 2007; 
Orsetti, Ghi, & Di Carlo, 2001) for review see: (Esbenshade, Fox, & Cowart, 
2006; Witkin & Nelson, 2004)]. Therefore, these H3-antagonists may have 
therapeutic potential in humans for treatment of disorders associated with 
histaminergic dysfunction (Leurs, Blandina, Tedford, & Timmerman, 1998; 
Passani, Lin, Hancock, Crochet, & Blandina, 2004). 
In order to assess the efficacy of the H3-antagonists for treatment of 
cognitive dysfunction in patients a pharmacological model of histaminergic 
dysfunction in healthy volunteers would be very useful. Such a model may 
provide a method to quickly obtain indications for efficacy of H3-antagonists, 
before initiation of long term clinical trials in patients. 
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 One way to decrease histaminergic activity is by blocking H1 
receptors in the central nervous system using antihistamines. Due to their 
sedative effects and impairment of motor vehicle control, the behavioural 
effects of antihistamines have been extensively studied in the context of 
traffic safety [for reviews see: (McDonald, Trick, & Boyle, 2008; O'Hanlon & 
Ramaekers, 1995; Shamsi & Hindmarch, 2000; Theunissen, Vermeeren, 
Vuurman, & Ramaekers, In prep)]. These studies clearly indicate that the so 
called ‘first generation’ antihistamines exert much larger sedative effects 
compared to the newer ‘second generation’. Therefore, a first generation 
antihistamine may be a useful tool drug to model histaminergic dysfunction 
in healthy volunteers. Since the aim of previous research and consecutive 
reviews was mainly to establish whether particular drugs or doses are likely 
to impair driving performance the differential effects of antihistamines on 
cognitive domains, such as memory and learning received relatively little 
attention.  
The suitability of H1-antagonism as a model for low histamine 
functioning depends on the magnitude and specificity of the effects. Too few 
effects results in too many false negatives when testing H3 drugs. For 
example, if H1-antagonists do not impair a certain cognitive function, which 
an H3-antagonist is capable of improving, the cognition enhancing effect may 
not be detected. In contrast, if a drug is highly sedative through which 
performance on many tasks deteriorates it is not specific for the cognitive 
domains sensitive for histaminergic dysfunction. In order to determine 
which cognitive processes are affected by H1-antagonism, the aim of this 
review is to investigate the impairments of different cognitive domains after 
administration of a ‘first generation’ antihistamine.  
 
METHODS 
 
Literature search 
A computer assisted literature search was conducted in the PsychInfo, 
Medline, PubMed and EMbase databases to identify placebo controlled 
studies, which reported the acute effects of orally administered first 
generation H1-antagonists on cognitive performance in healthy young 
human volunteers. To be included papers should have a sound methodology 
(e.g. suitable number of subjects and time of testing around Tmax) and be 
published in peer reviewed journals until August 2008. Studies in which the 
antihistamine was administered only in combination with other treatments 
were excluded. Search terms were ’antihistamines’, ‘H1-antagonists’, 
‘psychometric’, ‘sedation’, ‘cognitive function’, ‘psychomotor’, ‘learning’, 
‘memory’, ‘attention’, ‘event related potentials’ and specific antihistamine 
names. 
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Data collection 
The tests used in studies to evaluate treatment induced impairment were 
categorized by clustering tasks that measure aspects of the same cognitive 
domain (see table 1). The clustering was mainly based on that of the 
‘Theoretical Framework for Substance Effects on Safe Driving’, a programme 
for a project funded by the European Union to investigate the effects of 
drugs on driving performance. The clustering was extended where tasks 
were not mentioned in the original clustering and changed where we judged 
the task to measure a different domain/aspect of cognitive performance. In 
case a test measures more than one aspect of cognitive performance, the test 
was categorized according to the function it most saliently measures. 
Performance on most tasks is a resultant of many cognitive subprocesses, e.g. 
sensory, central and motor information processing. As the large majority of 
the studies do not investigate the effects on these specific subprocesses, the 
tasks were clustered such that the cognitive domains consist of tasks in 
which the emphasis is on measuring particular processes, as opposed to 
measuring the processes themselves. 
The effects of treatments at all doses were listed as ‘impairment’ or 
‘no impairment’. When an impairing effect was significantly different from 
placebo with p<0.05 the effect was considered as an example of impairment 
on a certain cognitive domain according to a liberal criterion (LC). An effect 
was considered to be an impairment according to a more strict criterion (SC) 
if p<0.01. The strict criterion was used to control for type I errors. However, 
performance differences in 15 papers were not tested for significance at a 
0.01 level, e.g. only with a 95% confidence interval. Non-significant effects 
were noted as such in the ‘no impairment’ column of the tables. The 
impairing acute effects of treatments were determined for all studies and all 
treatments (See table 2 for abbreviations). 
 
RESULTS AND DISCUSSION 
 
The literature search resulted in 70 papers from January 1966 until August 
2008. The papers described the effects of a total of 16 different sedative first 
generation H1-antagonists in different dosages (table 2) on 531 assessments. 
Of these assessments 292 (55%) indicated impaired performance according to 
the LC (p<0.05). There were 101 (19%) assessments that indicated an 
impairment according to the SC (p<0.01). The results indicate that not all 
cognitive domains have been equally studied nor are equally impaired by 
the H1-antagonists. 
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Table 1: Tasks assessing functions within cognitive domains.  
Cognitive domain Task 
  
Driving  
Simulated driving Driving simulator tests 
Actual driving Weaving, Speed consistency 
Psychomotor skills  
Eye-hand coordination Pursuit rotor, Spiral maze, Visuomotor coordination, Fine 
motoric test, Word typing, Compensatory tracking, Critical 
tracking 
Postural stability Body sway 
Motor speed Symbol copying. Finger tapping 
Speed of discrete responding  
Simple reaction time Simple reaction time 
Choice reaction time Choice reaction time 
Perception  
Pattern matching Speeded inference, Letter matching 
Visual threshold  Visual discrimination 
Perceptual processing speed Critical Flicker/Fusion Frequency 
Complex perceptual 
functions 
Speed anticipation, Temporal estimation 
Sensory visual function  
Physiology of the eye Pupillary functions 
Eye movements Eye saccades 
Attention  
Spatial attention Visual attention, , Covert attention, D2 cancellation, 
Alphabetical cross-out, Visual search 
Alertness Sustained attention, Vigilance, Rapid Visual Information 
Processing 
Selective attention Auditory selective attention, Focussed attention, Stroop 
Divided attention Divided attention 
Categorization tasks Trial making, Digit symbol substitution, Card sorting, 
Attention shift rule finding 
Memory  
Working memory ANAM running memory, Digit memory recall/Digit span, 
N-back, Sternberg’s memory scanning, Logical reasoning, 
Syntactic reasoning, Arithmetic 
Semantic memory Semantic verification 
Episodic memory Word association, Spatial paired associates learning, Word 
learning, Pattern recognition, Information recall, Source 
memory 
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Table 2: Treatments and their respective abbreviations. 
Treatment Dose Abbreviation 
Astemizole 10 mg A10 
Azatadine 2 mg, 4 mg, 8 mg AZ2, AZ4, AZ8 
Brompheniramine 10 mg, 12 mg, 20 mg B10, B12 
 12 mg extended release B12er 
Carbinoxamine 12 mg CA12 
Cinnarizine 15 mg, 30 mg, 45 mg CI15, CI30, CI45 
Chlorpheniramine 4 mg, 8 mg, 10 mg, 12 mg,  C4 
 12 mg extended release C12er 
Clemastine 1 mg, 2 mg CL1, CL2 
Cyclizine 25 mg, 50 mg, 100 mg CY25, CY50, CY100 
Dexchlorpheniramine 2 mg 4 mg DC2, DC4 
 1 mg (i.v.), 2 mg (i.v.), DC1iv, DC2iv 
 6 mg extended release DC6er 
Diphenhydramine 25 mg, 50 mg, 75 mg, 100 mg,  DH25, DH50, DH75, DH100,  
 1mg/kg, 50 mg (i.v.) DH1mg/kg, DH50iv 
Emedastine 2 mg, 4 mg E2, E4 
Hydroxyzine 20 mg, 25 mg, 30 mg, 50 mg H20, H25, H30, H50 
Ketotifen 1 mg, 2 mg K1, K2 
Olopatadine 5 mg O5 
Promethazine 10 mg, 20 mg, 25 mg, 30 mg, 50 mg P10, P20, P25, P30, P50 
Triprolidine 2.5 mg, 5 mg, 7.5 mg, 10 mg, 25 mg T2.5, T5, T7.5, T10 
 10 mg extended release T10er 
 
The drug most studied is diphenhydramine in oral doses ranging between 
25 mg and 100 mg. The effects of the 50 mg dose have been assessed using 
tests in all cognitive domains discussed in the present paper. Therefore, in 
addition to the impairment ratio of all drugs studied within a domain, the 
effects of diphenhydramine will be used as the prototypical drug to 
determine which domains are sensitive to its impairing effects 
 
Sedation 
 
Sleepiness 
Histamine has been known to be involved in sleep wake regulation (Saper, 
Chou, & Scammell, 2001; Saper, Scammell, & Lu, 2005). During sleep 
histaminergic activity is decreased while in a waking state histaminergic 
neurons in the tuberomammillary nucleus are most active. Therefore, 
blockade of the excitatory H1-receptor leads to decreased wakefulness (table 
3). 
This is reflected in the measures of sleepiness, which was assessed 20 
times by the sleep onset latency. In 95% (LC) the latency was shortened by 
the H1-antagonist as compared with placebo. Applying the SC resulted in 
45% of the measurements indicating shorter sleep onset latencies. A study 
using wrist actigraphy showed a significant reduction in daytime 
behavioural activity following the use of a sedative antihistamine.  
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Effects of diphenhydramine on sleep latency were assessed 6 times 
after doses between 50 and 100 mg. All doses had significant effects 
according to the LC and once according to the SC. These results show that 
diphenhydramine is capable of inducing clear sedation and sleepiness in 
doses of 50 mg and higher. 
 
Subjective alertness 
Subjective sedation (table 4) has been assessed most frequently of all 
assessments i.e. 107 times and has been most frequently assessed using 
visual analogue scales. 
The sedative effects were clearly shown by the 80% rate of subjective 
sedation as determined by the LC. When applying the SC subjects felt less 
alert in 25% of the assessments. Diphenhydramine was studied 36 times and 
almost all found significant effects on subjective alertness (LC: 97%; SC: 
33%). The lowest dose studied (25 mg) already induced subjective sedation 
in 80% of the cases. 
 
Cognition 
 
Driving 
The impairing effects of H1-antagonists are highly relevant for traffic safety 
as assessed with tests of car driving performance (table 5). 
As car driving is a highly complex task involving many cognitive 
functions it may be expected that performance is sensitive to the sedative 
effects of H1-antagonists. An impairment on any function incorporated in car 
driving may result in impaired driving performance. Effects on driving 
performance have been assessed 13 times. Overall, performance was 
impaired on 11 occasions (85%) of which 2 times (15%) according to the SC. 
On 3 occasions a simulator was used and on 10 occasions actual driving 
performance was assessed in an ‘on the road driving test’. All 3 simulated 
driving tests indicated impaired performance after the administration of the 
H1-antagonist as determined using the LC (100%), but once according to the 
SC. Actual driving performance was impaired in 8 out of the 10 assessments 
(LC: 80%) of which 2 (20%) as determined by the SC. 
Diphenhydramine 50 mg was studied 6 times and consistently 
impaired performance on all occasions. The effects of 25 mg have not been 
studied using tests of actual driving. 
  
 
 
 
Table 3: Effects of first generation H1-antagonists on measures of sleepiness 
 
Cognitive domain/task No 
impairment 
Impairment  References 
  p<0.05 p<0.01  
Sleepiness (n=21)  95% (20/21) 43% (9/21)  
Sleep onset latency 
(n=20) 
 
 
CI307 
95% (19/20) 
CI157, CI457 
DH501,20,104,112, DH751 
DH1001 
H2579,80,111, H50111 
P107,8,74, P255 
T2.529, T529,31 
45% (9/20) 
CI157, CI457 
DH5020,104, DH751 
DH1001 
 
P255, P107, T529  
1Turner, et al., 2006; 5Nicholson, et al., 2003;  
7Nicholson, et al., 2000; 8Nicholson, et al., 2002; 
20Roth, Roehrs, Koshorek, Sicklesteel, & Zorick, 
1987; 22Nicholson, Pascoe, & Stone, 1985;  
29Nicholson & Stone, 1986; 31Volkerts, Van 
Willigenburg, Van Laar, & Maes, 1992; 
74Nicholson & Turner, 1998; 79Seidel, et al., 1990; 
80Seidel, Cohen, Bliwise, & Dement, 
1987;104Richardson, et al., 2002; 111Alford, 
Rombout, Jones, Foley, & AIdzikowski, 1992; 
112Roehrs, Tietz, Zorick, & Roth, 1984 
Motoric activity (n=1)  100.0% (1/1) 
DC432 
0.0% (0/1)  
32Kamei, et al., 2003;  
  
Table 4: Effects of first generation H1-antagonists on measures of subjective alertness 
Cognitive 
domain/task 
No 
impairment 
Impairment  References 
  p<0.05 p<0.01  
Subjective 
alertness (n=107) 
 80% (86/107) 25% (27/107)  
Subjective 
ratings 
(n=107) 
 
A1064, 
 
 
CA1271 
CI307 
CL165 
CY5025,26 
 
DC432,104,106 
DC1iv34, 
DC2iv34 
DH259 
 
 
 
 
E293 
 
H2538,79, H509 
 
 
P107,82, P202, 
P3057 
 
T2.525 
80% (86/107) 
 
B1271, 
C414,14,53,82, C12er(increase)18 
 
CI157, CI457 
CL171, CL263 
CY25(increase)26, CY10025,26, 
DC235,45,  
DC445, DC6er35,58,76, 
 
 
DH254,14,14,105, 
DH501,1,3,9,13,13,14,14,15,17,21,44,47,50,72 
DH5072,77,81,90,95,100,104,113, 
DH751,1,110,  DH1001,1,108, 
DH1mg/kg41, DH50iv44 
E493, 
H2040, 
H2579, H3037,89,89, H5059,91,99 
 
K1103, K248, 
O588, 
P108,8,74,74,  
P255,5,60,68,78, P302,56, P5078 
T2.539, T539, T7.516, T1019,29,55,61,84 
25% (27/107) 
 
 
 
 
CI157, CI457 
 
 
 
DC445 
 
 
 
 
DH501,1,21,47,72,72,104,  
 
DH751,1, DH1001,1,108 
 
 
H3089,89,89, H5059,91,99 
 
K1103 
O588 
P108,8, 
P255,5,68 
1Turner, Handford, & Nicholson, 2006; 2Acons, Chan, 
Drummond, & Tiplady, 2006; 3Vuurman, Rikken, Muntjewerff, 
de Halleux, & Ramaekers, 2004; 4Gupta, Kapoor, Gillani, Kapoor, 
& Gupta, 2004;5Nicholson, Handford, Turner, & Stone, 2003; 
7Nicholson, Stone, Turner, & Mills, 2000; 8Nicholson, Stone, 
Turner, & Mills, 2002; 9Curran, Pooviboonsuk, Dalton, & Lader, 
1998; 13Witek, Canestrari, Miller, Yang, & Riker, 1992; 14Witek, 
Canestrari, Miller, Yang, & Riker, 1995; 15Gengo, Gabos, & 
Mechtler, 1990; 99De Brabander, 1990; 16Swire, Marsden, Barber, & 
Birmingham, 1989; 17Gengo, Gabos, & Miller, 1989;  18Lee, Lader, 
& Kitler, 1988; 19Bradley & Nicholson, 1987; 21Mattila, Mattila, & 
Konno, 1986; 25Hamilton, Bush, Bye, & Peck, 1982; 26Clubley, Bye, 
Henson, Peck, & Riddington, 1979; 29Nicholson & Stone, 1986;  
32Kamei, et al., 2003; 33Barbanoj, et al., 2006; 34Okamura, et al., 
2000; 35Tagawa, et al., 2002; 37Tashiro, et al., 2004; 39Cohen, 
Hamilton, Liao, Findlay, & Peck, 1985; 40Levander, Stahle-
Backdahl, & Hagermark, 1991; 41Oken, Kishiyama, & Salinsky, 
1995; 44Carruthers, Shoeman, Hignite, & Azarnoff, 1978; 45Van 
Ruitenbeek et al., 2008; 46Goetz, Jacobson, Apaliski, Repperger, & 
Martin, 1991; 47Grunberger, Saletu, Linzmayer, & Barbanoj, 1988; 
48Adamus, Oldigs-Kerber, & Lohmann, 1987; 50Cohen, Hamilton, 
& Peck, 1987; 53Kulshrestha, Gupta, Turner, & Wadsworth, 1978; 
55Hindmarch & Shamsi, 2001; 56Hindmarch, Shamsi, & Kimber, 
2002; 57Hindmarch, Shamsi, Stanley, & Fairweather, 1999; 
58Mochizuki, et al., 2002; 59Ridout, Shamsi, Meadows, Johnson, & 
Hindmarch, 2003; 60Shamsi, Kimber, & Hindmarch, 2001; 61Kerr, 
Dunmore, & Hindmarch, 1994; 63Vuurman, Uiterwijk, 
Rosenzweig, & O'Hanlon, 1994;  
  
    64Dhorranintra, Limsuvan, & Bunnag, 1986; 65Gaillard, et al., 1988; 
66Gaillard & Verduin, 1983; 68Levin, Barbat, Hedges, & Turner, 
1984; 70Millar & Standen, 1982; 71Seppala, Nuotto, & Korttila, 
1981; 72Kay, et al., 1997; 74Nicholson & Turner, 1998; 76Theunissen, 
Vermeeren, van Oers, van Maris, & Ramaekers, 2004; 77Verster, 
Volkerts, et al., 2003; 78Schroeder, Collins, & Elam, 1985; 79Seidel, 
Cohen, Bliwise, & Dement, 1990; 81Simons, Fraser, Reggin, & 
Simons, 1996; 82Clarke & Nicholson, 1978; 84Nicholson & Stone, 
1982; 88Takahashi, Ishida-Yamamoto, & Iizuka, 2004; 89Tashiro, et 
al., 2005; 90Verster, de Weert, et al., 2003; 91Vuurman, Theunissen, 
van Oers, van Leeuwen, & Jolles, 2007; 93Vermeeren, Ramaekers, 
& O'Hanlon, 2002; 95Gengo & Gabos, 1987; 100Gandon & Allain, 
2002; 103Tsujii, Yamamoto, Ohira, Saito, & Watanabe, 2007; 
104Richardson, Roehrs, Rosenthal, Koshorek, & Roth, 2002; 105Fine, 
et al., 1994; 106Serra-Grabulosa, Grau, Escera, & Sanchez-Turet, 
2001; 108Moser, Huther, Koch-Weser, & Lundt, 1978; 110Hou, 
Langley, Szabadi, & Bradshaw, 2007; 113Simons, Fraser, Reggin, & 
Simons, 1995 
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Psychomotor skills 
The effects on psychomotor skills (table 6) were measured on 96 occasions of 
which 50 (LC: 52%) indicated impaired performance of which 21 (22%) 
according to the SC. 
Similar to the driving performance, psychomotor skills involve 
many cognitive operations. Eye-hand coordination – typically assessed by 
tracking tests- was most frequently assessed (67 times) and 39 (LC) and 20 
(SC) times H1-antagonists induced impaired performance (LC: 58% and SC: 
30%, respectively). In contrast, motor speed as assessed by symbol copying 
and finger tapping tests, involves less cognitive operations and was slowed 
less frequently i.e. in 29% (LC) of the 24 measurements and only once as 
determined by the SC (4%). Postural stability was impaired in 3 out of 4 
measurements (CL: 75%). However, postural stability was assessed only 4 
times. 
 
Table 5: Effects of first generation H1-antagonists on measures of driving performance. 
 
 
Cognitive 
domain/task 
No 
impairment 
Impairment  References 
  p<0.05  p<0.01   
Driving (n=13)  85% (11/13) 15% (2/13)  
Simulated 
driving 
(n=3) 
 100% (3/3) 
DH5015,17,95  
0% (0/3) 95Gengo & Gabos, 1987; 
17Gengo, et al., 1989; 15Gengo, 
et al., 1990;  
Actual 
driving 
(n=10) 
 
 
 
 
H3089, H5059 
80% (8/10) 
DC6er75,76 
DH503,90 
E293, E493  
H5091 
T531 
20% (2/10) 
 
DH503 
 
H5091 
3Vuurman, et al., 2004; 
31Volkerts, et al., 1992; 59Ridout, 
et al., 2003; 75Theunissen, 
Vermeeren, & Ramaekers, 
2006; 76Theunissen, et al., 2004; 
89Tashiro, et al., 2005; 90Verster, 
de Weert, et al., 2003; 
91Vuurman, et al., 2007; 
93Vermeeren, et al., 2002 
  
Table 6: Effects of first generation H1-antagonists on measures of psychomotor skills 
Cognitive 
domain/task 
No impairment Impairment  References 
  p<0.05 p<0.01  
Psychomotor skills 
(n=96) 
 52% (50/96) 22% (21/96)  
Eye-hand 
coordination 
(n=67) 
 
A1064, 
AZ243, AZ443 
B1271 
C414,53 
CA1271 
CI157, CI457 
CL130,71, CL230,  
DC452, DC6er75,76 
DH2530,69 
DH5030,69 
 
H2040, H2538 
 
P107, P202,2, P2560,86, 
P302,2 
58% (39/67) 
 
AZ843 
B12er83, B483 
C482,83, C12er114 
 
CI307 
CL165, CL263 
DC245, DC432,43,45 
DH2514, DH503,13,14,21,50,72,73,77 
DH7527 
 
 
O588 
P108,74,82, P255,78, P3056, P5078,87  
T2.583, T1019,24,29,61,84, T10er83 
30% (20/67) 
 
AZ843, 
B12er83, 
C482, 
 
 
CL165, CL263, 
DC245, DC432,43,45  
DH503, 
 
 
 
P255,78 P108, P1082 
 
T2.583, T1019,24,29,83,84 
 
2Acons, et al., 2006; 3Vuurman, et al., 2004; 
5Nicholson, et al., 2003; 7Nicholson, et al., 
2000; 8Nicholson, et al., 2002; 13Witek, et al., 
1992; 14Witek, et al., 1995; 19Bradley & 
Nicholson, 1987; 21Mattila, et al., 1986; 
24Nicholson & Stone, 1983;27Baugh & 
Calvert, 1977; 29Nicholson & Stone, 1986; 
30Pishkin, Sengel, Lovallo, & Shurley, 1983; 
32Kamei, et al., 2003; 38Barbanoj, et al., 2004; 
40Levander, et al., 1991; 43Biehl, 1979; 45Van 
Ruitenbeek, 2008; 50Cohen, et al., 1987; 
52Franks, Hensley, Hensley, Starmer, & Teo, 
1978; 53Kulshrestha, et al., 1978; 
56Hindmarch, et al., 2002; 60Shamsi, et al., 
2001; 61Kerr, et al., 1994; 63Vuurman, et al., 
1994; 64Dhorranintra, et al., 1986; 65Gaillard, 
et al., 1988; 69Linnoila, 1973; 71Seppala, et al., 
1981; 72Kay, et al., 1997; 73Moskowitz & 
Burns, 1988; 74Nicholson & Turner, 1998; 
75Theunissen, et al., 2006; 76Theunissen, et 
al., 2004; 77Verster, Volkerts, et al., 2003; 
78Schroeder, et al., 1985; 82Clarke & 
Nicholson, 1978; 83Nicholson, 1979; 
84Nicholson & Stone, 1982; 85Seppala & 
Savolainen, 1982; 86Hedges, Maclay, 
Newman-Taylor, & Turner, 1971; 87Molson, 
Mackey, Smart, & Turner, 1966; 88Takahashi, 
et al., 2004;114Hindmarch & Bhatti, 1987;  
  
Postural 
stability (n=4) 
 
 
DH503 
75% (3/4) 
DC452 
DH5050,100 
0% (0/4) 3Vuurman, et al., 2004; 50Cohen, et al., 1987; 
52Franks, et al., 1978; 100Gandon & Allain, 
2002 
Motor speed 
(n=24) 
 
AZ443, AZ243 
 
CY2526 CY5025,26 
CY10025,26 
 
DH259,9, DH509,44 
DH1mg/kg41,DH50iv44 
H2040, H2538 
T2.525,39, T539 
29% (7/24) 
AZ843 
C12er18,18  
 
 
DC443 
DH509,20 
 
 
T1029 
4% (1/24) 
 
 
 
 
 
 
 
 
T1029 
9Curran, et al., 1998; 18Lee, et al., 1988; 
20Roth, et al., 1987; 25Hamilton, et al., 1982; 
26Clubley, et al., 1979; 29Nicholson & Stone, 
1986; 38Barbanoj, et al., 2004; 39Cohen, et al., 
1985; 40Levander, et al., 1991; 41Oken, et al., 
1995; 43Biehl, 1979; 44Carruthers, et al., 1978;  
CHAPTER 1 
 35 
Diphenhydramine 50 mg impaired performance on eye-hand 
coordination on 8 out of 10 occasions (LC: 80%), postural stability 2 out of 
the 3 times (LC: 67%) and motor speed 2 out of 4 times (LC: 50%). The lower 
dose impaired eye-hand once out of 3 (33%), but did not slow motor speed 
The results suggest that H1-antagonists affect psychomotor 
performance to a large extent. The tasks that were used do not discriminate 
between different cognitive processes underlying performance. The affected 
processes that cause the impairment may be motor related processes as these 
are also affected. However, these are affected to a lesser extent than eye-hand 
coordination, which suggests that other processes are impaired as well. 
 
Speed of discrete responding 
Performance on reaction time tasks (table 7) depends less on central 
cognitive processes as compared with psychomotor skills e.g. compensatory 
tracking. Performance on reaction time tasks does depend greatly on sensory 
and motor processes. Slowing of any of those process, results in a decrease in 
performance. 
Of the 78 measurements assessing reaction time 40 (LC: 51%) and 9 
(SC: 12%) indicated slowed performance. Simple reaction time was slowed 
on 14 and 2 of the 35 measurements (LC: 40%, SC: 6%, respectively). In 
comparison, performance on the choice reaction time task was slowed on 26 
occasions of the 43 assessments (LC: 61%) and on 7 occasions using the SC 
(16%). Assuming pure insertion, the choice reaction time task includes the 
additional process of ‘response choice’ as compared with the simple reaction 
time task. It may be that antihistamines affect the choice of the response in 
addition to slowed sensory and motor processes. 
 This pattern was also seen after diphenhydramine administration, 
albeit to a lesser extend. Two doses of diphenhydramine (25 and 50mg) were 
used in both simple and choice reaction time tasks. Simple reaction time 
speed was slowed in 4 cases of the 8 measurements (LC: 50%). Choice 
reaction time was slowed 6 times of the 11 times measured (LC: 55%). 
Performance after administration of lowest dose of diphenhydramine (25 
mg) was impaired on both tasks, indicating that both measures are sensitive 
to the impairing effects. 
Apart from ‘response choice’, the simple- and choice reaction time 
tasks mostly do not discriminate between different processes in cognitive 
functioning (e.g. sensory and motor processes). However, some authors have 
assessed specific processes involved in performance on the choice reaction 
time task. In two studies of Gaillard et al. (Gaillard & Verduin, 1983; 
Gaillard, Gruisen, & De Jong, 1988) the interaction between the effect of an 
antihistamine and the presentation of visually degraded stimuli was studied. 
One of these studies found that the antihistamine tended to interact with the 
task manipulation i.e. stimulus degradation (Gaillard & Verduin, 1983). 
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Stimulus degradation is known to affect the processing of sensory 
information. The interaction indicates the effect of antihistamines on at least 
that same process (Sanders, 1980; Sternberg, 1969). In contrast, in their 
second study (Gaillard, et al., 1988) they concluded that the antihistamine 
mainly affected motoric processes. Next to these two studies there are no 
studies examining the specificity of the effects of antihistamines. 
 
Perception 
Tasks in which the emphasis is on perceptual functions (visual and 
temporal) (table 8) were used on 49 occasions of which 24 showed an 
impairment according to the LC (49%) and on 6 occasions using the SC 
(12%). 
Within this domain perceptual processing speed (Critical 
Flicker/Fusion Frequency) has been assessed most frequently (i.e. 34 times). 
These measurements indicated slowed perceptual speed 18 times (LC: 53%) 
and 4 times (SC: 12%). Visual threshold was measured only 6 times, but was 
impaired on 5 occasions (LC: 83%) and twice using the SC (33%). These 
results suggest that perceptual processes are sensitive to the effects of 
antihistamines. In contrast, pattern matching was assessed 5 times of which 
an impairment was detected only once (LC: 20%) 
Finally, temporal processing (time and speed perception) was 
assessed 4 times and showed no impairment. Processing of complex 
patterns, time and speed appear to be less affected by the H1-antagonists 
than processing of visual information. 
The conclusion that visual processing speed is affected is supported 
when considering the impairments induced by diphenhydramine. 
Diphenhydramine 25 mg, 50 mg and 75 mg together impaired perceptual 
processing speed in a total of 44% of the cases (LC), diphenhydramine could 
not impair pattern recognition on the 2 occasions measured (LC: 0%). 
However, the effect of this drug on visual threshold and complex perceptual 
functions were not assessed. 
More sensory visual functions have only been assessed 4 times of 
which 2 (LC: 50%) indicated an impairment (table 9). Pupillary function was 
impaired in 1 of 3 assessments (LC 33%), due to effects of diphenhydramine 
75 mg. Effects of diphenhydramine 50 mg on pupillary functions were not 
significant, but this dose did impair saccadic eye movements. No other H1-
antgonists were studied using saccadic eye movements. These four 
assessments indicate that visual sensory functions can be affected by H1-
antagonists, but data are limited as to few studies have been done. 
  
Table 7: Effects of first generation H1-antagonists on measures of speed of discrete responding 
Cognitive domain/task No impairment Impairment  References 
  p<0.05 p<0.01  
Speed of discrete responding 
(n=78) 
 51% (40/78) 12% (9/78)  
Simple reaction time 
(n=35) 
 
AZ243, AZ443 
C453 
CL130, CL230, 
CY2526,CY5025,26 
CY10026, 
DC235, DC452  
DC6er35  
DH503.20,30,50 
 
H2040, H2530 
K248 
T2.525,39 
40% (14/35) 
AZ843 
C12er18, 
 
CY10025 
 
DC245, DC443,45 
 
DH254, DH5044,47 
DH50iv44 
H2538, H3036,37 
T539  
6% (2/35) 
 
 
 
 
 
DC445,  
 
DH5047 
 
3Vuurman, et al., 2004; 4Gupta, et al., 2004; 18Lee, 
et al., 1988; 20Roth, et al., 1987; 25Hamilton, et al., 
1982; 26Clubley, et al., 1979; 30Pishkin, et al., 1983; 
35Tagawa, et al., 2002; 36Tashiro, et al., 2002; 
37Tashiro, et al., 2004; 38Barbanoj, et al., 2004; 
39Cohen, et al., 1985; 40Levander, et al., 1991; 
43Biehl, 1979; 44Carruthers, et al., 1978; 45Van 
Ruitenbeek et al., 2008; 46Goetz, et al., 1991; 
47Grunberger, et al., 1988; 48Adamus, et al., 1987; 
50Cohen, et al., 1987; 52Franks, et al., 1978; 
53Kulshrestha, et al., 1978; 54Roberts, 1971  
Choice reaction time 
(n=43) 
 
A1064 
AZ243, AZ443, AZ843 
B1271 
 
 
CL171 
DC432,43,52 
DH2569, DH501,21,47,69 
 
H2538 
P202  
T1055 
61% (26/43) 
 
 
B1070 
C414 
CA1271 
CL165 
DC235,45, DC445 DC6er35,58 
DH254,14,DH5013,14, 
DH751, DH1001 
H3036,37,57, H5059, 
P255,60,68, P302,56 
T531, T1061 
 
16% (7/43) 
 
 
B1070 
 
 
 
DC6er35 
DH1001 
 
H5059 
P255, P302,56 
 
 
1Turner, et al., 2006; 2Acons, et al., 2006; 4Gupta, 
et al., 2004; 5Nicholson, et al., 2003; 14Witek, et al., 
1995; 21Mattila, et al., 1986; 31Volkerts, et al., 1992; 
32Kamei, et al., 2003; 35Tagawa, et al., 2002; 
36Tashiro, et al., 2002; 37Tashiro, et al., 2004; 
38Barbanoj, et al., 2004; 43Biehl, 1979; 45Van 
Ruitenbeek, 2008; 46Goetz, et al., 1991; 
47Grunberger, et al., 1988; 52Franks, et al., 1978; 
55Hindmarch & Shamsi, 2001; 57Hindmarch, et al., 
1999; 58Mochizuki, et al., 2002; 59Ridout, et al., 
2003; 60Shamsi, et al., 2001; 61Kerr, et al., 1994; 
63Vuurman, et al., 1994; 64Dhorranintra, et al., 
1986; 65Gaillard, et al., 1988; 66Gaillard & 
Verduin, 1983; 68Levin, et al., 1984; 69Linnoila, 
1973; 70Millar & Standen, 1982; 71Seppala, et al., 
1981 
  
 
Table 8: Effects of first generation H1-antagonists on measures of perception 
Cognitive domain/task No impairment Impairment  References 
  p<0.05 p<0.01  
Perception (n=49)  49% (24/49) 12% (6/49)  
Pattern recognition (n=5)  
CL130, CL230 
DH2530, DH5030 
20% (1/5) 
 
 
T531 
0% (0/5) 30Pishkin, et al., 1983; 31Volkerts, et al., 1992 
Visual threshold (n=6)  
DC1iv34 
83% (5/6) 
DC235, 
DC6er35,DC2iv34 
H3036,37 
33% (2/6) 
DC235 
DC6er35 
34Okamura, et al., 2000; 35Tagawa, et al., 2002; 
36Tashiro, et al., 2002; 37Tashiro, et al., 2004 
Perceptual processing speed 
(n=34) 
 
B1271 
C453, C12er18 
CA1271 
CL130,71 
DC432, DC6er76, 
DH259, DH503,9,30,47 
H2530 
K248 
 
 
T1055 
53% (18/34) 
 
 
 
CL230,63 
 
DH254, DH5021,100 
DH75110 
H2538, H5059 
K1103 
P2560,68,86, P3056,57  
T7.516, T1024,29,61 
 
12% (4/34) 
 
 
 
 
 
 
 
 
K1103 
P2586 
T7.516, T1029 
 
3Vuurman, et al., 2004; 4Gupta, et al., 2004; 
9Curran, et al., 1998; 16Swire, et al., 1989; 18Lee, et 
al., 1988; 21Mattila, et al., 1986; 24Nicholson & 
Stone, 1983; 29Nicholson & Stone, 1986; 30Pishkin, 
et al., 1983; 32Kamei, et al., 2003; 38Barbanoj, et al., 
2004; 47Grunberger, et al., 1988; 48Adamus, et al., 
1987; 53Kulshrestha, et al., 1978;  55Hindmarch & 
Shamsi, 2001; 56Hindmarch, et al., 2002; 
57Hindmarch, et al., 1999; 59Ridout, et al., 2003; 
61Kerr, et al., 1994; 63Vuurman, et al., 1994; 
68Levin, et al., 1984; 71Seppala, et al., 1981; 
76Theunissen, et al., 2004; 86Hedges, et al., 1971; 
100Gandon & Allain, 2002; 103Tsujii, et al., 2007; 
110Hou, et al., 2007  
Complex perceptual functions 
(n=4) 
 
B1271 
CA1271 
CL171 
H2538 
0% (0/4) 0% (0/4) 38Barbanoj, et al., 2004; 71Seppala, et al., 1981 
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Table 9: Effects of first generation H1-antagonists on measures of sensory visual functions 
 
Attention 
The effects of the H1-antagonists on tasks assessing attention have been 
assessed extensively and often lead to impaired performance (table 10). 
Effects on attention have been assessed 91 times of which 40 
assessments (44%) indicated impaired performance using the LC. Using the 
SC, 17 assessments (19%) indicated impaired performance. 
Of these measures divided attention was most frequently impaired 
as determined using both the LC (58%) and SC (26%). However, divided 
attention tasks often include tracking as one of two tasks and as shown 
earlier, eye-hand coordination is very sensitive to H1-antagonism. This may 
therefore have confounded the results.  
Performance on categorization tasks (e.g. Digit Symbol Substitution 
Tasks, Card Sorting Task), which also include considerable eye-hand 
coordination in addition to executive processes, was impaired 14 of the 37 
assessments (LC: 38%) and 9 times using the SC (24%). The impairment on 
these tasks is of similar magnitude as found in divided attention tasks as 
judged by the SC (i.e. 24 and 26%). Nevertheless, tasks including less eye-
hand coordination and executive functions like sustained attention and 
vigilance were also impaired on 11 out of 23 times (LC: 48%) but only once 
(4%) using the SC. 
Spatial attention was found to be impaired 3 out of 8 times and was 
impaired as determined by the LC (38%) of which 2 times according to the 
SC (25%). Selective attention was impaired only once (LC) out of 4 times. So, 
even though impaired performance on some tasks may not result purely 
from impaired attentional processes, other tasks do suggest that attention is 
impaired after the administration of H1-antagonists 
Diphenhydramine impaired performance on divided attention and 
categorization tasks the most. Effects of doses ranging between 25 and 100 
mg were assessed. Impaired performance was found on all assessments of 
divided attention (100%) and on 7 of the 16 assessments using categorization 
tasks (LC: 44%). Similar to the impairment ratio from all drugs, the divided 
attention task appears to be a very sensitive task. Tasks in which the 
Cognitive 
domain/task 
No 
impairment 
Impairment  References 
  p<0.05 p<0.01  
Sensory Visual 
function (n=4) 
 50% (2/4) 0% (0/4)  
Physiology of 
the eye (n=3) 
 
DC6er76 
DH5047 
33% (1/3) 
 
DH75110 
0% (0/3) 47Grunberger, et al., 1988; 
76Theunissen, et al., 2004; 
110Hou, et al., 2007 
Eye 
movements 
(n=1) 
 100% (1/1) 
DH5050 
0% (0/1) 50Cohen, et al., 1987 
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psychomotor component is smaller, like measures of spatial attention, are 
reasonably sensitive as performance was impaired twice of the 6 assessments 
and twice of the 4 assessments for spatial attention and alertness, 
respectively. 
 
Memory 
The effects of H1 blockade on memory performance (table 11) has been 
assessed 73 times of which 19 (26%) showed impaired performance as 
determined using the LC and 10 times (14%) using the SC. 
Within this domain, working memory has been assessed most 
frequently (i.e. 50 times). In 36% (LC) subjects showed impaired 
performance, which was the case in 18% when SC was applied. In contrast, 
episodic memory performance was assessed 23 times and an impairment 
was indicated only once (4%) using both LC and SC. Semantic memory was 
measured once and was not impaired. 
Working memory was clearly more frequently impaired compared 
with explicit and semantic memory. Performance on tasks assessing working 
memory frequently relies on response speed. For example, overall response 
speed is often the dependent outcome measure of the Sternberg’s memory 
scanning task and N-back task and, therefore, resembles a choice reaction 
time task. In such cases antihistamines impair performance in 60% (LC) of 
the assessments, which resembles the 61% (LC) impaired choice reaction 
time task performance. In contrast to the working memory tasks, explicit and 
semantic memory is frequently measured using word learning tasks or recall 
of information, which is largely irrespective of speed and show impaired 
performance in only 4% (LC and SC) of the cases. In addition, Performance 
on working memory tasks not dependent on response speed, e.g. digit recall, 
was impaired in only 27% (LC) of the assessments. It may be that 
information processing speed is affected, but not the functional integrity e.g. 
correctly recalled words. 
The effects of diphenhydramine were only assessed on working 
memory. In correspondence with the impairment ratio of all drugs, working 
memory was impaired in 26% (LC) of the cases. The 25 mg dose was capable 
of impairing the performance on one occasion. However, in several studies 
the 50, 75 and 100 mg doses were able to impair performance. Therefore, in 
contrast to all the impairment ratio of all drugs working memory seems to be 
rather insensitive to the effects of diphenhydramine 
  
 
 
Table 10: Effects of first generation H1-antagonists on measures of attention 
Cognitive domain/task No impairment Impairment  References 
  p<0.05 p<0.01  
Attention (n=91)  44% (40/91) 19% (17/91)  
Spatial Attention (n=8)  
DH259, DH509,47, 
DH1mg/kg41 
H2538 
38% (3/8) 
DH254 
DH1mg/kg41 
H2538 
25% (2/8) 
 
DH1mg/kg41 
H2538 
4Gupta, et al., 2004; 9Curran, et al., 1998; 33Barbanoj, et al., 
2006; 38Barbanoj, et al., 2004; 41Oken, et al., 1995; 
47Grunberger, et al., 1988 
Alertness (n=23)  
CI157, CI457 
CL263 
CY2526, CY5026, 
CY10026 
DC432 
DH501,20, DH751, 
DH1001 
 
P107 
48% (11/23) 
CI307 
 
 
 
 
DH25105, DH5072,73 
 
H2579,80, 
P108,74, P255 
T2.539, T539 
4% (1/23) 
 
 
 
 
 
DH5072 
 
1Turner, et al., 2006; 5Nicholson, et al., 2003; 7Nicholson, et 
al., 2000; 8Nicholson, et al., 2002; 20Roth, et al., 1987; 
26Clubley, et al., 1979; 32Kamei, et al., 2003; 39Cohen, et al., 
1985; 63Vuurman, et al., 1994; 71Seppala, et al., 1981; 72Kay, 
et al., 1997; 73Moskowitz & Burns, 1988; 74Nicholson & 
Turner, 1998; 79Seidel, et al., 1990; 80Seidel, et al., 1987; 
105Fine, et al., 1994  
Selective attention (n=4)   
 
P202, P302  
T1061 
25% (1/4) 
DC4106 
0% (0/4) 2Acons, et al., 2006; 61Kerr, et al., 1994; 106Serra-Grabulosa, 
et al., 2001 
 Divided attention (n=19)  
B1271 
CA1271 
C414 
CL165,71 
DC245, DC6er75,76  
58% (11/19) 
 
 
 
CL263 
DC445 
DH2514, 
DH5013,14,21,72,73,77,104  
26% (5/19) 
 
 
 
CL263 
DC445  
 
DH5021,72 
13Witek, et al., 1992; 14Witek, et al., 1995; 21Mattila, et al., 
1986; 45Van Ruitenbeek, 2008; 55Hindmarch & Shamsi, 
2001; 63Vuurman, et al., 1994; 65Gaillard, et al., 1988; 
71Seppala, et al., 1981; 72Kay, et al., 1997; 73Moskowitz & 
Burns, 1988; 75Theunissen, et al., 2006; 76Theunissen, et al., 
2004; 77Verster, Volkerts, et al., 2003; 104Richardson, et al., 
2002  
  
 
 
 
 
T1055 
P108 
 
Categorization tasks 
(n=37) 
 
 
C414C12er18 
CI157, CI457 
CY2526, 
CY5025,26, 
CY10025,26, 
DH259,14, 
DH503,13,14,15,9, 
DH751,27 
H5099, 
P107, P202, P302 
T2.525 
38% (14/37) 
 
 
CI307, 
 
 
DH254, 
DH501,15,17,20,21, 
DH1001, 
 
P255, P108 
T7.516, T1024,19,299 
24% (9/37) 
A1064 
 
CI307, 
 
 
DH5017,44, 
DH50iv44 
 
 
P255 
T7.516, T1024,29 
1Turner, et al., 2006; 2Acons, et al., 2006; 3Vuurman, et al., 
2004; 4Gupta, et al., 2004; 5Nicholson, et al., 2003; 
7Nicholson, et al., 2002; 8Nicholson, et al., 2000; 9Curran, 
et al., 1998; 13Witek, et al., 1992; 14Witek, et al., 1995; 
15Gengo, et al., 1990; 16Swire, et al., 1989; 17Gengo, et al., 
1989; 18Lee, et al., 1988; 19Bradley & Nicholson, 1987; 
20Roth, et al., 1987; 21Mattila, et al., 1986; 24Nicholson & 
Stone, 1983; 25Hamilton, et al., 1982; 26Clubley, et al., 1979; 
27Baugh & Calvert, 1977;  29Nicholson & Stone, 1986; 
44Carruthers, et al., 1978; 64Dhorranintra, et al., 1986; 99De 
Brabander, 1990  
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CONCLUSION 
 
Taken together, if the LC is applied driving (85%) is most sensitive to the 
effects of centrally active H1-antagonists followed by psychomotor skills 
(52%, in particular tracking), speed of discrete responding (51%, in particular 
choice reaction time), perception (49%, in particular CFF) and attention (44%, 
in particular divided attention). Finally, memory performance was impaired 
in 26% of the assessments (in particular working memory). When applying 
the SC driving was only impaired in 15% of the assessments. In accordance 
with the LC psychomotor skills (22%) and attention (19%) were highly 
sensitive to H1-antagonism. Speed of discrete responding (12%), perception 
(12%) and memory (14%) were affected less frequently. 
There are some limitations to these numbers that need to be 
considered. First of all, the effects on memory may be related to effects on 
working memory task performance. As most tasks assess a product of 
cognitive processes as opposed to a single process, also working memory 
performance frequently depends on psychomotor speed e.g. as measured 
with reaction time. It should also be taken into account that only 12 studies 
assessed episodic memory. Compared to, for example, eye-hand 
coordination (45 studies), choice reaction time (31 studies), perceptual 
processing speed (27 studies) and simple reaction time (23 studies) it may be 
suggested that future studies need to further test the effects of H1-
antagonists on episodic memory. 
Furthermore, sensory visual functions were affected in 50% as 
judged using the LC, but were only investigated 4 times. Regarding the use 
of the SC it should also be taken into account that 15 studies did not test for 
significance at a 0.01 level. These studies provided only information about 
whether the p value was smaller than 0.05 or not. However, the above stated 
profile is not expected to be greatly affected by results from these studies. 
Effects of diphenhydramine show a similar pattern of results 
compared with the impairment ratio of all drugs (table 12). The 50 mg dose 
has been used most frequently and the effects of this dose on all domains 
have been assessed. Driving (100%), psychomotor skills (71%), attention 
(61%) and sensory visual function (50%) (i.e. saccadic eye movements and 
papillary functions) seem to be the most sensitive cognitive domains to the 
effects of diphenhydramine. However, sensory visual function has been very 
scarcely studied and therefore further research is needed before it can be 
determined whether the function is sensitive. Speed of responding and 
perception are also frequently affected by diphenhydramine 50 mg (33% and 
29%, respectively). Finally, memory appears to be least sensitive (17%), 
especially when considering episodic memory. 
  
Table 11: Effects of first generation H1-antagonists on measures of memory 
Cognitive domain/task No impairment Impairment  References 
  p<0.05 p<0.01  
Memory (n=83)  23% (19/83) 12% (10/83)  
Working memory (n=51)  
AZ243, AZ443, AZ843, 
 
CY2526,26, CY5026,26, 
CY10026 
DC245,45, DC443,45, 
DC6er76, 
DH501,1,3,13,13,21,47,47,77 
DH751,1, DH1001,1, 
DH1mg/kg41 
 
 
P202, P2586, P302 
T7.516, T1061 
35% (18/51) 
 
CL263, 
CY10026, 
 
DC245, DC452 
DH254, 
DH5072,72,102, 
DH7527 
H2538,38 
K1103,103 
P255,5 
T531, T1019,55 
18% (9/51) 
 
 
 
 
DC245, DC452 
DH5072,72,102 
 
 
 
K1103 K1103, 
P255,5 
1Turner, et al., 2006; 2Acons, et al., 2006; 3Vuurman, 
et al., 2004; 4Gupta, et al., 2004; 5Nicholson, et al., 
2003; 13Witek, et al., 1992; 16Swire, et al., 1989; 
19Bradley & Nicholson, 1987; 21Mattila, et al., 1986; 
26Clubley, et al., 1979; 26Clubley, et al., 1979; 
27Baugh & Calvert, 1977; 31Volkerts, et al., 1992; 
38Barbanoj, et al., 2004; 41Oken, et al., 1995; 43Biehl, 
1979; 45Van Ruitenbeek, 2008; 47Grunberger, et al., 
1988; 52Franks, et al., 1978; 55Hindmarch & Shamsi, 
2001; 61Kerr, et al., 1994; 63Vuurman, et al., 1994; 
72Kay, et al., 1997; 76Theunissen, et al., 2004; 
77Verster, Volkerts, et al., 2003; 97Higgins, et al., 
1979; 102Gevins, Smith, & McEvoy, 2002; 103Tsujii, et 
al., 2007 
Semantic memory (n=1) DH503 0.0% (0/1) 0.0% (0/1) 3Vuurman, et al., 2004 
Episodic memory (n=23)  
C498,98,98, C12er18 
DC245,45, DC445,45, 
DC6er76 
DH259, DH501,3,9,47,77,100 
DH751, DH1001 
H5099,  
P202, P302 
4% (1/23) 
 
 
 
 
 
 
P255 
4% (1/23) 
 
 
 
 
 
 
P255 
1Turner, et al., 2006; 2Acons, et al., 2006; 5Nicholson, 
et al., 2003; 9Curran, et al., 1998; 18Lee, et al., 1988, 
45Van Ruitenbeek, 2008; 47Grunberger, et al., 1988; 
76Theunissen, et al., 2004; 77Verster, Volkerts, et al., 
2003; 98Carter & Cassaday, 1998; 99De Brabander, 
1990; 100Gandon & Allain, 2002  
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Table 12: The typical H1-antagonist diphenhydramine used to indicate cognitive domains 
sensitive to H1-antagonism. Percentages indicate the proportion of the treatments that 
impaired performance on tasks assessing a certain cognitive domain. 
 Diphenhydramine dose    
Cognitive domain 100 mg 75 mg 50 mg 25 mg 
Driving n.a. n.a. 100% n.a. 
Psychomotor skills n.a. 100% 71% 20% 
Attention 50% 0% 61% 57% 
Sensory visual function n.a. 100% 50% n.a. 
Speed of discrete responding 100% 100% 33% 75% 
Perception n.a. 100% 29% 50% 
Memory 0% 25% 17% 50% 
 
In conclusion, this review indicates that H1-blockade impairs speed of 
cognitive information processing, which makes performance on tasks that 
rely on speed (e.g. critical tracking) most sensitive to H1-blockade and tasks 
that rely little on speed least sensitive (e.g. episodic memory). In accordance, 
driving performance and psychomotor skills have shown to be most 
sensitive. We suggest that deficits in these functions may be modelled using 
H1-antagonists and used for screening new H3-antagonists for their potential 
to improve such deficits. The results suggest that perceptual functions are 
impaired by H1-antagonism, which may partly underlie the psychomotor 
impairments. As discussed above, driving and psychomotor functions 
include multiple cognitive processes related to stimulus perception, decision 
making and response preparation and execution. However, so far, only a few 
studies have assessed effects of H1 antagonists on separate underlying 
processes and came to contradictory conclusions. The specificity of the 
effects of centrally active H1-antagonists therefore deserves further study.  
In contrast to results form animal studies results from this review 
suggests that memory in healthy human volunteers is not likely to be 
impaired after H1-antagonist administration. Therefore, deficits in this 
domain do not seem to be modelled adequately using H1 antagonists. Data 
are limited however, as memory and episodic memory in particular, have 
been investigated by only a few authors when compared to functions like 
divided attention and psychomotor performance. Effects of H1 antagonist on 
memory therefore also deserve further study. 
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INTRODUCTION 
 
Recently interest in role that histamine might play in cognition has increased 
(Bacciottini et al. 2001; Blandina et al. 2004). Especially the cognitive domain 
of learning and memory is of interest. Animal studies have shown that 
increases in histaminergic functioning improve memory performance and 
decreases impair it [c.f.(Giovannini et al., 1999; Hancock and Fox, 2004; 
Komater et al., 2005; Meguro et al., 1995; Orsetti et al., 2001; Witkin and 
Nelson, 2004)]. 
Currently, evidence supporting a role of histamine in learning and 
memory is mainly based on studies in animals. So far there are hardly any 
studies specifically addressing this subject in humans. Although there are 
many studies assessing the behavioural effects of histaminergic blockade by 
centrally acting H1-antagonists in humans, they provide little support for the 
hypothesis that decreased histaminergic functioning is associated with 
impaired memory functions. This is largely due to the fact that most of these 
studies simply did not include tests for memory functioning. Most of them 
have been conducted in the context of behavioural safety of antihistamines 
with an emphasis on car-driving (for reviews see: (Hindmarch and Shamsi, 
1999; O'Hanlon and Ramaekers, 1995; Shamsi and Hindmarch, 2000; White 
and Rumbold, 1988). Since driving performance is more strongly dependent 
on perceptual-motor and attentional functions than on memory, only a few 
studies included memory tests.  
The studies that did assess the effects of H1 blockade on memory, 
show inconsistent results. The majority found no significant effects on 
memory (Acons et al., 2006; Bower et al., 2003; Curran et al., 1998; De 
Brabander, 1990; Kerr et al., 1994; Lee et al., 1988; Turner et al., 2006), 
whereas others did (Hindmarch et al., 2001; Katz et al., 1998, Sands et al., 
1997; Vuurman et al., 1994). Two studies (Katz et al., 1998; Sands et al., 1997) 
found significant effects of diphenhydramine 50 mg on memory 
performance in healthy elderly subjects. Vuurman et al. (1994, 1996) found a 
significant learning impairment in children and adolescents after the use of 
diphenhydramine, and Hindmarch and Shamsi (2001) found a significant 
effect of triprolidine 10 mg on performance of healthy young volunteers in a 
memory-scanning task.  
The contradictory results may be partly explained by the methods 
used. The use of insensitive memory tests and assessing memory functions 
before or after the time of peak behavioural impairments might explain the 
absence of effects. Alternatively, the significant effects found in some studies 
might be due to the antimuscarinic effects of the antihistamines used.  
The aim of the present study was therefore to assess the effects of the 
relatively selective H1-antagonist dexchlorpheniramine (2 and 4 mg) on 
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performance of healthy female volunteers. The decision to select only female 
subjects was based on results from a number of previous studies suggesting 
that females are more sensitive to effects of H1-antagonists than males 
(Ramaekers and O'Hanlon, 1994; Robbe, 1990; Vermeeren et al., 2002; 
Vuurman et al., 1994). The effects were to be compared to those of the 
muscarinic antagonist scopolamine that was included as a verum. 
To detect potential effects of the dexchlorpheniramine on memory, a 
number of tests were selected that had previously been shown sensitive to 
detect drug induced impairments, and together covered a range of important 
aspects of memory function, such as short-term or working memory, long 
term memory, memory for verbal and visual material, and implicit and 
explicit (declarative) memory (Ramaekers et al., 1992; Riedel et al., 1990; 
Rubensztein et al 2001; Vermeeren et al. 1995; Vuurman et al., 1994).  A word 
learning test and a pattern recognition test were included to assess effects on 
short and long term memory for verbal and visual material, respectively; a 
memory scanning task and a syntactic reasoning task were included to 
assess integrity of working memory functions; and a spatial paired associate 
learning test was included to assess effects on implicit memory and learning. 
A simple reaction time test and a choice reaction test were added to the 
battery for the purpose of measuring effects on response speed without the 
cognitive components of the memory tests. To assess time of peak 
impairment of dexchlorpheniramine two tasks were included that have 
repeatedly been shown to be among the most sensitive tests to assess the 
impairing effects of H1-antagonists; i.e., a critical tracking test, and a divided 
attention test (Burns and Moskowitz, 1980; Hindmarch and Shamsi, 1999; 
Meltzer, 1991; Theunissen et al., 2004; Vermeeren and O'Hanlon, 1998; 
Verster et al., 2003). 
Dexchlorpheniramine was selected as a tool drug, because it is a first 
generation H1-antagonist having a moderately high binding affinity for the 
H1-receptors, but relatively low affinities for muscarinic, alpha-1, alpha-2 
and beta receptors. The affinity for the muscarinic receptor is especially low 
(Kd=3300 for chlorpheniramine) as compared to scopolamine (Kd=0.1) 
(Wiech and Martin, 1982). The half-life of chlorpheniramine is approximately 
28 hours (range 19-43 hours) and maximum plasma concentrations are 
reached at 2.8 hours (range 2-4 hours) after oral doses (Huang et al., 1982; 
Paton and Webster, 1985). Two studies have shown that single oral doses of 
4 mg chlorpheniramine produced significant performance impairment which 
was most pronounced shortly after tmax (Kamei et al., 2003; Witek et al., 
1995). Yet, in a third study performance was significantly impaired only at 
1.5 hours after drug administration (Clarke and Nicholson, 1978). Based on 
these results it was decided to measure the effects of dexchlorpheniramine at 
both times reported for peak impairment i.e. between 1.5 and 2.5 hours and 
between 3.5 and 4.5 hours after administration.  
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Scopolamine 1 mg in oral doses (p.o.) was included as an active 
control because the drug is well known for its impairing effects on learning 
and memory (Bartus et al., 1985). Oral doses of 1 mg or above have been 
reported to impair cognitive functioning (Kennedy et al., 1990; Rammsayer 
et al., 2000). Peak plasma concentrations are reached at approximately 0.8 
hours after oral intake and scopolamine has an average elimination half-life 
of 4.3 hours (Golding et al., 1991). 
 
METHODS 
 
Subjects 
Twenty healthy female volunteers aged between 18 and 45 years were 
recruited as subjects for the study by means of advertisements in local 
newspapers and paid for their participation. Subjects were screened using a 
medical history questionnaire and a physical examination, including a 12-
lead electrocardiogram, blood chemistry and haematology, and urinary tests 
for pregnancy and drugs of abuse (opiates, benzodiazepines, cocaine, 
tricyclic antidepressants and cannabis). Exclusion criteria were pregnancy or 
lactation, a history or presence of any mental or physical disorder; 
gastrointestinal, hepatic, renal, cardiovascular or neurological. Also, drug 
abuse, a body-mass index value outside the limits of 18 and 28 kg/m2, blood 
pressure outside the limits of 100 and 150 Hg systolic and 60 and 90 Hg 
diastolic and drinking more than 20 standard alcoholic units per week or 
more than 5 beverages containing caffeine per day, were regarded as 
exclusion criteria. No drugs or medication except oral contraceptives, aspirin 
and acetaminophen, were allowed to be taken from a week before the first 
test-day until the end of the study. Smoking and use of caffeine was 
prohibited on test-days and the use of alcohol from 24 hours before and 
during each test-day. 
Three volunteers did not complete the study for reasons unrelated to 
treatment. Two of them withdrew before the second treatment session and 
the third subject was excluded for smoking on the first test-day as 
determined by measurement of carbon monoxide in expired air, using a 
Smokerlyzer Micro® (Bedfont Scientific Ltd.). These subjects were replaced. 
Mean ± SD age of the 20 subjects who completed the study was 23.7 ±7.3 
years. Their mean ± SD body mass index was 21.6 ± 3.0 kg/m2. Five subjects 
were smokers, who on average (± SD) smoked 4.6 (± 2.1) cigarettes and no 
more that 10 per day. Eighty percent of the subjects were in college or had a 
similar level of education. The remaining twenty percent had all at least 
finished high school at an average level of education.  
All subjects received written information about the study procedures 
and were able to ask questions. They signed an informed consent form prior 
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to enrolment. The study was approved by the Ethics committee of Maastricht 
University and University Hospital Maastricht and carried out in accordance 
with the World Medical Association Declaration of Helsinki (Edinburgh, 
2000). 
 
Study design and treatments 
The study was conducted according to a double blind, placebo-controlled, 4-
way crossover design. Treatments were single oral doses of 
dexchlorpheniramine 2 mg and 4 mg, scopolamine 1 mg (all immediate 
release formulations) and placebo. Treatments were spaced apart by a 
washout period of at least 7 days.  
 
Procedure 
Subjects were individually trained to perform all psychomotor and memory 
tests within two weeks prior to their first treatment day. On treatment days 
they arrived at the University around 9:00 hours. Between 9:45 and 10:45 
hours a battery of psychometric tests was completed to obtain baseline 
performance scores. At 11:00 hours subjects ingested the study medication. 
Thereafter the test battery was repeated at 12:30 hours and 14:30 hours, i.e. 
between 1.5 and 2.5 hours, and 3.5 and 4.5 hours after ingestion, henceforth 
indicated as t2 and t4. 
The duration of the test battery was approximately one hour and 
consisted of the tasks and assessments in the following sequence: critical 
tracking, divided attention, subjective alertness, syntactic reasoning, 
immediate pattern recognition, memory scanning, simple reaction time, 
choice reaction time, spatial paired associate learning, delayed pattern 
recognition and critical tracking. The t4 test battery included a 30-words 
learning task, that was completed only once per test day to prevent 
interference of the previously learned words that same day. The immediate 
recall part was done following the syntactic reasoning test and delayed recall 
part was done following the spatial paired associated learning test. At 0.5 
hours after drug intake an additional critical tracking task was performed, 
with performance on this test then assessed at hourly intervals after drug 
administration. This allowed better monitoring of the time of peak 
impairment induced by both drugs.  
 
Assessments 
 
Memory performance 
30-Words learning task - The 30-words learning task (Klaassen et al., 2002; 
Rey, 1964; Riedel et al., 1999) assesses short and long term verbal memory. 
Thirty Dutch mono-syllabic meaningful nouns and adjectives are presented 
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for 1000 ms at a rate of 1 per 2 seconds and subjects are required to read 
them aloud. When the presentation ends, subjects are required to verbally 
recall as many words as possible (immediate recall). This procedure is 
repeated three times, with the same words presented in the same sequence. 
After a 45 minutes delay subjects are requested again to recall as many 
words as possible (delayed recall). Finally, subjects are presented a series of 
30 words on a computer screen that include 15 words from the original list 
and 15 comparable but new words. Subjects are asked to indicate as quickly 
as possible whether the presented words are from the original list or not by 
pressing one of two buttons (delayed recognition). Dependent variables 
were the total number of words correctly recalled over the three immediate 
recall trials, the number of correctly recalled words after the delay and 
median reaction time (ms) of correct answers during recognition. Since the 
distribution of reaction times is generally skewed to the right, the median RT 
was selected as dependent variable in all tasks except when indicated 
otherwise. The median is less sensitive to the presence of one sided outliers 
as compared to the mean. 
Pattern recognition task - The pattern recognition task assesses short 
and long term memory for visual information. In this test subjects are 
presented a series of 15 randomly generated black and white block patterns 
of a 6x4 grid, at a rate of 1 pattern per 3 seconds. Subjects are asked to 
memorize the patterns. The same series of patterns is presented three times 
in the same order. Immediately thereafter a series of 30 patterns is presented, 
including 15 patterns from the original set and 15 new patterns. Subjects are 
asked to indicate as quickly as possible whether the presented patterns are 
from the original list or not by pressing one of two buttons. After 
approximately 30 minutes this recognition procedure is repeated. The 
dependent measures are the median reaction time and the number of 
patterns correctly recognized in the immediate and delayed recognition 
tests. 
Memory scanning task - The memory scanning task (Sternberg, 1969) 
measures the time it takes to scan items held in memory as part of working 
memory integrity, separating it from other processes required to respond. 
When subjects judge whether a test symbol is contained in a short 
memorized sequence of symbols, their mean reaction time increases linearly 
with the length of the sequence. The linearity and slope of the function imply 
the existence of an internal serial comparison process whose average rate is 
between 20 and 30 items per second. In this test the subjects are presented 
with a set of 1, 2 or 4 consonants, which they are asked to memorize. 
Hereafter a series of 48 consonants is presented on a computer screen of 
which 24 are targets and 24 are non-targets. The subjects’ task is to indicate 
as fast as possible whether or not the presented letter was one from the 
memory set by pressing one of two buttons. The task consists of 6 blocks of 
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48 stimuli with different memory sets. The order of the blocks is 1, 2, 4, 4, 2 
and 1 letters, respectively. The median reaction time for correct responses is 
recorded and used to calculate individual linear regression lines between 
reaction time and memory set size. The slope of this line is a measure of 
speed of scanning short term memory, whereas the intercept is a measure of 
psychomotor speed. Both slope (ms/letter) and intercept (ms) are outcome 
measures. 
Spatial paired associate learning - Spatial memory and learning is 
assessed by the spatial paired learning task. In this task the subject is 
presented with two highly discriminative pictures flanking a central 
crosshair on a computer screen for 1000 ms. Hereafter, one of the two 
original stimuli (target) or a third (new picture) is presented in the centre of 
the screen and subjects were asked to indicate the original location (left or 
right) of the stimulus by pressing a corresponding button as fast as possible. 
Targets appear either left or right with a 50% probability. In total there are 32 
different targets of which 16 targets are presented only once and 16 targets 
are presented 8 times at the same location with random intervals over the 
test. Reaction time following repeated presentation of a target is 
hypothesized to diminish during the test as a result of implicit learning of 
the location associated with each target picture. Therefore, the median 
reaction time following the repeated items should be lower than that 
following the non-repeated items. The dependent variables are the median 
reaction times (ms) for repeated and non-repeated targets. 
Syntactic reasoning task - The syntactic reasoning task (Baddeley, 
1968) assesses speed and accuracy of logical reasoning processes in working 
memory (Repovs and Baddeley, 2006). The task consists of 32 short sentences 
each describing the order of the letters ‘A’ and ‘B’ and belonged to one of 
four categories: active positive, active negative, passive positive and passive 
negative (e.g. A follows B, A does not follow B, A is followed by B, A is not 
followed by B, respectively). The sentence is immediately followed by a 
letter-pair (‘A-B’ or ‘B-A’) in the same or opposite order as in the sentence. 
The required response is to indicate as quickly as possible whether or not the 
letters are in the same order as in the sentence. Dependent variables are the 
number of correct responses and the mean reaction time (ms). The mean 
reaction time was chosen, because the categories differed to a large extend in 
terms of difficulty and the median is very sensitive to fluctuations in 
performance on the different categories. 
 
Psychomotor performance and attention 
Simple and choice reaction time tasks - The simple and choice reaction time 
tasks assess the speed of perceptual-motor processing without the cognitive 
components of the other tests. The simple reaction time test consists of a 
white square that appears on a computer screen and turns red after a 
CHAPTER 2 
 65 
variable interval. The subject has to press a single button as fast as possible. 
The choice reaction time task is similar to the simple reaction time task, with 
the exception that two squares are presented and the subject should press 
one of two buttons corresponding to the left or right square turning red. Both 
tasks consist of 48 trials and the dependent measure is the median reaction 
time (ms). 
Critical tracking task - The critical tracking task measures the ability to 
control an unstable triangle, which is displayed on a horizontal axis on a 
computer screen, using a joystick (Jex et al., 1966). An error signal causes the 
triangle to become increasingly unstable and therefore it tends to diverge 
from the centre of the axis. The subject has to make compensatory 
movements to null the error in order to keep the triangle in the middle. As 
the correction frequency of the cursor deviations increases as a stochastic 
function of time, the subject is required to make compensatory movements 
with an increasingly higher frequency to the limit of her ability, whereupon 
control is lost. This frequency decreases under the influence of sedating 
drugs. The dependent measure is the average frequency at which control is 
lost of five trials after removing the lowest and highest score. This is called 
the ‘critical frequency’ or ‘lambdac’ (rad/s).  
Divided attention task - The divided attention task (Moskowitz, 1973) 
assesses the ability to perform two tasks simultaneously and evaluates 
cognitive processing resources. The primary task is similar to the critical 
tracking task described above, with the exception that the level of difficulty 
is held constant at 50% of that, which is just controllable by the subject. 
Tracking error is measured by the absolute distance (in mm) between the 
cursors position and the centre. The secondary task involves the monitoring 
of 24 digits (0-9) that are arranged around the display’s periphery. The digits 
change asynchronously every 5 seconds. The requirement is to respond as 
rapidly as possible by lifting her foot from a pedal anytime the digit “2” 
appears. Because relative long reaction times are recorded, outliers are 
expected to be present at both ends of the distribution. Therefore, average 
reaction time to targets is recorded as the response measure in this task. 
Performance scores in the subtasks were combined to overall performance 
scores before analysis, because performance in the two subtasks is related 
within subjects and tests. First, average reaction times and tracking error of 
each test were transformed to z-scores using data from all subjects, test days 
and test sessions. Second, the standardized scores of the subtasks were 
summed to yield an overall performance score for each subject, test day and 
test session. Overall scores were used for further analysis.  
 
Subjective alertness 
Subjective alertness was assessed using a mood rating scale consisting of 16 
visual analogue scales (i.e. 100 mm lines) each representing a continuum 
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between two extremes of a certain mood (e.g. alert and drowsy; (Bond and 
Lader, 1974)). Subjects are required to indicate how they feel by placing a 
vertical line on the scale corresponding to their mood at that moment. 
Together these scales provide three factor-analytically defined summary 
scores- “alertness”, “contentedness” and “calmness”, of which the factor 
‘alertness’ was of primary interest. 
 
Statistical analysis 
After unblinding treatments turned out to be not completely balanced over 
periods, due to errors in the ordering of replacement medication. Since 
baseline scores of some tasks showed significant Period effects in spite of 
prior training, assessments at t2 and t4 were analysed as changes from 
baseline at the same day. This is a valid method of analysing the data (Van 
Breukelen, 2006). Changes from baseline were screened for normality of the 
distributions. No significant deviations were found.  
Dependent variables expressed as differences from baseline were 
analysed in repeated measures multivariate analysis of variance, according 
to a 2 (Time) x 4 (Treatment) factorial model to test the main effect of 
Treatment and the interaction of Treatment and Time. The data from the 
critical tracking task were analysed according to a 5 (Time) x 4 (Treatment) 
factorial model, but otherwise in a similar fashion. Regardless of the 
outcome of the overall F-tests, three planned univariate comparisons were 
carried out between the treatments and placebo for t2 and t4 separately. This 
is a legitimate procedure since the comparisons are suggested by the 
theoretical basis of the experiment (Winer, 1971). All data were analysed 
using SPSS for Windows (version 12.0.1).  
 
RESULTS 
 
Memory 
A summary of mean (±SEM) performance scores of tasks assessing memory 
performance is presented in table 1. 
No significant main effects of Treatment or interactions between 
Treatment and Time were found in any memory test except for the 
simplified spatial paired associate learning task. Analysis showed that there 
was a main effect of Treatment on speed of responses to repeated stimuli. 
(F3,17 = 5.5, p< 0.008). Longer reaction times as compared to placebo were 
observed after administration of dexchlorpheniramine 2 mg at t2 (F1,19= 
14.5, p< 0.001), and after administration of scopolamine 1 mg at t2 (F1,19= 
12.7, p< 0.002) and t4 (F1,19= 13.6, p< 0.002). 
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Psychomotor performance and attention 
A summary of mean (±SEM) performance scores of tasks assessing 
psychomotor functioning and attention is presented in table 2. 
Analysis of variance of simple reaction time showed a significant 
main effect of Treatment and a significant interaction between Treatment 
and Time (F3,17= 5.2, p< 0.010, F3,17= 4.9, p< 0.012, respectively). Drug-
placebo comparisons showed that dexchlorpheniramine 2 mg, 
dexchlorpheniramine 4 mg and scopolamine 1 mg all significantly increased 
reaction times at t2 (F1,19= 5.3, p< 0.032; F1,19= 8.4, p< 0.009; F1,19= 15.5, p< 
0.001, respectively). These differences were no longer significant at t4. 
Similar results were obtained from the choice reaction time task. The 
main effect of Treatment on response speed was nearly significant (F3,17= 
2.7, p< 0.078) and drug-placebo comparisons at t2 showed significantly 
longer reaction times after administration of dexchlorpheniramine 2 mg 
(F1,19= 6.3, p< 0.021), dexchlorpheniramine 4 mg (F1,19= .9, p< 0.025) and 
scopolamine 1 mg (F1,19= 10.4, p< 0.004). 
A main effect of Treatment was also found on critical tracking 
performance at (F3,17= 3.3, p< 0.044). Tracking was impaired at both 1.5 
hours as 2.5 hours following the administration of dexchlorpheniramine 2 
mg (F1,19= 7.6, p< 0.012, F1,19= 5.5, p< 0.030), dexchlorpheniramine 4 mg 
(F1,19= 14.7, p< 0.001, F1,19= 7.8, p< 0.012) and scopolamine 1 mg (F1,19= 
13.7, p< 0.001, F1,19= 12.3, p< 0.002). The effects were no longer significant at 
3.5 and 4.5 hours after administration (figure 1).  
Due to a technical error, reaction times in the visual search task of 
the divided attention test were not recorded for one subject during baseline 
measurements before administration of dexchlorpheniramine 4 mg. Her data 
were excluded from all analyses of performance in this task.  
A significant main effect of Treatment was found on the overall 
performance measure (F3,16= 7.7, p< 0.002). Dexchlorpheniramine 4 mg 
produced a significant impairment at t2 (F1,18= 9.9, p< 0.006) and at t4 
(F1,18= 7.4, p< 0.014). Similarly, scopolamine 1 mg impaired performance at 
both times of assessment (F1,19= 19.9, p< 0.001 and F1,19= 15.6, p< 0.001). 
 
Subjective alertness 
There were significant main effects of Treatment and a significant interaction 
between Treatment and Time on subjective ratings of alertness (F3,17= 8.6, 
p< 0.001 and F3,17= 3.3, p< 0.045, respectively). Table 2 shows that subjects 
judged themselves to be less alert at t2 after intake of dexchlorpheniramine 2 
mg (F1,19= 5.6, p< 0.029), and at t2 and t4 after intake of 
dexchlorpheniramine 4 mg (F1,19= 9.5, p< 0.006, F1,19= 5.0, p< 0.037) and 
scopolamine 1 mg (F1,19= 33.0, p< 0.001, F1,19= 8.8, p<0.008). 
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Figure 1. Mean changes (±SEM) from baseline of the critical frequency in the critical tracking task 
at 0.5, 1.5, 2.5, 3.5 and 4.5 hours after administration of placebo (PLA), dexchlorpheniramine 2 mg 
(D2), dexchlorpheniramine 4 mg (D4) and scopolamine 1 mg (S1). Significant (p < 0.05) a-priori 
drug-placebo contrasts at each time are indicated as *. 
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Table 1. Summary of data obtained from tests assessing memory performance after administration of placebo (PLA) dexchlorpheniramine 2 mg (D2), 
dexchlorpheniramine 4 mg (D4), and scopolamine 1 mg (S1). Significant (p < 0.05) a-priori drug-placebo contrasts are indicated as *. 
 Overall analyses  
of changes from baseline 
Mean (± SEM) scores  
 
 Main Effect  
of  Treatment  
Interaction of  
Treatment X Time 
Test 
Session 
Treatment    
 p = p =  PLA D2 D4 S1 
Syntactic reasoning task        
number correct (#) 0.620 0.253 
 
Baseline 28.4 ± 1.0 28.1 ± 1.0 28.2 ± 1.0 29.2 ± 1.1 
   t2 28.4 ± 1.0 27.8 ± 1.0 28.4 ± 1.1 28.3 ± 1.0 
   t4 29.2 ± 1.0 29.0 ± 1.0 28.9 ± 0.0 29.3 ± 1.0 
Mean reaction time (ms) 0.487 0.500 Baseline 1651 ± 169 1591 ± 163 1652 ± 118 1614 ± 121 
   t2 1594 ± 138 1546 ± 155 1654 ± 124 1544 ± 105 
   t4 1582 ± 141 1464 ± 139 1629 ± 115 1556 ± 120 
Spatial paired associate learning task        
Median reaction time (ms) 0.008 0.176 Baseline 509 ± 15 495 ± 15 503 ± 18 481 ± 13 
repeated items   t2 501 ± 16 520 ± 20* 512 ± 17 504 ± 16* 
   t4 479 ± 12 485 ± 16 488 ± 17 497 ± 17* 
Median reaction time (ms) 0.097 0.432 Baseline 521 ± 22 501 ± 16 494 ± 16 487 ± 15 
non-repeated items    t2 504 ± 19 502 ± 20 514 ± 22 503 ± 14 
   t4 472 ± 15 489 ± 19 481 ± 16 495 ± 18 
Word learning task       
Immediate recall (# words correct)   t4 45.3 ± 1.8 42.9 ± 1.9 46.9 ± 1.7 44.7 ± 1.5 
Delayed recall (# words correct)   t4 15.1 ± 1.0 14.6 ± 0.8 15.6 ± 0.9 14.6 ± 0.8 
Recognition (ms)   t4 647 ± 20 644 ± 17 652 ± 17 643 ± 13 
  
 
Pattern recognition task        
Immediate recognition        
Patterns correct (#) 0.075 0.767 Baseline 26.5 ± 0.5 26.9 ± 0.5 26.7 ± 0.5 27.4 ± 0.5 
   t2 26.6 ± 0.7 26.5 ± 0.7 25.5 ± 0.8 25.2 ± 1.0 
   t4 27.1 ± 0.5 27.3 ± 0.5 26.8 ± 0.6 26.7 ± 0.5 
Median reaction time (ms) 0.056 0.663 Baseline 972 ± 59 904 ± 51 928 ± 70 945 ± 46 
   t2 916 ± 42 905 ± 46 936 ± 57 871 ± 43 
   t4 880 ± 50 858 ± 60 886 ± 68 891 ± 48 
Delayed recognition        
Patterns correct (#) 0.760 0.308 Baseline 25.8 ± 0.5 25.7 ± 0.9 25.5 ± 0.8 25.9 ± 0.6 
   t2 24.8 ± 0.7 24.5 ± 0.8 23.8 ± 0.8 23.3 ± 0.9 
   t4 24.5 ± 0.7 24.4 ± 0.9 24.3± 0.7 24.2 ± 0.9 
Median reaction time (ms) 0.135 0.370 Baseline 1033 ± 74 995 ± 65 970 ± 74 961 ± 47 
   t2 1004 ± 63 1039 ± 78 1022 ± 70 1022 ± 82 
   t4 986 ± 59 965 ± 67 993 ± 63 978 ± 64 
Sternberg memory scanning task     
Slope (ms/letter) 0.880 0.337 Baseline 44 ± 4 49 ± 3 52 ± 5 47 ± 4 
   t2 47 ± 3 50 ± 4 56 ± 5 53 ± 5 
   t4 44 ± 3 50 ± 4 49 ± 5 50 ± 4 
Intercept (ms) 0.379 0.340 Baseline 345 ± 11 334 ± 9 331 ± 10 332 ± 11 
   t2 338 ± 9 338 ± 1 336 ± 12 338 ± 8 
   t4 333 ± 10 317 ± 9 328 ± 10 329 ± 9 
  
Table 2. Summary of data obtained from tests assessing psychomotor performance and subjective alertness after administration of placebo (PLA) 
dexchlorpheniramine 2 mg (D2), dexchlorpheniramine 4 mg (D4), and scopolamine 1 mg (S1). Significant ( p < 0.05) a-priori drug-placebo contrasts are indicated 
as *. 
 
Overall analyses of  
changes from baseline 
Mean (±SEM) scores 
 Main Effect  
of  
Treatment  
Interaction of  
Treatment X Time 
Test 
Session 
 Treatment    
 p = p =  PLA D2 D4 S1 
Simple reaction time task        
Median reaction time 
(ms) 
0.010 0.012 
Baseline 246 ± 8 249 ± 7 258 ± 12 246 ± 7 
   t2 258 ± 10 283 ± 11* 294 ± 11* 288 ± 12* 
   t4 257 ± 11 261 ± 10 257 ± 10 271 ± 11 
Choice reaction time task     
Median reaction time 
(ms) 
0.078 0.174 
Baseline 308 ± 9 312 ± 7 314 ± 10 309 ± 8 
   t2 322 ±10 346 ± 11* 355 ± 12* 356 ± 14* 
   t4 312 ± 8 317  ± 10 325 ± 10 333 ± 12 
Divided attention task        
0.002 0.400 Baseline -0.31 ± 0.30 -0.33 ± 0.31 -0.54 ± 0.30 -0.63 ± 0.25 Overall performance (z-
score)   t2 -0.31 ± 0.31 0.25 ± 0.28 0.60 ± 0.32* 0.97 ± 0.40* 
   t4 -0.43 ± 0.26 -0.02 ± 0.33 0.32 ± 0.38* 0.30 ± 0.32* 
        
Subjective alertness scale  0.001 0.045 Baseline 25.6 ± 3.1 27.4 ± 3.8 26.8 ± 4.0 28.1 ± 3.5 
   t2 32.0 ± 4.3 41.2 ± 3.4* 44.1 ± 4.8* 53.3 ± 4.0* 
   t4 31.6 ± 3.5 37.9 ± 4.9 41.0 ± 4.5* 41.3 ± 4.4* 
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DISCUSSION 
 
This study assessed the effects of the H1-antagonist dexchlorpheniramine on 
memory and psychomotor performance in humans. Based on results from 
animal studies it was hypothesized that the drug would impair performance 
in humans in one or more memory tests, in addition to its well known effect 
on psychomotor performance. Results failed to confirm this hypothesis 
however - no significant effects of dexchlorpheniramine were found on 
memory. At the same time dexchlorpheniramine did impair performance in 
psychomotor tasks in both doses, indicating that the drug reached sufficient 
concentrations in the central nervous system to have behavioural effects. 
Significant impairing effects were found on simple and choice reaction time, 
critical tracking and divided attention. In addition subjects reported 
significant decreases in subjective feelings of alertness after 
dexchlorpheniramine. These results are in line with findings from several 
studies showing that centrally active antihistamines produce sedation and 
impair psychomotor performance (Hindmarch and Shamsi, 1999; White and 
Rumbold, 1988; Witek et al., 1995).  
There was only one parameter in a memory related task that was 
impaired by dexchlorpheniramine – reaction time to repeated targets in the 
spatial paired associate learning task. This response was significantly slowed 
at t2 by dexchlorpheniramine 2 mg and scopolamine in comparison to 
placebo. Since the effects were only found for repeated and not for novel 
items it could be argued that it reflects an effect on implicit learning. Implicit 
learning in this test was hypothesized to decrease reaction times to repeated 
items relative to non-repeated items. However, comparison of reaction times 
to repeated and non-repeated items within the baseline and placebo 
conditions did not reveal any difference. This does not support the 
hypothesis that implicit learning took place. Consequently, it is difficult to 
conclude that learning was impaired by the drugs. Alternatively, the effects 
may be related to speed of psychomotor processing, similar to that found in 
the simple and choice reaction time tasks.  
Surprisingly, the active control scopolamine also failed to impair 
memory performance in the present study, which is in contrast with most 
other studies using similar or slightly higher oral doses. For example, Parrott 
et al. (1986) found that 1.2 mg scopolamine (p.o.) impaired performance on 
memory storage. Similarly, Rammsayer et al. (2000) found that 1 mg 
scopolamine (p.o.) impaired recall performance on a word list learning task.  
Performance on the Word Learning Task and Memory Scanning Task has 
also been shown to be affected by scopolamine (Ebert et al., 1998; Riedel et 
al., 1995). Both studies showed that 0.6 mg (s.c.) and 0.5 mg scopolamine 
(s.c.), respectively decreased the number of recalled words and increased 
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memory search time. Considering this it might be argued that the memory 
tests or procedures in the present study were not sufficiently sensitive to 
detect impairing effects of drugs on memory. We do not believe this was the 
case, however. Most importantly, all the memory tests have shown to be 
sensitive to the effects of drugs in previous studies  (Riedel et al., 1995; 
Riedel et al., 1999; Rubinsztein et al., 2001; Schmitt et al., 2000; Vermeeren et 
al., 1995). In addition, there are pharmacokinetic factors related to the oral 
dose of scopolamine that could explain its lack of effects on memory in the 
present study and are mentioned below.  
First of all, the second test battery after drug administration might 
have been too late to detect behavioural impairment of scopolamine. This 
could have resulted in a failure of this drug to show significant effects on the 
Word Learning Task, which was only administered at t4. Scopolamine has a 
relatively short half-life (t1/2 = 4.3 hours) and it rapidly reaches peak plasma 
concentrations after oral administration (tmax = 0.8 hours), indicating that it 
has a rapid onset and fast decline of action (Golding et al., 1991). Results 
from the critical tracking task support that the effect of scopolamine at 
peaked between 1.5 and 2.5 hours and had rapidly returned to baseline at 3.5 
hours after drug intake. It can therefore be assumed that only very few 
effects could have been found 4 hours after its intake. Furthermore, it has 
been reported that compared to subcutaneous, intravenous and 
intramuscular administration oral doses of scopolamine result in relatively 
low and variable blood plasma concentrations, which are associated with 
small and relatively inconsistent effects found on behaviour (Kennedy et al., 
1990; Renner et al., 2005; Wesnes, 1988). In line with this, the data show that 
average performance generally decreases on memory related tasks after 
administration of scopolamine as compared to placebo. The effects were 
probably too weak and variable to be statistically significant. In this respect, 
the selection of an oral dose of scopolamine instead of using a more intrusive 
method seems to have been an unfortunate choice.  
Post-hoc inspection of average effect sizes (Rosnow & Rosenthal, 
2000) (baseline versus t2) showed that scopolamine’s effects on memory 
were almost twice as strong as those of dexchlorpheniramine 4 mg (ES 0.41 
vs. 0.22, respectively). Effects of both drugs on psychomotor performance 
were more pronounced than those on memory, but the difference between 
the drugs was much smaller (ES 0.58 and 0.47, respectively). Although this 
may indicate that the memory tests are not as sensitive as the psychomotor 
tests, it seems consistent with the notion that scopolamine and 
dexchlorpheniramine have differential effects on memory and psychomotor 
performance. So assuming that the tests used were sufficiently sensitive to 
detect potential effects of dexchlorpheniramine on memory, we conclude 
that the blockade of central H1 receptors does not produce clinically relevant 
effects on memory in humans.  
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This conclusion was recently supported by results from another 
study addressing the same issue. Turner et al. (2006) recently published a 
study designed with comparable objectives as the present study. They 
assessed the effects of multiple doses of diphenhydramine and lorazepam on 
memory and psychomotor performance, and found impairing effects of both 
drugs in tasks without a memory component, whereas lorazepam, but not 
diphenhydramine, impaired performance in tasks with a memory 
component. Similarly, Curran et al (1998) conducted a study to dissociate the 
sedative and amnestic effects of lorazepam (2 mg p.o.), and therefore 
compared the effects with those of scopolamine (0.6 mg s.c.) and 
diphenhydramine (25, 50 mg p.o.). All drugs reduced levels of arousal, while 
only scopolamine and lorazepam caused impairments of memory. The doses 
of diphenhydramine were relatively low, however, as compared to those of 
lorazepam and scopolamine. Taken together, these studies indicate that 
antihistamines impair psychomotor performance and reduce levels of 
arousal but may not be able to disrupt memory functioning. 
In summary, oral doses of 2 mg and 4 mg dexchlorpheniramine and 
of 1 mg scopolamine produced significant cognitive impairments compared 
to placebo shown by the effects on performance on psychomotor and 
attention related tasks. Clear effects on most memory related tasks were 
absent in this study. Supported by results from other studies it can be 
concluded that blockade of histaminergic function using an H1 antagonist 
does not impair memory functions in man, as opposed to the findings in 
animals. This suggests that histamine does not play an obvious role in 
memory and learning in humans. 
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CHAPTER 3 
 
MEMORY IN HUMANS IS UNAFFECTED BY 
CENTRAL H1-ANTAGONISM WHILE 
OBJECTIVELY AND SUBJECTIVELY 
MEASURED SEDATION IS INCREASED 
Van Ruitenbeek, P., Vermeeren, A., Riedel, W. J. (submitted). Memory in 
humans is unaffected by central H1 antagonism while objectively and 
subjectively measured sedation is increased 
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INTRODUCTION 
 
Animal studies indicate an important role for histamine in memory 
functioning. Decreasing histaminergic activity leads in most studies to 
impaired performance on tasks assessing memory. For example, H1 knock-
out animals were impaired on maze learning and showed a decrease in long-
term potentiation (Dai, et al., 2007). Knock-out animals for the synthesizing 
enzyme histidine decarboxylase showed impaired performance on maze 
tasks, although no effects were found on object recognition (Acevedo, Ohtsu, 
Benice, Rizk-Jackson, & Raber, 2006). On the other hand, increasing 
histaminergic activity leads to improved performance on tasks assessing 
memory functioning. For example, administration of histamine improves 
retrieval of information (Zarrindast, Parsaei, & Ahmadi, 2008). Therefore, 
there especially is a large interest in H3-antagonists which increase histamine 
levels and have shown to be able to reverse impaired memory performance 
in animals (Bacciottini, Passani, Mannaioni, & Blandina, 2001).  
The role of histamine in human memory, however, is not clear. 
Increasing levels of histamine in man using H3-antagonists is currently 
hardly possible as most compounds are unsuitable to be used in man. 
However, histaminergic activity can be lowered using H1-antagonists. 
Studies to determine the behavioural effects of H1-antagonists on cognitive 
performance have been conducted many times but mostly in the context of 
driving safety and not memory. These studies have therefore not assessed 
memory performance after the administration of an antihistamine in much 
detail. Results from studies that did include memory tests are somewhat 
conflicting. Whereas the majority found no significant effects of sedative H1-
antagonists on memory performance (De Brabander, 1990; Patat, et al., 1994; 
Theunissen, Vermeeren, van Oers, van Maris, & Ramaekers, 2004; Verster, et 
al., 2003; Vuurman, Rikken, Muntjewerff, de Halleux, & Ramaekers, 2004), a 
few studies (Hindmarch & Shamsi, 2001; Vuurman, Uiterwijk, Rosenzweig, 
& O'Hanlon, 1994; Volkerts, Van Willigenburg, Van Laar, & Maes, 1992) 
have reported impaired performance on measures of memory function. Yet, 
it is also possible that these effects are due to the sedative effects of 
antihistamines. 
Three studies attempted to dissociate the effects of antihistamines on 
memory and sedation in humans, but none of them found effects on memory 
(Curran, Pooviboonsuk, Dalton, & Lader, 1998; Turner, Handford, & 
Nicholson, 2006; Van Ruitenbeek, Vermeeren, & Riedel, 2008). So, contrary to 
findings in animal studies, results from studies in humans do not support a 
specific role of histamine in human memory functioning. It is possible, 
however, that the failure to find any effects on memory in these studies was 
related to methodological issues. 
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First, Curran et al. (1998) studied the effects of scopolamine (0.6 mg 
sc), lorazepam (2 mg oral) and diphenhydramine (25 and 50 mg oral) on 
memory and measures of sedation. As expected, they showed that these 
treatments all had some effects on measures of sedation and psychomotor 
performance. However, diphenhydramine only affected two of the six 
psychomotor performance measures that were used, while lorazepam and 
scopolamine all had an effect on performance on at least five tasks. 
Compared with the relative high dosages of scopolamine and lorazepam the 
effects of diphenhydramine may not have been pronounced enough to be 
measured. This is supported by studies that reported a larger increase in 
weaving in car driving after lorazepam 2 mg administration (increase of 
approximately 18 cm) (O'Hanlon, Vermeeren, Uiterwijk, van Veggel, & 
Swijgman, 1995)  as compared with diphenhydramine 50 mg (increase of 
approximately 4 cm) (Vuurman, et al., 2004). 
Second, Turner et al. (2006) have measured the effects of lorazepam 
(0.5 and 1.5 mg oral) and diphenhydramine (50, 75 and 100 mg oral) on tasks 
with and without a memory component and concluded that 
diphenhydramine affected only the performance on tasks without a memory 
component. However, to measure the effects on memory performance they 
used a word learning task, but presented the words before drug intake so the 
effects on encoding could not be measured. 
Finally, Van Ruitenbeek et al. (2008) have studied the effects of 
dexchlorpheniramine (2 and 4 mg) on several measures of cognitive 
performance and compared these with the effects of scopolamine. 
Dexchlorpheniramine did not have any effect on memory performance. 
However, they also did not find an effect of scopolamine as the active control 
on their most sensitive test of memory performance. Their main task 
assessing memory was administered 4 hours after drug intake, which is most 
likely too late to pick up any effects. It can therefore be questioned whether 
the assessment was able to pick up the effects on memory. 
Taken together the failure to find effects of histamine blockade on 
memory in these studies may have been due to the relatively low doses of 
antihistamines used and the time between drug intake and learning and 
memory testing. The present study was therefore designed to assess the 
effects of behaviourally effective dose of the selective H1-antagonist 
dexchlorpheniramine (4 mg) on several measures of memory during time of 
peak impairment, i.e. between 1.5 and 2.5 hours after oral administration as 
established in a previous study (Van Ruitenbeek, et al., 2008). The 
benzodiazepine lorazepam 1 mg was included as an active control to 
demonstrate sensitivity of the tests and procedures. This drug-dose has been 
shown to impair memory performance in several studies (Bishop, 1996; 
Curran, et al., 1998; Hanks, O'Neill, Simpson, & Wesnes, 1995; Mintzer & 
Griffiths, 2003; Turner, et al., 2006). 
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Drug effects on memory were assessed measuring performance and 
brain activity (Event Related Potentials i.e. P300) during a 30-Words 
Learning Task (WLT-30) and an n-back task. These memory tests were 
selected because previous studies show them to be sensitive to drug effects 
on memory. Performance on the WLT has been found highly sensitive to the 
effects of know memory reducing drugs like scopolamine (Riedel, 1995) and 
lorazepam (File & Lister, 1982). Speed and accuracy of performance on the n-
back task have previously shown sensitive to the effects of the antihistamine 
diphenhydramine (50 mg oral) (Gevins, Smith, & McEvoy, 2002). 
Brain activity was measured using EEG. The P300 was measured 
during encoding in the WLT and during performance on the n-back task. It 
has been found that the amplitude of the P300 component measured during 
encoding is larger for words that are later recalled than for words that are 
not recalled (Friedman & Johnson, 2000; Otten & Donchin, 2000) and has 
been shown to decrease with an increased memory load in the n-back task 
(Watter, Geffen, & Geffen, 2001). Drug effects on memory are therefore 
expected to decrease the P3 amplitude during encoding in the WLT and 
interact with memory load in the n-back task. 
Finally, the EEG frequency spectrum was measured during the 
encoding phase of the WLT. The spectrum can be divided into delta (1-4 Hz), 
theta (4-8 Hz), alpha (8-12 Hz) and beta (12-30 Hz) frequency bands. 
Sedation is characterized by a decrease in beta power and an increase in 
theta and alpha power (Galliaud, et al., 2008) and, in case of more severe 
sedation also delta power (Borbely, 1982; Griffiths, Preece, & Green, 1991). 
The antihistamine induces mild sedation and it is therefore hypothesized 
that it will decrease the power of the beta frequency band and increase theta 
(Duschek, Meinhardt, & Schandry, 2006) and alpha (Sannita, Crimi, Riela, 
Rosadini, & Brusasco, 1996) frequency band power. Benzodiazepines and 
antihistamines have been shown to differentially affect the alpha and beta 
frequency bands. Benzodiazepines are able decrease the alpha frequency 
band (Ebert, Oertel, & Kirch, 2000) and increase the beta frequency band 
(Greenblatt, et al., 2000; Saletu, Grunberger, & Sieghart, 1986). Therefore, it is 
hypothesized that lorazepam will increase the beta and decrease the alpha 
frequency bands. As a subjective measure of sedation the Mood Scale 
developed by Bond and Lader (1974) will be used and it is expected that 
alertness will decrease after the administration of both treatments. 
 
METHODS 
 
Subjects 
Eighteen healthy right handed subjects (nine male) between 18 and 45 years 
(mean ± SE: 24.2 ± 1.7 years) were recruited by means of advertisements in 
local newspapers and were paid for their participation. Subject’s health was 
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screened using a medical history questionnaire and a physical examination, 
including a 12-lead electrocardiogram, blood chemistry and haematology, 
and urinary tests for pregnancy and drugs of abuse (amphetamine, 
benzodiazepine, cocaine, opiates, cannabis and methamphetamine). 
Exclusion criteria were a significant history or presence of any mental or 
physical disorder; gastrointestinal, hepatic, renal, cardiovascular or 
neurological. Also, drug abuse, a body-mass index outside the limits of 18 
and 28 kg/m2, blood pressure outside the limits of 100 and 150 Hg systolic 
and 60 and 90 Hg diastolic and drinking more than 20 standard alcoholic 
consumptions per week or 5 beverages containing caffeine per day were 
regarded as exclusion criteria. For women, pregnancy and lactation were 
also regarded as exclusion criteria. No drugs or medication, except oral 
contraceptives, aspirin and acetaminophen, were allowed to be taken from a 
week before the first test-day until the end of the study. Smoking and the use 
of caffeine were prohibited on test-days and the use of alcohol from 24 hours 
before and during each test-day. Subjects were allowed to have breakfast at 
home before 7:30am, i.e. at least 3 hours before drug intake. 
All subjects received written information about the study procedures 
and were given the opportunity to ask questions. They signed an informed 
consent form prior to enrolment. The study was approved by the Ethics 
committee of Maastricht University and University Hospital Maastricht and 
carried out in accordance with the World Medical Association Declaration of 
Helsinki and its amendments (Edinburgh, 2000). 
 
Study design and treatments 
The study was conducted according to a double blind, placebo-controlled, 3-
way crossover design. Treatments were single oral doses of 
dexchlorpheniramine 4 mg and lorazepam 1 mg (all immediate release 
formulations) and placebo and were spaced apart by a washout period of at 
least 4 days. The order of treatment was counterbalanced across subjects. 
 
Procedure 
Subjects were individually trained to perform all tasks on two separate 
occasions within two weeks prior to their first treatment day. On treatment 
days subjects arrived at the University at 9:00am. Between 9:00am and 
9:30am the inclusion and exclusion criteria were checked. At 10:30am, the 
study medication was ingested and the tests were performed between 
12:00am and 1:00pm. The battery consisted of the WLT-30, N-back task and 
subjective evaluations of drowsiness/alertness. 
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Behavioural assessments 
 
30-Words Learning Task  
The WLT-30 is a verbal memory test for the assessment of immediate and 
delayed free recall, and recognition performance (Klaassen, Riedel, Deutz, & 
Van Praag, 2002; Rey, 1964; Riedel, Klaassen, Deutz, van Someren, & van 
Praag, 1999). Thirty monosyllabic nouns and adjectives were presented for 
1000 ms at a rate of 1 per 2 seconds and subjects were instructed to memorize 
them. When the presentation ends, subjects were required to verbally recall 
as many words as possible (immediate recall). This procedure was repeated 
three times, with the same words presented in the same sequence.  
 After a 45 minutes delay subjects were requested again to recall as 
many words as possible (delayed recall). Finally, subjects were presented a 
series of 60 words on a computer screen that included 30 words from the 
original list and 30 comparable but new words. Subjects were asked to 
indicate as quickly as possible whether the presented words are from the 
original list or not by pressing one of two buttons (delayed recognition). 
Dependent variables were the number of words correctly recalled 
on the three immediate recall trials, the number of correctly recalled words 
after the delay, the number of correctly recognized words and their average 
reaction time and the relative recall. The relative recall indicates how many 
of the initially remembered words are recalled after the delay. The relative 
recall is defined as the number of words recalled in the third trial of the 
immediate recall minus the number of words recalled in the delayed recall, 
which is divided by the number of words recalled in de third trial ((IR3-
DR)/IR3). In addition, during the word learning phase EEG was recorded as 
a measure of sedation and the P300 amplitude was measured as an 
indication of word encoding. 
 
N-back Task 
The N-back Task (Veltman, Rombouts, & Dolan, 2003) was used to assess 
working memory performance. In this task subjects were required to 
monitor a series of letters presented in the centre of a computer screen, and 
to respond whenever a letter was presented that is the same as the one 
presented one, two or three trials previously (i.e. 1-back, 2-back and 3-back, 
respectively). In the fourth (control) condition subjects had to press a button 
as fast as possible whenever they detected a pre-specified letter (e.g. X; 0-
back). Letters were presented for 1000 ms or until the subjects responded 
and at a rate of 1 per 2 seconds.  
In this study subjects completed four blocks consisting of 0-, 1-, 2-, 
or 3-back trials, each block was repeated three times in pseudorandom order. 
Within each block 21 stimuli were presented, including 3 or 4 targets, 
totalling 11 targets per n-back level. Number and speed of correct responses 
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were averaged and were the dependent variables. In addition, the P300 
amplitude was measured and is an indicator of processing capacity related 
to comparing stimuli (Watter, et al., 2001) 
 
Subjective alertness 
Subjective alertness is assessed using a series of 16 visual analogue scales of 
100 mm. These provide three factors which are analytically defined 
summary scores for ‘alertness’, ‘contentedness’, and ‘calmness’ (Bond & 
Lader, 1974) of which alertness was of main interest. 
 
EEG recordings 
During performance on the WLT-30 and N-Back Task EEG activity was 
recorded by means of an electrocap from an array of 32 electrodes from the 
standard 10-20 system (Jasper, 1957). All electrodes were filled with 
electrode-gel and were referenced to the mastoid electrodes both left and 
right. The FPz electrode was used as ground electrode. Horizontal EOG was 
recorded using electrodes attached to the outer canthi of the eyes and 
vertical EOG was recorded from electrodes attached above and below the 
left or right eye and in line with the pupil when the subject looks straight 
ahead. 
All electrode impedances were kept under below 5 kΩ. Signals were 
amplified using Neuroscan Synamps amplifiers and collected using 
neuroscan software. All signals were sampled at a 1000 Hz and filtered 
online using a 100 Hz low-pass filter and a 0.1 Hz high-pass filter. 
 
Signal analysis 
Continuous signals obtained during the performance on the WLT-30 were 
epoched in 1100 ms sweeps starting 100 ms before stimulus presentation. 
EEG was corrected for vertical and horizontal eye movements according to a 
procedure by Semlitisch et al. (1986). The interval between sweep onset and 
stimulus served as baseline. EEG and EOG epochs were filtered off-line 
using a 1.0 Hz high-pass filter and a 3.6 Hz low-pass filter for the WLT-30 
and a 10.0 Hz low-pass filter for the N-Back Task. Sweeps containing 
artefacts exceeding +75 or -75 µV were rejected. 
For both the N-Back task and theWLT-30 the length of the interval 
between the stimulus and the P300 component was determined at the Cz 
electrode sites. The P300 signals were determined as the time between onset 
of the stimulus and the latency of the largest maximum in a window 
between 238 and 338 ms for the 30-WLT and between 290 and 490 for the N-
Back task as determined by a visual inspection of the peak latency of the 
grand average of the P300 for both tasks separately. 
The power of the delta (1-4 Hz), theta (4-8 Hz), alpha (8-12 Hz) and 
beta (12-30 Hz) frequency bands were measured during the presentation of 
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the words in the WLT-30 and were calculated by means of a fast Fourier 
transformation of the means of the midline electrodes (Fz, Cz and Pz ). These 
were taken as dependent variables and indicators of cortical activity and 
sedation. 
 
Statistical analysis 
All variables were screened for normality of the distributions. There were no 
indications of non-normal distributions. 
The immediate recall data were analysed according to a 3x3 two-
factorial model with Treatment (dexchlorpheniramine, lorazepam, placebo) 
and Trial (1, 2 and 3) as factors using Analysis of Variance for repeated 
measures. All other data derived from the WLT-30 were analysed for effects 
of Treatment using Analysis of Variance for repeated measures with 
Treatment as factor. For the N-Back task, the data were analysed using a 3x4 
two-factorial model with Treatment and Memory Load (0, 1, 2 and 3 back) as 
factors. If overall F-tests indicate significant main effects or interactions 
(p<0.05), the data were further analysed using two drug-placebo contrasts. 
In case of an effect of Trial or Memory load the data were further analysed 
using linear contrasts. All data were analysed using SPSS for Windows 
(version 12.0.1). 
 
RESULTS 
 
Missing data 
Analyses of the EEG frequency band power were performed on 17 subjects 
because data from one subject showed extremely large delta frequency 
values and was therefore considered an outlier. 
 
Behavioural assessments 
 
30-Words Learning Task 
Mean (±SE) immediate and delayed recall scores for separate treatments are 
shown in figure 1. There were significant main effects of Trial and Treatment 
on the number of words recalled during the immediate recall (F(2,16)=84.5, 
p<0.01 and F(2,16)=7.7, p<0.01, respectively). Overall, the number of words 
recalled increased linearly in every consecutive trial as shown by the 
significant linear contrast (F(1,17)=170.1, p<0.01). However, fewer words 
were recalled after lorazepam administration as compared with placebo 
(F(1,17)=12.9, p<0.01). The difference between lorazepam and placebo was 
significant in all three immediate recall trials (F(1,17)=6.0, p<0.03, 
F(1,17)=8.7, p<0.01 and F(1,17)=9.6, p<0.01, for trials 1, 2 and 3, respectively). 
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There was no difference in immediate recall scores observed between the 
dexchlorpheniramine and placebo (F(1,17)=2.7, p=0.12). 
There were also significant differences between treatments on the 
delayed recall scores (F(2,16)=6.1, p<0.01), but not in the relative recall 
(F(2,16)=1.6, p=0.24). Compared with placebo delayed recall was impaired 
after lorazepam administration (F(1,17)=10.8, p<0.01), but not after the 
administration of dexchlorpheniramine (F<1). 
In line with the above there were significant differences between 
treatments in reaction time and accuracy during the recognition task 
(F(2,16)=21.4, p<0.01 and F(2,16)=5.27, p<0.02, respectively). Again the effect 
was due to the lorazepam induced impairment (F(1,17)=23.6, p<0.01 and 
F(1,17)=10.0, p<0.01, respectively). 
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Figure 1: Effects of treatments on immediate and delayed word recall. Subjects recalled fewer 
words on all trials after administration of lorazepam. * Indicates p<.05 when compared with 
placebo. 
 
N-Back task 
Accuracy in the N-Back task differed significantly between the number of 
trials back the subject had to recall the digit (Memory Load) (F(3,15)=11.5, 
p<0.01). Linear contrast showed that the number of errors increased when 
the Memory Load increased from 0 to 3 (F(3,15)=8.1, p<0.01). However, 
subjects made more errors in the 0-back condition as compared with the 1-
back condition (F(1,17)=4.4, p<0.05). In addition, subjects responded slower 
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when the Memory Load increased as indicated by the main effect of Memory 
Load (F(3,15)=24.6, p<0.01) and the linear contrasts (F(1,17)=31.2, P<0.01). 
However, the 2-back condition was not significantly different from the 3-
back condition (F<1). 
Treatment effects on performance in the N-Back task differed 
significantly as measured by reaction time (F(2,16)=7.1, p<0.01) and 
approached significance as measured by the accuracy (F(2,16)=3.1, p<0.07). 
Compared with placebo lorazepam increased reaction time (F(1,17)=13.5, 
p<0.01) and decreased the accuracy significantly (F(1,17)=6.5, p<0.02), while 
dexchlorpheniramine did not (Fs(1,17)<1). There was no significant 
interaction between Treatment and Memory Load (Fs(2,16)<1) (table 1). 
 
Visual Analogue Scales 
Subjective ratings of alertness were significantly different between 
treatments (F(2,16)=7.8, p<0.01). Dexchlorpheniramine decreased alertness 
scores from 65.5 (±5.0) for placebo to 49.3 (±4.3) (F(1,17)=7.9, p<0.01) and 
lorazepam to 40.6 (±4.4) (F(1,17)=16.6, p<0.01). 
 
EEG data 
 
30-Words Learning Task 
P300 amplitude during word learning differed significantly between 
treatments. (F(16,2) = 6.2, p < 0.01). Lorazepam decreased the amplitude 
(F(1,17) = 13.0, p < 0.01), but dexchlorpheniramine did not (F< 1) (figure 2). 
 
Figure 2: Effects of treatments on the P300 amplitude. Lorazepam, but not 
dexchlorpheniramine, decreased the amplitude significantly, indicating reduced encoding. 
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Table 1: Effects of treatments on working memory as measured using the N-Back task. 
Lorazepam increased reaction time and decreased accuracy as indicated by the main effects of 
Treatment and the respective drug-placebo contrasts. Treatment did not significantly affect 
P300 peak amplitude or interact with N-Back. 
 
N-Back Task 
P300 amplitude decreased with the number of trials back the subject has to 
recall the digit (F(3,15) = 11.2, p = 0.01). Contrast showed that the effect was 
linear (F(1,17)=20.0, p<0.01). P300 amplitude did not differ between 
treatments (F<1) and there was no significant interaction between Treatment 
and Memory Load (F(6,12) = 1.3, p = 0.34) (table 1). 
 
Frequency band power 
There were significant or nearly significant differences between treatments 
in alpha (F(2,15)=11.6, p<0.01) and theta (F(2,15)=3.1, p<0.08) power. Power 
in the alpha and theta frequency band was highest after 
dexchlorpheniramine and lowest after lorazepam. Compared to placebo 
alpha power was significantly increased following dexchlorpheniramine 
(F(1,67)=11.4, p<0.01), and decreased following lorazepam (F(1,16)=17.1, 
p<0.01). For theta power the differences from placebo were not significant. 
Post-hoc analysis showed that theta power was significantly lower after 
lorazepam as compared to dexchlorpheniramine (F(1,16)=6.4, p<0.02). Power 
in the beta and delta frequency bands did not differ significantly between 
treatments 
N-back task Main effect of 
Treatment 
PLC D4 
 
L1 
 
 p =  p = 
(D4 vs. PLC) 
p = 
(L1 vs. PLC) 
Reaction Time (± SEM) (ms) 0.006  0.456 0.002 
0-back  342 (7.3) 351 (8.0) 378 (11.3) 
1-back  362 (8.7) 372 (8.9) 395 (14.2) 
2-back  396 (14.9) 401 (14.3) 444 (16.3) 
3-back  403 (17.0) 416 (17.2) 431 (13.0) 
Accuracy (± SEM) (%) 0.071  0.474 0.021 
0-back  95.3 (.01) 94.2 (.02) 93.8 (.01) 
1-back  96.3 (.01) 96.4 (.01) 96.1 (.01) 
2-back  95.2 (.01) 94.7 (.01) 91.4 (.02) 
3-back  93.3 (.01) 92.7 (.01) 87.8 (.02) 
P300 Amplitude (± SEM) (µV) 0.397  0.229 0.244 
0-back  12.3 (3.8) 12.1 (4.6) 11.5 (6.6) 
1-back  14.1 (5.0) 13.4 (5.0) 13.1 (3.9) 
2-back  11.8 (3.9) 9.4 (3.5) 9.9 (4.9) 
3-back  8.6 (4.2) 8.8 (3.5) 8.6 (4.6) 
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Table 2: Mean (± SEM) absolute power of the delta (1-4 Hz), theta (4-8 Hz), alpha (8-12 Hz) and 
beta (13-30 Hz) frequency bands after the administration of placebo, dexchlorpheniramine and 
lorazepam. Dexchlorpheniramine significantly increased and lorazepam decreased the alpha 
power. * Indicates p<0.05 when compared to placebo. 
 
DISCUSSION 
 
This study was designed to assess effects of an antihistamine on memory 
performance. Results clearly showed that the active control lorazepam 
impairs memory performance as measured by immediate and delayed word 
recall and speed and accuracy of working memory. In contrast, 
dexchlorpheniramine did not affect any of these measures. Both treatments 
increased feelings of drowsiness and affected cortical activity as measured 
with EEG indicating that treatments were effective. Although, 
dexchlorpheniramine induced sedation, it did not affect memory 
performance.  
 
Memory 
Lorazepam impaired memory functioning while dexchlorpheniramine did 
not. Benzodiazepines are known to produce anterograde amnesia as shown 
by the findings that recall of material learned after drug intake is impaired, 
but recall of material learned before drug intake is not. The latter also implies 
that retrieval processes are still intact (Turner, et al., 2006). The anterograde 
amnesia therefore seems to result from shallow encoding (Curran, et al., 
1998), or impaired storage and consolidation. 
In the present study lorazepam impaired immediate recall but not 
the relative recall as compared with the placebo condition suggesting 
encoding deficits. This is supported by psychophysiological data as the P300 
was significantly reduced after lorazepam administration. The P300 is 
regarded as being involved in attentional processes and the updating of 
memory (Polich, 2007). It has been shown that information later not 
remembered coincides with a decreased P300 amplitude at the time when 
  PLC D4 L1 
delta power (µV2) Fz 9.7 (0.8) 9.3 (0.6) 10.7 (1.1) 
 Cz 10.1 (0.6) 9.9 (0.7) 10.6 (0.9) 
 Pz 9.6 (0.6) 9.3 (0.6) 9.1 (0.8) 
theta power (µV2) Fz 7.1 (0.7) 7.5 (0.7) 7.0 (0.6) 
 Cz 7.3 (0.7) 7.7 (0.7) 6.9 (0.6) 
 Pz 5.8 (0.6) 6.2 (0.6) 5.3 (0.5) 
alpha power (µV2) Fz 5.8 (0.8) 7.4 (1.2)* 4.4 (0.8)* 
 Cz 6.9 (1.2) 8.7 (1.6)* 4.8 (1.0)* 
 Pz 8.7 (2.1) 11.1 (2.8)* 5.4 (1.6)* 
beta  power (µV2) Fz 1.2 (0.1) 1.4 (0.1) 1.3 (0.1) 
 Cz 1.3 (0.1) 1.6 (0.2)  1.5 (0.2) 
 Pz 1.3 (0.1) 1.4 (0.1) 1.3 (0.1) 
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stimuli were learned, i.e. larger P300 amplitudes during encoding predicts 
better recall (Friedman & Johnson, 2000). The lack of effect of 
dexchlorpheniramine on the P300 amplitude is in line with the finding that 
dexchlorpheniramine did not affect immediate recall. 
In contrast to the present study, anatomical studies suggest that the 
histamine system may be involved in memory processes. For example, H1-
receptors are found in many areas in the human brain, including prefrontal 
and temporal cortices in humans (Tashiro, et al., 2002; Yanai, et al., 1992) and 
in the CA3 and CA4 regions of the hippocampus in rats (Palacios, Wamsley, 
& Kuhar, 1981). These findings suggest that the H1-receptor may be involved 
in memory processes. It may be that subjects who are treated with a centrally 
active antihistamine, which results in blockade of the central H1-recptors, are 
able to compensate for the induced impairment. Subjects are often aware of 
the drug effects and increase effort or use alternative strategies in an attempt 
to counteract the drug induced impairment. In contrast, effects of lorazepam 
in this study may be slightly too large to be counteracted. Such hypotheses 
could be studied by measuring possible compensatory brain activity using 
imaging techniques such as fMRI. However, to the best of our knowledge 
there have been no imaging studies investigating the effects of H1-
antagonists on brain activity in areas related to memory. Further fMRI 
studies may elucidate the role of the histamine system in memory 
functioning. 
Studies with H3-receptor compounds in animals suggest that 
histamine is involved in memory functioning (Passani, Bacciottini, 
Mannaioni, & Blandina, 2000). For example, H3-receptor agonists induce 
memory impairment (Garbarg, et al., 1992) and inverse agonists and 
antagonists improve memory performance in animals (Wijtmans, Leurs, & 
de Esch, 2007). Thus, there might be a discrepancy between the effects of 
manipulating the histaminergic system through H1 and H3-receptors. An 
explanation may be that the H3-receptor plays a relatively large role as a 
heteroreceptor in memory functioning (Passani, Lin, Hancock, Crochet, & 
Blandina, 2004). It has been shown that H3-receptor compounds are able to 
modulate cholinergic activity in the cortex (Blandina, Efoudebe, Cenni, 
Mannaioni, & Passani, 2004) and it has been suggested that cholinergic 
neurons may mediate these effects on memory (Passani, et al., 2000). This 
hypothesis is supported by the finding that bilateral lesions of the 
tuberomammillary nucleus, which leads to decreased tonic activation of H3-
heteroreceptor and thus less inhibition of other neurotransmitters (e.g. 
acetylcholine and norepinephrine), produced facilitation of learning 
(Klapdor, Hasenohrl, & Huston, 1994). In contrast to H3-receptors, the H1-
receptor antagonism may not affect the cholinergic system, which is greatly 
involved in memory. 
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An alternative explanation is that effects of H3 compounds seen in 
animals may not be directly translated to man. For example, memory 
performance in rats is highly dependent on the hippocampus, while 
humans are able to use more strategies (e.g. use of language) and, therefore, 
brain structures. This may result in a higher sensitivity of rats for effects on 
memory. As H3 compounds are still hardly available to be tested in man, the 
question whether the translation can be made is yet to be answered. 
 
Effects on sedation 
In accordance with our results many studies found increased subjective 
drowsiness after intake of lorazepam 1 mg [e.g. (Bond & Lader, 1988; Hanks, 
et al., 1995; Preston, et al., 1988)] and dexchlorpheniramine 4 mg (Van 
Ruitenbeek, et al., 2008). The shift of the power in the EEG frequency 
spectrum from an alert waking state to mild sedation is usually 
characterized by increased theta and alpha power (Galliaud, et al., 2008; 
Griffiths, et al., 1991) and a decrease in beta power. In accordance, the power 
of the alpha frequency band after dexchlorpheniramine administration was 
significantly increased in this study. Sannita and colleagues (1996) also 
observed chlorpheniramine 4 mg to increase the alpha power. However, we 
did not observe any significant differences between treatments on beta 
frequency power. 
In contrast to the effects of dexchlorpheniramine, lorazepam 
decreased the power of the alpha frequency band which was also observed 
by Ebert et al. (2000) who administered midazolam (5 mg i.v.). It would be 
expected that lorazepam as a sedative agent would increase alpha power. 
The reduction in alpha frequency power after lorazepam administration has 
been explained by reductions in thalamic activity. Schreckenberger et al. 
(2004) in a PET study have found decreased alpha power to exclusively 
correlate with a decrease in thalamic metabolic activity. They argue that 
decreased occipital cortical input to the thalamus results in 
desynchronisation of thalamic output and, therefore, decreased oscillatory 
alpha activity. Lorazepam 1 mg also reduced the power of the theta 
frequency significantly as compared to dexchlorpheniramine 4 mg. 
However, the decrease in power was not significant as compared with 
placebo, possibly indicating that the effect is an incidental finding. 
Alternatively, as distinctions between frequency bands are sometimes 
arbitrary, theta frequency may be decreased for similar reasons as alpha 
frequency power decreases. 
The effects on subjective alertness suggest that lorazepam induced 
more sedation that dexchlorpheniramine. This may be explained by the fact 
that an alert waking state is typically dependent on multiple transmitter 
systems like the cholinergic, noradrenergic, serotonergic, dopaminergic and 
orexinergic system and activity of the histaminergic neurons arising from the 
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tuberomammillary nucleus (Espana & Scammell, 2004; Saper, Chou, & 
Scammell, 2001). In contrast, induction of sleep is largely orchestrated by 
GABA-ergic activity in the ventrolateral preoptic nucleus. Therefore, 
reductions in activity of a single system involved in actively maintaining a 
waking state may result in mild sedation, while increasing the GABA-ergic 
activity as a single modulator reduces activity in all waking systems and 
may thus induce more severe sedation. 
Effects on memory may be partly secondary to the induced 
drowsiness, possibly explaining why the effects of lorazepam on memory 
were larger that those of dexchlorpheniramine. Brookhuis & de Waard 
(1993) have shown that increased sedation as measured with theta and alpha 
power significantly correlates with decreased performance on actual car 
driving, suggesting that performance impairment is secondary to sedation. 
To determine whether the memory performance is secondary to the sedative 
effects effect sizes (ES) of the treatments on measures of memory 
performance and sedation were calculated (Fredrickson, et al., 2008; Rosnow, 
1996). Absolute ESs of lorazepam on immediate word recall on trials one, 
two, three, the delayed recall and P300 amplitude were larger than those of 
dexchlorpheniramine (0.61, 0.55, 0.62, 0.68 and 0.74 vs. 0.16, 0.09, 0.03, 0.01 
and 0.16, respectively). Lorazepam also caused more sedation as measured 
by subjective drowsiness (lorazepam: ES=1.24, dexchlorpheniramine: 
ES=0.86). However, the difference in ES between lorazepam and 
dexchlorpheniramine on measures of memory performance was much 
bigger. It is, therefore concluded that the sedative effects are insufficient to 
explain the effects of the treatments on memory performance. 
In conclusion, the hypothesis that antihistamines do not affect 
memory performance which was tested in studies attempting to dissociate 
the effects of different types of drugs on memory performance and arousal 
(Curran, et al., 1998; Turner, et al., 2006; Van Ruitenbeek, et al., 2008) is 
supported by our data. Both the EEG data and the subjective measure of 
drowsiness indicated that subjects were sedated after the administration of 
dexchlorpheniramine 4 mg. Effects on working memory, the recall of words 
presented around peak impairment and indications of impaired encoding 
were not observed, while the active control clearly affected performance on 
the memory tasks. It is concluded that H1-receptor activation is not crucial 
for human memory functioning. 
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CHAPTER 4 
 
SPECIFIC ANTIHISTAMINERGIC EFFECTS 
ON COGNITION: IMPAIRED CENTRAL 
PROCESSING SPEED AND UNAFFECTED 
ATTENTION AND WORD LEARNING 
Van Ruitenbeek, P., Vermeeren, A., Riedel, W. J. (submitted). Specific 
anthistaminergic effects on cognition: impaired central processing speed 
and unaffected attention and word learning 
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INTRODUCTION 
The histamine neurotransmitter system has recently been discovered as a 
possible target for the pharmacological treatment of cognitive deficits in 
clinical disorders. Over the past years evidence has accumulated that 
histamine plays an important role in such disorders. The findings are mainly 
characterized by a histamine hypofunction. For example, Higuchi et al. 
(Higuchi, 2000) found decreased H1-receptor binding in the frontal and 
temporal cortex in Alzheimer’s disease patients as compared with age 
matched controls. Evidence for the histamine system as a possible drug 
target has also come from animal studies. These studies have shown that H3-
antagonists improve performance in models for many cognitive deficits and 
clinical disorders, like Alzheimer’s disease, ADHD and schizophrenia [for 
review see: (Esbenshade, Fox, & Cowart, 2006)]. 
If histamine hypofunction is involved cognitive deficits seen in 
clinical disorders an artificial histaminergic hypofunction may reveal what 
cognitive functions are vulnerable in these disorders. Histamine H1-receptor 
blockade decreases histaminergic activity and may be used as model for 
histamine hypofunction as seen in clinical disorders. 
Recent studies attempted to investigate the specific effects of H1 
blockade in humans [e.g. (Turner, Handford, & Nicholson, 2006; Van 
Ruitenbeek, Vermeeren, & Riedel, 2008)]. Although some of the first 
generation antihistamines used in these studies are relatively selective (Van 
Ruitenbeek, et al., 2008), most antihistamines causing central effects are less 
specific in their receptor binding as compared with second generation 
antihistamines. However, second generation antihistamines cross the blood-
brain barrier to a much lesser extend which make them less suitable as a tool 
drug. One possible exception may be cetirizine. Cetirizine is a selective 
second generation H1-antagonist that has been shown to cross the blood-
brain barrier. For example, Tashiro et al. (2002; 2004) have found that after a 
20 mg dose cetirizine occupied 20 to 50% of the H1 receptors in the brain. 
There are also studies that show effects of cetirizine on behavioural 
performance measures and measures of alertness (Gengo & Gabos, 1987; 
Gupta, Kapoor, Gillani, Kapoor, & Gupta, 2004; Patat, et al., 1995; Nicholson 
& Turner, 1998; Ramaekers, Uiterwijk, & O'Hanlon, 1992; Sannita, Crimi, 
Riela, Rosadini, & Brusasco, 1996; Vermeeren, Ramaekers, & O'Hanlon, 
2002). In contrast, Gupta, et al., (2004) found no effects on objective 
performance measures. In addition, several studies also did not find 
behavioural effects of cetirizine (Gengo, Gabos, & Mechtler, 1990; Seidel, 
Cohen, Bliwise, & Dement, 1987; Shamsi, Kimber, & Hindmarch, 2001; 
Theunissen, Vermeeren, van Oers, van Maris, & Ramaekers, 2004; Volkerts, 
Van Willigenburg, Van Laar, & Maes, 1992). So, despite the advantage of 
selectivity it is very unclear if cetirizine is suitable as a tool drug to model 
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cognitive deficits secondary to histaminergic hypofunction. Therefore, the 
aim of this study was to investigate the behavioural effects of cetirizine. 
The recommended therapeutic dose of 10 mg may be insufficient to 
induce reliable behavioural effects. The effects of twice this dose (20 mg) 
have only been studied by some authors in the past and results are 
contradictory. Gengo & Gabos (1987) have shown that cetirizine 20 mg 
increases subjective drowsiness. In addition, Sannita et al. (1996) have shown 
that cetirizine 20 mg produced increased alpha frequency band power using 
electroencephalography as a sign of sedation. However, Seidel et al. (1987), 
Seidel, Cohen, Bliwise, & Dement (1990), Gengo, Dabronzo, Yurchak, Love, 
& Miller (1987), Gengo & Gabos (1987) and Gengo, et al. (1990) all found no 
effects of cetirizine 20 mg on behavioural performance. Therefore, the effects 
of two oral doses (10 and 20 mg) of cetirizine on cognitive performance were 
measured. 
It is also unclear when the effects of cetirizine after administration 
occur. Peak blood-plasma concentrations (Tmax) of cetirizine are shown at 
approximately 1 hour after oral dosing (Campoli-Richards, Buckley, & 
Fitton, 1990) and the elimination half life (T1/2) is approximately 7 to 11 
hours (Simons & Simons, 1991). However, there is some evidence that the 
behavioural effects occur after Tmax. Volkerts et al. (1992) and Theunissen et 
al. (2004) failed to find effects of cetirizine 10 mg on driving performance 1 
hour after acute dosing. In contrast, Ramaekers et al. (1992) and Vermeeren 
et al. (2002) found that 10 mg cetirizine impaired driving performance 3 to 4 
hours after dosing. Therefore, in this study behavioural effects are assessed 
at both 1 hour and 3 hours after treatment. 
To detect cognitive deficits tasks were used that have been shown to 
be sensitive to central H1 blockade and that cover a range of important 
cognitive functions. The Critical Flicker/Fusion Frequency (CFF) is a 
sensitive measure to detect sedation which is caused by centrally active 
antihistamines [e.g. (Hou, Langley, Szabadi, & Bradshaw, 2007)]. The Visual 
Vigilance Test (VVT) (Nuechterlein, Parasuraman, & Jiang, 1983; O’ Hanlon 
and Vermeeren, 1988) was added to the task battery as a measure of 
vigilance. Vigilance is known to be affected by sedating agents (Kay, 2000). 
The Critical Tracking Task and Divided Attention task are sensitive 
measures to detect slowing in sensorimotor performance and impaired 
attention (Van Ruitenbeek, et al., 2008). Explicit short term and long term 
memory was assessed using a Word Learning Task (Rey, 1964). Finally, to 
separate memory processes from the slowing of other processes the 
Sternberg’s Memory Scanning Task was used (Sternberg, 1969). 
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METHODS 
 
Subjects 
Eighteen (9 female) healthy volunteers were recruited for this study and 
were paid for their participation. One female subject withdrew from the 
study for reasons unrelated to treatments. The mean ± SD age of the 17 
remaining subjects was 23 ± 2.6 years. Subject’s health was screened using a 
medical history questionnaire and a physical examination. Exclusion criteria 
were hypertension, body mass index outside the limits of 18 and 28 kg m-2, 
history of alcohol and drug abuse, history of psychiatric disorders, presence 
of cardiovascular, respiratory, renal, hepatic, metabolic or endocrine 
disorders, history of glaucoma, overt allergy, history of allergic reactions to 
antihistamine drug or any sensory or motor impairment. Subjects were not 
allowed to take any medication during or between treatments, except oral 
contraceptives, aspirin and acetaminophen. 
All subjects received written information and were given the 
opportunity to ask questions. They signed a written informed consent prior 
to enrolment. The study was approved by the Ethics Committee of 
Maastricht University and University Hospital Maastricht and was carried 
out in accordance with the World Medical Association Declaration of 
Helsinki and its amendments (Edinburgh, 2000). 
 
Study design and treatments 
The study was conducted according to a 3 x 2 three-way, double blind, cross 
over design. The two factors were Treatment and Time of testing. Treatments 
were single oral doses of cetirizine 10 mg, cetirizine 20 mg and placebo. 
Subjects were tested twice on each testday, at 1 and 3 hours after drug 
administration. All test days were separated by a wash out period of one 
week. The order of treatments was counterbalanced using six independent 3 
x 3 Latin squares. 
 
Procedure 
Subjects were trained on two separate occasions to perform the tasks until 
they reached a plateau level. On treatment days subjects arrived at the test 
facility well rested. Drugs administration occurred at 9:00 a.m., at least 3 
hours after consuming a meal. Test sessions started 1 hour (T1) and 3 hours 
(T3) after drug administration. The duration of the battery was 1 hour and 
consisted of the 15-Words Learning Task (WLT), Critical Flicker/Fusion 
Frequency (CFF), Visual Vigilance Task (VVT), Critical Tracking Task (CTT), 
Divided Attention Task (DAT) and Sternberg’s Memory Scanning (SMS) 
presented in the mentioned order. CFF was measured at both the beginning 
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and end of the test battery. Ten minutes before the first test battery subjects 
consumed a light meal. 
 
Assessments 
 
15-Words Learning Task 
The WLT (Rey, 1964; Riedel, et al., 1995) assesses short and long term verbal 
memory. Fifteen Dutch monosyllabic meaningful nouns and adjectives are 
presented for 1000 ms at a rate of 1 per 2 seconds and subjects are required to 
read them aloud. When the presentation ends, subjects are required to 
verbally recall as many words as possible (immediate recall). This procedure 
is repeated five times, with the same words presented in the same sequence. 
After a 20 minutes delay subjects are requested again to recall as many 
words as possible (delayed recall). Dependent variables were the sum of the 
number of words correctly recalled on the five immediate recall trials (IR), 
the number of correctly recalled words after the 20 minute delay (DR). 
 
Sternberg’s Memory Scanning Task 
The SMS (Riedel, et al., 1995; Sternberg, 1969) measures the time it takes to 
scan items held in memory as part of working memory integrity, separating 
it from other processes required to respond. When subjects judge whether a 
test symbol is contained in a short memorized sequence of symbols, their 
mean reaction time increases linearly with the length of the sequence. The 
linearity and slope of the function imply the existence of an internal serial 
comparison process whose average rate is between 20 and 30 items per 
second. In this test the subjects are presented with a set of 1, 2 or 4 
consonants, which they are asked to memorize. Hereafter a series of 90 
consonants is presented on a computer screen of which 45 are targets and 45 
are non-targets. The subjects’ task is to indicate as fast as possible whether 
the presented letter was one from the memory set by pressing one of two 
buttons. The task consists of 3 blocks of 90 stimuli with memory sets of 1, 2 
and 4 digits. The average reaction time for correct responses (detections and 
rejections) were recorded and used to calculate individual linear regression 
lines between reaction time and memory set size. The slope of this line is a 
measure of speed of scanning short term memory, whereas the intercept is a 
measure of psychomotor speed. Both slope (ms/letter) and intercept (ms) are 
outcome measures. 
 
Critical Flicker/Fusion Frequency 
The CFF measures the frequency threshold, which separates the perception 
of light flickering from fusion and light constancy. The threshold is 
fundamentally determined by the speed of information processing of the 
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visual system, which can be influenced by sedative drugs. Subjects 
discriminated the flicker from fusion of a flickering of four light emitting 
diodes held at 0.75 m from the subject’s eye using the Leeds Psychomotor 
Tester. The threshold (Hz) was determined by averaging three ascending 
and three descending frequency trials (Hindmarch, 1980). 
 
Visual Vigilance Task 
The VVT [(Nuechterlein, et al., 1983) and adjusted by (O’Hanlon and 
Vermeeren, 1988)] consists of rapidly presenting visual stimuli for 8 minutes 
and was used to assess sustained visual discrimination. The stimuli were 
presented for 34 ms at a rate of 1 per second and consisted of digits (0, 2, 3, 5, 
6, 8 and 9) of which the ‘0’ was considered the target and was presented at a 
25% target rate. To visually degrade the stimuli a glass diffusion screen was 
positioned between the subject and the display. Upon appearance of the 
target subjects were instructed to press a response button as fast as possible. 
The reaction times of the false and correct detections were measured. From 
these measures the perceptual sensitivity index d’ and the response criterion 
β were calculated to determine the effects on stimulus and response related 
processes, respectively. 
 
Critical Tracking Task 
The CTT measures the ability to control an unstable triangle, which is 
displayed on a horizontal axis on a computer screen, using a joystick (Jex, 
McDonnell, & Phatak, 1966). An error signal causes the triangle to become 
increasingly unstable and therefore it tends to diverge from the centre of the 
axis. The subject has to make compensatory movements to null the error in 
order to keep the triangle in the middle. As the correction frequency of the 
cursor deviations increases as a stochastic function of time, the subject is 
required to make compensatory movements with an increasingly higher 
frequency to the limit of her ability, whereupon control is lost. This 
frequency decreases under the influence of sedating drugs. The dependent 
measure is the average frequency at which control is lost of five trials after 
removing the lowest and highest score. This is called the ‘critical frequency’ 
or ‘lambdac’ (rad s-1).  
 
Divided Attention Task 
The DAT (Moskowitz, 1973) assesses the ability to perform two tasks 
simultaneously and evaluates cognitive processing resources. The primary 
task is similar to the critical tracking task described above, with the 
exception that the level of difficulty is held constant at 50% of that, which is 
just controllable, by the subject. Tracking error is measured by the absolute 
distance (in mm) between the cursors position and the centre. The secondary 
task involves the monitoring of 24 digits (0-9) that are arranged around the 
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display’s periphery. The digits change asynchronously every 5 seconds. 
Subjects were required to respond as rapidly as possible by lifting the foot 
from a pedal anytime the digit “2” appears. The average reaction time (in 
ms) to targets is recorded as the response measure in this task. Average 
reaction times and tracking error of each measure were transformed to z-
scores using data from all subjects, test days and test sessions. Second, the 
standardized scores of the subtasks were summed to yield an overall 
performance score for each subject, test day and test session. Overall scores 
were used for further analysis.  
 
Statistical analysis 
All variables were screened for normality of the distribution. There were no 
signs of non-normal distributions. All dependent variables were analysed 
according to a 3x2 two factorial model with Treatment (cetirizine 10 mg, 
cetirizine 20 mg, placebo) and Time of testing (T1, T3) as factors using 
Analysis of Variance for repeated measures. The CFF data were analysed 
according to a 3x2x2 three factorial model with Treatment (3 levels), Time of 
testing (2 levels) and Time in battery (2 levels: begin, end). Time of testing 
comprised 4 levels as CFF was measured before and after each test battery. If 
overall F-tests indicate a significant (p<0.05) main effect of Treatment, the 
data were further analysed using two drug-placebo contrasts. In case of a 
significant interaction (p<0.05) between Treatment and Time of testing, the 
data were analysed post-hoc per level of Time of testing. All data were 
analysed using SPSS 15.0 for the Windows operating system. 
 
RESULTS 
 
A summary of mean (±SEM) performance scores in tasks assessing critical 
flicker-fusion frequency, visual vigilance, critical tracking and divided 
attention is presented in Table 1. 
 
15-Words Learning Task 
There were no differences between the treatments and between the two test 
sessions. Thus, cetirizine did not affect immediate word recall on any of the 
trials at T1 or T3 after drug administration (figure 1). 
There were also no differences between treatments on the number of 
words recalled during the delayed recall. Subjects tended to recall less words 
at T3 as compared with T1 (F(2,15) = 3.2, p = 0.091), but the difference was 
not affected by treatment (F(2,15)=1.2, p=0.327) (figure 1). 
 
  
Table 1: Performance scores after treatment with cetirizine 10 mg, 20 mg or placebo. Bold p-values indicate significant or near significant main effects or interaction. 
Significant treatment placebo contrasts are indicated with an asterisk. In addition, at the end of each test battery (T1e and T3e) the CFF was significantly lower as compared 
with the beginning of the battery (T1b and T3b) as indicated by the main effect of Time in battery (F(1,16)=14.1, p=0.002). 
Overall analysis   Mean (±SEM) scores 
Main effect of 
Treatment 
 
Main effect of 
Time of Testing 
Interaction between 
Treatment x Time of 
Testing 
 Test 
session 
Treatment 
 
  
 
F =  df p = F = df p = F = df p =   PLA CET10 CET20 
CFF         
   Critical Frequency (Hz) 1.4 2,15 0.280 < 1 1,16 0.366 < 1 2,15 0.865  T1b 29.2 ± 0.8 28.7 ± 0.7 29.1 ± 0.8 
     T1e 28.4 ± 0.8 28.3 ± 0.8 28.4 ± 0.8 
     T3b 28.8 ± 0.9 28.9 ± 0.8 29.0 ± 0.8 
     T3e 28.4 ± 0.9 27.9 ± 0.7 28.5 ± 0.8 
VVT         
   Hits (%) 1.5 2,15 0.262 3.1 1,16 0.096 < 1 2,15 0.800  T1 79.1 ± 3.5 75.1 ± 5.1 67.4 ± 5.4 
     T3 75.5 ± 4.4 73.2 ± 5.4 65.9 ± 5.5 
   Reaction time (ms) 1.9 2,15 0.187 2.3 1,16 0.147 < 1 2,15 0.647  T1 503 ± 16 517 ± 9 522 ± 18 
     T3 492 ± 11 502 ± 8 520 ± 24 
   d prime 2.2 2,15 0.150 < 1 1,16 0.393 < 1 2,15 0.590  T1 2.6 ± 0.3 2.8 ± 0.2 2.3 ± 0.3 
     T3 2.8 ± 0.2 2.7 ± 0.2 2.1 ± 0.3 
   Beta < 1 2,15 0.589 < 1 1,16 0.672 1.2 2,15 0.316  T1 5.0 ± 1.0 7.1 ± 2.0 6.8 ± 1.7 
     T3 6.5 ± 1.3 5.9 ± 1.6 7.2 ± 2.2 
CTT         
   Lambda (rad/s) 4.2 2,15 0.035 < 1 1,16 0.752 1.1 2,15 0.363  T1 5.4 ± 0.2 5.1 ± 0.2* 5.4 ± 0.2 
     T3 5.4 ± 0.3 5.2 ± 0.2 5.2 ± 0.3 
DAT         
   Overall performance (z-score) < 1 2,15 0.664 2.6 1,16 0.129 < 1 2,15 0.416  T1 -0.12 ± 0.3 0.02 ± 0.4 -0.26 ± 0.4 
     T3 -0.05 ± 0.4 0.32 ± 0.4 0.09 ± 0.4 
   Tracking error (mm) 1.8 2,15 0.199 2.4 1,16 0.144 2.4 2,15 0.124  T1 16.9 ± 1.3 19.3 ± 1.4 17.9 ± 1.6 
     T3 17.9 ± 1.6 18.7 ± 1.5 19.2 ± 1.7 
   Reaction time (ms) < 1 2,15 0.629 1.5 1,16 0.237 3.0 2,15 0.083  T1 1811 ± 81 1723 ± 102 1701 ± 76 
     T3 1771 ± 102 1862 ± 86 1750 ± 78 
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Figure 1: Administration of cetirizine 10 or 20 mg did not affect the number of recalled word 
during the immediate recall. 
 
Sternberg’s Memory Scanning Task 
The slope of the regression line of reaction time on memory load tended to 
differ between treatments (F(2,15) = 3.1, p = 0.074). Drug-placebo contrast 
indicated that both 10 and 20 mg cetirizine increased the slope significantly, 
indicating a slowing of memory scanning speed (F(1,16)=5.2, p=0.037 and 
F(1,16)=4.8, p=0.044, respectively). Although treatment effects did not differ 
significantly on T1 and T3 (F(2,15)=1.7, p=0.223), post hoc analysis indicated 
that cetirizine 10 mg increased the slope at T1 (F(1,16)=6.7, p=0.020) and 
cetirizine 20 mg tended to increase the slope at T3 (F(1,16)=4.3, p=0.054) 
(figure 2). There was no overall differences in slopes between T1 and T3 
(F(1,16) = 1.8, p=0.203) (figure 2). 
The intercept of the regression line of reaction time on memory load 
were not affected by Treatment or Time and these factors did not interact 
(Fs<1) (figure 2). 
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Figure 2: The slope of the regression line of reaction time on memory load increased after 
administration of cetirizine. The increase was significant at T1 for cetirizine 10 mg and at T3 for 
cetirizine 20 mg. 
 
Critical Flicker/Fusion Frequency 
The critical frequency was decreased at the end of every test battery as 
indicated by the significant effect of Time in battery (F(1,16)=14.1, p=0.002). 
However, this difference was not affected by Treatment (F<1). The 
differences between the treatments (F(2,15)=1.4, p=0.280) and times of testing 
(F<1) were not significant. 
 
Visual Vigilance Task 
The number of hits did not differ between the treatments. The number of hits 
tended to be less on T3 as compared with T1 (F(1,16)= 3.1, p=0.096), but the 
difference was not affected by cetirizine treatment. 
No differences between the treatments or between the times of 
testing on reaction time, the perceptual sensitivity index or response 
criterion were detected. 
 
Critical Tracking Task 
Tracking performance was significantly different between treatments 
(F(2,15)=4.2, p=0.03). Drug placebo contrasts showed that 10 mg cetirizine 
decreased tracking performance (F(1,16)=7.1, p=0.017). There were no 
differences between T1 and T3.  
 
Divided Attention Task 
The overall performance scores, tracking errors and reaction times did not 
differ between the treatments or times of testing. However, the interaction 
between Time of testing and Treatment approached significance (F(2,15)=3.0, 
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p=0.083). Subjects tended to respond faster at T3 as compared with T1. 
However, after cetirizine 10 and 20 mg administration subjects responded 
slower at T3 as compared with placebo. 
 
DISCUSSION AND CONCLUSIONS 
 
The aim of the present study was to investigate if cetirizine would be a 
suitable tool drug to induce histamine hypofunction and the associated 
cognitive impairments. Histamine is known to be involved in attention, 
psychomotor functioning and possibly memory. It was, therefore, 
hypothesised that cetirizine would affect performance measures of these 
functions. In this study cetirizine tended to affect psychomotor performance 
and memory scanning speed. In contrast, cetirizine did not affect word 
learning, vigilance and divided attention.  
 Memory functioning as measured with the memory scanning task 
was impaired in this study. This is in accordance with results from a study 
by Ramakers et al. (1992) who found an increase in variability in memory 
scanning speed after administration of cetirizine 10 mg. In contrast, we did 
not observe effects on word learning and recall. Our results are consistent 
with those from another study, although these lack of effects may explained 
by the fact that they only used 10 mg cetirizine (Theunissen, et al., 2004). 
Studies assessing the effects of other centrally active antihistamines usually 
also find no effects on word learning and recall [e.g. (Turner, et al., 2006; Van 
Ruitenbeek, et al., 2008)]. The difference between the word learning task and 
the memory scanning task is that performance on the former is characterized 
by the capability to store and retrieve new information mostly irrespective of 
speed. In contrast, performance on the memory scanning task depends 
largely on speed of information processing. It may be that cetirizine affects 
the speed, but not the integrity of information processing in working 
memory. 
Slower information processing speed can also result in impaired 
tracking performance. The critical tracking task is a complex, sensitive and 
frequently used measure to assess drug induced psychomotor impairment 
[e.g. (Van Ruitenbeek, et al., 2008)]. Performance requires many cognitive 
processes like perceptual and motor processes, but also central executive 
processes like anticipation and inhibition of responses in case the anticipated 
response is not required to be executed. A delay in such central processes 
can result in impaired tracking performance. This study showed that 
tracking performance was impaired one hour after cetirizine 10 mg 
administration. In accordance, Nicholson & Turner (1998) and Patat et al. 
(1995) found impaired tracking performance after the administration of 
cetirizine. In contrast, Ramaekers et al. (1992), Theunissen, Vermeeren, & 
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Ramaekers (2006), Theunissen, et al. (2004) and Shamsi et al. (2001) found no 
impairments. This may indicate that the effects of cetirizine are small and 
may not always be detected. Ramaekers et al. (1992) suggested that some 
subjects are very sensitive to effects of cetirizine, while others are not. 
Looking at the individual data did reveal that almost all subjects performed 
worse after cetirizine administration as compared with placebo. However, 
some subjects improved their performance after administration of both 10 
mg and 20 mg of cetirizine, which indicates that some subjects may not have 
been sensitive to the effects of cetirizine. 
Both sensory and motor related information processing were not 
affected by cetirizine. From the Visual Vigilance Task in this study the 
perceptual sensitivity index (d prime) and response criterion (Beta) were 
calculated, which are measures related to stimulus processing and response 
readiness, respectively. Neither measures indicated an impairment induced 
by cetirizine. In addition, the critical flicker/fusion frequency, which is a 
measure of information processing speed of the visual system i.e. sensory 
information, did not show any effects of cetirizine. In contrast, there was an 
effect on memory scanning speed, which is regarded as a central process, 
while all other processes as measured with the intercept in the Sternberg’s 
Memory Scanning task remained unaffected. It may be concluded that the 
effects of cetirizine may not be located in sensory or response related 
processes, but may reside in a central processing speed. 
 It was expected that the effects of cetirizine would increase with 
increasing dosages. Surprisingly, the lower dose had more significantly 
impairing effects than the higher dose. Although both dosages impaired 
memory scanning speed, only the 10 mg dose impaired tracking 
performance. In addition, the effect of cetirizine 10 mg on memory scanning 
was also larger than that of cetirizine 20 mg, although the difference was not 
significant (F(1,16)=1.2, p=0.281). In contrast to our findings, three out of six 
previous studies that used both 10 and 20 mg cetirizine found effects of 
cetirizine 20 mg and not 10 mg (Gengo, et al., 1987; Gengo & Gabos, 1987; 
Gengo, et al., 1990; Sannita, et al., 1996; Seidel, et al., 1987, 1990). Taken 
together, cetirizine 20 mg seems to have larger effect than the 10 mg dose 
and our findings that cetirizine 20 mg has less effects that cetirizine 10 mg 
may have been incidental. 
From the literature (Ramaekers, et al., 1992; Vermeeren, et al., 2002) 
it was suggested that the effects of cetirizine may not coincide with the Tmax 
of approximately 1 hour and that the behavioural effects are delayed. This 
study assessed the effects both 1 and 3 hours after oral administration of 
cetirizine. The data did not suggest that performance after cetirizine was 
different at T3 as compared with T1. There was only one Treatment by Time 
of testing interaction as measured with the reaction time on the DAT. The 
interaction indicated that subjects responded slower at T3 after cetirizine 10 
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mg or 20 mg as compared with T1 and after placebo the responded faster at 
T3 as compared with T1. However, taken together all other measures did not 
show such an interaction. Thus, our data did not suggest that effects of 
cetirizine are bigger after Tmax. 
This study showed only marginal effects of cetirizine. Yanai, 
Okamura, Tagawa, Itoh, & Watanabe (1999) reported that H1-receptor 
occupancy in the brain is significantly correlated with the reported measures 
of sleepiness. Non-sedative antihistamines show receptor occupancy of 
approximately 30 percent, while sedative antihistamines occupy more than 
70 percent of the central H1-receptors. Tashiro et al. (2004) reported a trend 
of cetirizine 20 mg to induce sedation while it occupied approximately 26 
percent of the central H1-receptors. In addition, Tashiro et al. in an earlier 
study (2002) reported that cetirizine 20 mg slowed reaction times and 
occupied approximately 20 to 50 percent of the central H1-receptors. It may 
be concluded that cetirizine 20 mg occupies a moderate percentage of the 
central H1-receptors and induces marginal behavioural effects. 
  In conclusion, oral dosages of both cetirizine 10 mg and 20 mg enter 
the brain and cause slowing of central processes resulting in some 
behavioural effects. This study provides no evidence that these effects are 
delayed as compared with Tmax and twice the recommended dose does not 
clearly increase the behavioural effects. The effects of cetirizine are not 
pronounced enough to be used as a model for histamine hypofunction. 
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CHAPTER 5 
 
HISTAMINE H1 RECEPTOR BLOCKADE 
PREDOMINANTLY IMPAIRS SENSORY 
PROCESSES IN HUMAN SENSORIMOTOR 
PERFORMANCE 
Van Ruitenbeek, P., Vermeeren, A., Smulders, F. T. Y., Sambeth, A., 
Riedel, W. J. (In press). Histamine H1 receptor blockade predominantly 
impairs sensory processes in human sensorimotor performance. British 
Journal of Pharmacology 
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INTRODUCTION 
 
Several studies have shown that centrally active histamine H1 receptor 
antagonists, frequently used for the treatment of Seasonal Allergic Rhinitis 
and Urticaria, produce sedation and impair cognitive performance, in 
particular complex sensorimotor performance such as tracking and car 
driving (Hindmarch & Shamsi, 1999; Theunissen, Vermeeren, van Oers, van 
Maris, & Ramaekers, 2004; Van Ruitenbeek, Vermeeren, & Riedel, 2008; 
Verster & Volkerts, 2004). However, little is known about the specific effects 
of H1 receptor blockade on the cognitive subprocesses involved in 
performance on such tasks 
Better knowledge about the cognitive deficits associated with 
reduced histamine activity (e.g. as induced by H1-antagonists) can ultimately 
contribute to better diagnosis and treatment of clinical disorders in which 
histamine dysfunction seems one of the contributing factors. Degeneration or 
dysfunction of histamine neurons has been found in Alzheimer’s disease, 
Parkinson’s disease, epilepsy, ADHD and schizophrenia [For review see: 
(Esbenshade, Fox, & Cowart, 2006; Onodera, Yamatodani, Watanabe, & 
Wada, 1994; Passani, Bacciottini, Mannaioni, & Blandina, 2000; Witkin & 
Nelson, 2004; Yanai & Tashiro, 2007)]. So, drugs that increase histamine 
function, such as antagonists or inverse agonist for the H3-receptor, are 
expected to be valuable new treatments for such disorders.  
Better knowledge on the specific cognitive deficits associated with 
histamine dysfunction in humans can be derived from studies assessing the 
behavioural effect of centrally active H1-antagonists in healthy volunteers. 
The aim of the present study was to clarify which subprocesses underlying 
sensorimotor performance are impaired by the representative antihistamine 
dexchlorpheniramine, which has been shown to affect sensorimotor 
performance (Van Ruitenbeek, et al., 2008). To this end, we adopted a 
behavioural and a psychophysiological approach. 
 The behavioural approach consists of the Additive Factor Method 
(AFM) (Sternberg, 1969). Within this framework human information 
processing between stimulus and response is dissected into a series of 
discrete stages, which represent distinct elementary cognitive operations 
such as perceptual encoding, decision making and response preparation 
(Bonin-Guillaume, Blin, & Hasbroucq, 2004). Roughly, these can be regarded 
as sensory, central and motor stages. Several task factors have been 
established that influence individual stages. For example, by decreasing 
Stimulus Quality (SQ) the perceptual process of feature extraction can be 
slowed resulting in a longer reaction time. Identifying the specific processing 
stages that are affected by drugs can be done using the AFM. The basic logic 
is that if two factors interact they affect at least one common stage (Sanders, 
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1980; Smulders, Kenemans, Schmidt, & Kok, 1999; Sternberg, 1969). So, if a 
drug interacts with a task factor, which affects a specific stage, it is 
concluded that the drug affects at least that particular stage. [e.g. (Frowein, 
1981; Frowein, Gaillard, & Varey, 1981)]. Only two studies investigated the 
effects of antihistamines using this framework, but with inconsistent results. 
According to the investigators results of the first study suggested that 
antihistamines might compromise perceptual processing (Gaillard and 
Verduin 1983), whereas results of a subsequent study were taken to indicate 
that they primarily affect motor processes (Gaillard et al. 1988). In the first 
study, results were not significant, however, probably due to a small sample 
size and low dose of the drug. In the second study, the antihistamine was 
found to interact with SQ in a reaction time task, but also to impair tracking 
performance. As the latter study did not include manipulations of task 
demands affecting motor processing, it remains unclear whether the 
antihistamine had generally sedating or specific effects on sensorimotor 
processing.  
The second approach to identify the locus of effects of a drug is a 
psychophysiological approach, i.e. using event related potentials (ERPs) as 
markers to detect changes in specific stages of information processing. The 
latencies to the peak of the potentials are typically regarded as the time at 
which subprocesses occur after stimulus presentation. The P300 component 
is a central component and is thought to be associated with evaluation of a 
stimulus just before a decision takes place (Polich, 2007; Riedel, Mehta, & 
Unema, 2006). The amplitude of the P300 is thought to reflect the resources 
available for stimulus processing. For example, increased task demands to 
which attention is directed reduces the amplitude of the P300 (Beauducel, 
Brocke, & Leue, 2006). The latency of this component has been shown to 
increase after degradation of SQ (McCarthy & Donchin, 1981). In addition, 
the Lateralized Readiness Potential (LRP) is a response related component. 
Effects on response preparation, such as increasing response complexity 
(RC), increase the interval between the LRP-onset and the response. The 
locus of the drug effect can thus be determined using the P300 and LRP. 
Effects on stimulus related processes are identified by an increased interval 
between the stimulus and P300 (S-locked P300). Effects on response related 
processes are identified by an increased interval between the onset of the 
LRP and response (R-locked LRP). 
A consistent finding is that antihistamines delay the P300 latency. 
For example, studies have found that chlorpheniramine or pheniramine 
increased the P300 latency during performance on an Odd-Ball task (Loring 
& Meador, 1989; Seidl, et al., 1997; Simons, Reggin, Roberts, & Simons, 1994). 
A delay in the duration of any process occurring before the P300 leads to a 
delay of the P300 peak amplitude. Therefore, these findings are in line with 
studies in which SQ was manipulated and suggest that H1-blockade affects 
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sensory stages of information processing (Gaillard, Gruisen, & De Jong, 1988; 
Gaillard & Verduin, 1983). However, the effects of antihistamines on motor 
processes and associated ERP components are largely unknown. 
To demonstrate sensitivity of the tasks and procedures we included 
the benzodiazepine lorazepam (1 mg) as an active control drug. Similar to 
H1-antagonsists, benzodiazepines induce sedation and impair sensorimotor 
performance (Bond, Lader, & Shrotriya, 1983; Curran, 2000; Leufkens, 
Vermeeren, Smink, van Ruitenbeek, & Ramaekers, 2007; Turner, Handford, 
& Nicholson, 2006). Moreover, effects of benzodiazepines have been found to 
interact with SQ and motor processes (Pang & Fowler, 1994). In addition, 
they are known to affect latency and amplitude of several ERP components 
(Curran, Pooviboonsuk, Dalton, & Lader, 1998; Riba, Rodriguez-Fornells, 
Munte, & Barbanoj, 2005) including P300 (Pompeia, Manzano, Galduroz, 
Tufik, & Bueno, 2003) and motor-related evoked potentials (Riba, et al., 2005; 
Rockstroh, Elbert, Lutzenberger, & Altenmuller, 1991).  
To summarize, the specificity of antihistamine induced psychomotor 
impairment is unknown and such knowledge may aid the search for 
treatments for disorders in which specific processes are affected. Using 
Sternberg’s AFM and measuring ERPs, this study assessed the effects of 
dexchlorpheniramine as a representative centrally active and specific H1-
antagonist on sensory and motor stages of cognitive processing. 
Dexchlorpheniramine was expected to negatively affect sensory stages and 
therefore interact with SQ as measured by prolonged reaction time and S-
locked P300 peak latency. In addition, this is the first study to assess the 
effects on response related processes as measured with the response locked 
LRP onset latency. This study shows that central H1 blockade impairs the 
processing of sensory information. 
 
METHODS 
 
Subjects 
 
Eighteen healthy right handed subjects (nine female) between 18 and 45 
years (mean ± SD: 24.2 ± 7.3 years) were recruited by means of 
advertisements in local newspapers and were paid for their participation. 
Subject’s health was screened using a medical history questionnaire and a 
physical examination, including a 12-lead electrocardiogram, blood 
chemistry and haematology, and urinary tests for pregnancy and drug abuse 
(amphetamine, benzodiazepine, cocaine, opiates, cannabis and 
methamphetamine). Exclusion criteria were a significant history or presence 
of any mental or physical disorder; gastrointestinal, hepatic, renal, 
cardiovascular or neurological. Also, drug abuse, a body-mass index outside 
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the limits of 18 and 28 kg m-2, blood pressure outside the limits of 100 and 
150 Hg systolic and 60 and 90 Hg diastolic and drinking more than 20 
standard alcoholic consumptions per week or 5 beverages containing 
caffeine per day were regarded as exclusion criteria. For women, pregnancy 
and lactation were also regarded as exclusion criteria. No drugs or 
medication, except oral contraceptives, aspirin and acetaminophen, were 
allowed to be taken from a week before the first test-day until the end of the 
study. Smoking and the use of caffeine were prohibited on test-days and the 
use of alcohol from 24 hours before and during each test-day. Subjects were 
allowed to have breakfast at home before 7:30am so that drug intake 3 hours 
later would be on a nearly empty stomach. 
All subjects received written information about the study procedures 
and signed an informed consent form prior to enrolment. The study was 
approved by the ethics committee of Maastricht University and University 
Hospital Maastricht and carried out in accordance with the World Medical 
Association Declaration of Helsinki and its amendments (Edinburgh, 2000). 
 
Study design and treatments 
 
The study was conducted according to a double blind, placebo-
controlled, 3-way crossover design. Treatments were single oral doses 
of dexchlorpheniramine 4 mg (Schering-Plough BV, Utrecht, The 
Netherlands) and lorazepam 1 mg (Hexal BV, Hillegom, The 
Netherlands) (all immediate release formulations) and placebo and 
were spaced apart by a washout period of at least 4 days. Within the 
choice reaction time task SQ and RC were varied and consisted of two 
levels each. The order of treatment and sequence of task conditions 
were counterbalanced between subjects. 
 
Procedure 
 
Subjects were individually trained to perform all tasks in two practice 
sessions within two weeks prior to their first treatment day. On treatment 
days subjects arrived at the University at 9:00am. Between 9:00am and 
9:30am the inclusion and exclusion criteria were checked. At 10:00am 
subjects performed a short version of each task to remind them of the 
procedures. At 10:30am the study medication was ingested. The test-battery 
consisted of the Choice Reaction Time Task, Critical Tracking Task and 
Subjective Drowsiness and was performed between 12:00am and 1:00pm. A 
previous study (Van Ruitenbeek, et al., 2008) has shown that the peak 
impairment of dexchlorpheniramine is around 1.5 hours post treatment.  
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Behavioural assessments 
 
Choice reaction time task 
The choice reaction time task (CRT) used in this study was based on 
Smulders, Kok, Kenemans, & Bashore (1995). The speed of information 
processing of the sensory and motor stages were assessed by manipulating 
the quality of the visual stimuli and complexity of the responses, 
respectively. Smulders et al. (1995) found additive effects of SQ and RC on 
reaction time. In addition, they found selective effects of SQ on the interval 
between the stimulus and P300 peak latency and selective effects of RC on 
the interval between the LRP-onset and the response. 
The task consisted of a repeated presentation of the numbers 2 and 5 
on a computer screen for 200 ms. The stimuli consisted of small squares 
surrounded by a frame of squares. The squares consisted of grids of 6 by 6 
pixels. The time between offset of a stimulus and the presentation of the next 
stimulus was varied between 1500 and 2200 ms. Subjects had to respond as 
fast as possible by pressing a left or right hand button with their left or right 
index finger when a 2 or a 5 appeared, respectively. The task consisted of 
four blocks of 112 trials, which each lasted approximately 4 minutes and in 
which half of the stimuli were visually degraded and half of the stimuli were 
intact. Degradation was achieved by placing 20 squares (42%) from the 
frame at random positions in the field within the frame not occupied by the 
26 squares of the digit. There were 7 degraded versions of each digit of 
comparable difficulty to prevent subjects from responding to learned 
features of the stimulus instead of recognizing the digit.  
In two blocks (complex blocks; C) RC was increased by asking the 
subjects to press three buttons instead of one (simple blocks; S) in the 
following sequence; index, ring and middle finger. The pressing of the first 
button indicated the reaction time. The time (ms) between the first button 
press and the third was also recorded as ‘motor time’ (MT). The blocks were 
presented in the order SCCS to one half of the subjects and CSSC to the other 
half. 
 The primary performance variable in this task is the average reaction 
time of the correct responses for the four different task conditions, i.e. intact-
simple, degraded-simple, intact-complex and degraded-complex and 
accuracy scores, which were logarithmically transformed due to the non-
linear nature of a decrease in accuracy (Dickman & Meyer, 1988). 
 
Critical tracking task. 
The Critical Tracking Task (CTT) measures the ability to control an unstable 
error signal in a first-order compensatory tracking task (Jex, McDonnell, & 
Phatak, 1966). Error is displayed as a horizontal deviation of a yellow 
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triangle from the midpoint on a horizontal scale. Compensatory movements 
null the error by returning the triangle to the centre. The frequency of the 
error gradually increases until the subject loses control. The frequency at 
which control is lost is the critical frequency or lambda-c (rad s-1). The CTT 
includes five trials of which the highest and lowest scores are removed. The 
average of the three remaining scores is the final score. A previous study has 
shown that the critical tracking task is sensitive to the effects of H1-blockade 
between 1.5 and 2.5 hours after treatment (Van Ruitenbeek, et al., 2008). 
 
Visual analogue scales 
Subjective drowsiness is assessed using a series of 16 analogue scales of 100 
mm. These provide three factor analytically defined summary scores for 
‘drowsiness’, ‘contentedness’, and ‘calmness’ (Bond & Lader, 1974) of which 
drowsiness was of main interest. Visual analogue scales have been shown to 
be sensitive to the sedative effects of antihistamines (Van Ruitenbeek, et al., 
2008). 
 
Event related potentials 
 
During performance on the CRT subjects’ EEG activity was recorded to 
measure the P300, LRP and P150 associated with correct responses. 
Dependent variables were duration of the interval (ms) between stimulus 
and P300 peak amplitude (S-locked P300) and between the response and the 
P300 peak amplitude (R-locked P300), and the interval between the stimulus 
onset and LRP onset (S-locked LRP) and between the response and LRP 
onset (R-locked LRP). In addition, the amplitude of the S-locked and R-
locked P300 was determined as a measure of resource availability for 
stimulus processing. 
 
Recordings and signal analysis 
EEG activity was recorded from an array of 32 electrodes from the standard 
10-20 system using an electrocap (Jasper, 1957). All electrodes were filled 
with electrode-gel and were line referenced to the right mastoid electrode. 
Offline they were referenced to both left and right mastoids. The FPz 
electrode was used as ground electrode. Horizontal EOG was recorded using 
electrodes attached to the outer canthi of the eyes and vertical EOG was 
recorded from electrodes attached above and below the left or right eye and 
in line with the pupil. 
All electrode impedances were kept below 5 kΩ. Signals were 
amplified using Neuroscan Synamps amplifiers and collected using 
Neuroscan software. All signals were sampled at a 1000 Hz and filtered 
online using a 100 Hz low-pass filter and a 0.1 Hz high-pass filter. 
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Continuous signals obtained during the performance on the CRT 
were filtered off-line using a 1 Hz high-pass filter after which EEG was 
corrected for vertical and horizontal eye movements according to a 
procedure by. Semlitsch, Anderer, Schuster, & Presslich (1986). The S-locked 
sweeps were obtained by epoching from 100 ms before until 1000 ms after 
stimulus presentation and the interval between sweep onset and stimulus 
served as baseline. The R-locked sweeps were obtained by epoching from 
475 ms before to 625 ms after the response.  For the analysis of the P300 all 
sampled EEG and EOG epochs were low pass filtered using a 3.6 Hz low-
pass filter and for the LRP the data were filtered using a 11.1 Hz low-pass 
filter. Sweeps containing artefacts exceeding ±75 µV on the FZ, CZ, PZ, OZ, 
C3, or C4 electrodes were rejected. This resulted in an average acceptance of 
92% of the epochs.  
The length of the S-locked and R-locked intervals of the P300 were 
determined at the Cz electrode site. The S-locked P300 signals were 
determined as the time between onset of the stimulus and the latency of the 
largest maximum in a window between 333 and 463 ms as determined by 
the latency of the P300 of the grand average. The R-locked P300 intervals 
were determined as the time between the largest maximum of the P300 
component and the given response in a window between 132 ms before and 
68 ms after the response as determined by the latency of the grand average at 
the same site. 
LRP’s were computed by subtracting C4 from C3, point by point, for 
right and left hand trials and subtracting left hand from right hand trials. 
The onset latencies of the S-locked and R-locked LRP waveforms were 
determined using the jackknife scoring method with a fixed 1 µV criterium 
(Miller, Patterson, & Ulrich, 1998; Ulrich & Miller, 2001). 
 
Statistical analysis 
All dependent variables were screened for normality of their distributions 
and no non-normalities were detected. To determine whether task 
manipulations in the CRT were successful, performance scores and ERPs 
after placebo treatment were analyzed using repeated measures analysis of 
variance of a 2x2 factorial model. Within subject variables were SQ (intact, 
degraded) and RC (simple, complex).  
Effects of Treatment (dexchlorpheniramine, lorazepam, placebo) and 
interactions with SQ and RC on performance measures and ERPs in the CRT 
were analysed in a 3x2x2 factorial model. F-values for differences in S-locked 
and R-locked LRP onset latencies were divided by (n-1)2 to correct for the 
reduction of variance induced by the jackknife method (Ulrich & Miller, 
2001). If overall multivariate F-tests indicated a significant difference 
(p<0.05), data were further analysed using two univariate drug-placebo 
contrasts. 
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Performance on the CTT and subjective drowsiness scores were 
analysed for Treatment effects using repeated measures Univariate Analysis 
of Variance. All data were analysed using SPSS for Windows (version 12.0.1).  
 
RESULTS 
 
Results of task manipulations and treatments on performance and ERPs are 
presented in table 1. 
 
Choice reaction time task – task manipulations 
 
Degraded stimuli prolonged reaction time (SQ, F(1,17) = 153.7, p = 0.001), S-
locked P300 latency (F(1,17) = 6.2, p = 0.023) and the S-locked LRP-onset 
latency (F(1,17) = 23.4, p = 0.001). Stimulus degradation did not increase the 
interval between the R-locked P300 and the response and the R-locked LRP-
onset and the response (SQ, Fs(1,17) < 1). Degraded stimuli also decreased 
the accuracy of the response (F(1,17) = 20.9, p = 0.001), decreased the 
amplitude of the S-locked P300 (F(1,17) = 5.1, p = 0.038) and the R-locked 
P300 amplitude (F(1,17) = 5.0, p = 0.039). 
Increased response complexity prolonged reaction time (RC, F(1,17) 
= 15.5, p = 0.001), the interval between the R-locked P300 and the response 
(F(1,17) = 17.4, p = 0.001) and the interval between R-locked LRP-onset and 
the response (F(1,17)  = 8.5, p = 0.010). Contrary to expectations, increased 
response complexity led to a decrease in S-locked P300 latency (F(1,17) = 7.7, 
p = 0.013) and tended to increase the S-locked LRP-onset latency (F(1,17) = 
3.1, p = 0.097). Also, increased RC decreased the S-locked and R-locked P300 
amplitude (F(1,17) = 12.0 p = 0.003 and F(1,17) = 13.6, p = 0.002, respectively). 
There were no significant interactions between SQ and RC (RT: 
F(1,17) < 1, S-locked P300: F(1,17) < 1, R-locked P300: F(1,17) = 1.5, p = 0.225, 
S-locked LRP: F(1,17) < 1, R-locked LRP: F(1,17) < 1). Together these data 
indicate successful task manipulations. 
 
  
Table 1: Effects of treatments and task manipulations on reaction time and ERPs. Lorazepam (L1) increased the effect of stimulus degradation on reaction 
time and dexchlorpheniramine (D4) increased the effect of stimulus degradation on P300 peak latency. Significant (p<0.05) or near significant (p<0.10) 
difference in effects of SQ after Treatment when compared with placebo are indicated with ** and *, respectively. Near significant (p<0.10) difference in 
effects of RC after Treatment when compared with placebo is indicated with † 
Choice Reaction Time task Main 
effect 
Treatment 
Treatment*SQ Treatment 
*RC 
Placebo 
Mean (± 
SEM)  
 D4 
Mean (± 
SEM)  
 L1 
Mean (± 
SEM)  
 
 p =  p = p = Intact Degraded Intact Degraded Intact Degraded 
Reaction time (ms) < 0.01 < 0.07 n.s.      ** 
    Simple response    390 (10.6) 426 (12.6) 417 (14.7) 452 (17.3) 440 (14.8) 491 (17.8) 
    Complex response    420 (11.7) 455 (11.6) 436 (13.4) 478 (16.6) 472 (15.0) 517 (17.9) 
          
S-Locked P300 latency 
(ms) 
n.s. < 0.02 n.s.    *   
    Simple response    380 (5.2) 392 (8.3) 380 (7.1) 404 (7.7) 378 (8.7) 385 (9.7) 
    Complex response    370 (7.2) 384 (7.9) 375 (6.9) 395 (7.3) 373 (8.1) 381 (9.4) 
          
R-Locked P300 latency 
(ms) 
< 0.02 n.s. n.s.       
    Simple response    -14 (12.6) -22 (10.8) -20 (9.5) -18 (8.6) -35 (10.8) -37 (10.7) 
    Complex response    -57 (10.3) -55 (10.7) -57 (12.2) -55 (10.8) -68 (8.2) -80 (10.6) 
          
S-Locked LRP-onset 
latency (ms) 
< 0.01 n.s. 0.08    †   
    Simple response    237 (0.7) 267 (0.7) 247 (0.7) 300 (0.7) 278 (1.6) 334 (1.6) 
    Complex response    239 (0.5) 285 (0.8) 239 (0.5) 280 (0.7) 305 (1.1) 368 (2.8) 
          
R-Locked LRP-onset 
latency (ms) 
n.s. n.s. n.s.       
    Simple response    -137 (0.6) -131 (0.4) -142 (0.7) -149 (0.7) -130 (0.5) -133 (0.6) 
    Complex response    -169 (0.7) -166 (1.0) -183 (1.1) -202 (1.0) -176 (1.2) -162 (2.5) 
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Figure 1: Effects of treatment and manipulations of stimulus quality and response complexity on 
the stimulus locked P300. Stimulus quality increased the peak latency (p<0.01) and interacted 
with treatment (p<0.02) which was caused by an increased effect of the degraded stimulus by 
dexchlorpheniramine (p<0.10). 
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Figure 2: Effects of treatment and manipulations of stimulus quality and response complexity 
on the interval between the R-locked P300 and the response. Response complexity and 
lorazepam increased the interval duration (p < 0.05), but did not interact. 
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Choice reaction time task – Treatment effects 
 
Reaction time, accuracy and motor time 
Treatment had a significant main effect on overall reaction time (F(2,16) = 
15.5, p = 0.001). Drug-placebo contrasts showed that both 
dexchlorpheniramine and lorazepam prolonged reaction time (F(1,17) = 12.0, 
p = 0.003; F(1,17) = 29.8, p < 0.001, respectively). 
 Treatment tended to interact non-significantly with SQ (F(2,16) = 3.2, 
p < 0.069) but not with RC (F(2,16) < 1). Lorazepam increased the effect of SQ 
as compared with placebo (F(1,17) = 6.4, p = 0.022), but dexchlorpheniramine 
did not (F(1,17) < 1). 
 
S-locked and R-locked P300 latencies 
Treatment did not have a significant main effect on the S-locked P300 
latencies (F(2,16) = 2.7, p = 0.099). However, Treatment did interact with SQ 
(F(2,16) = 5.4, p = 0.016). Dexchlorpheniramine increased the effect of SQ on 
this interval nearly significant (F(1,17) = 4.4, p = 0.052), while lorazepam 
clearly did not (F(1,17) = 1.4, p = 0.246.) (figure 1). 
Mean duration of the interval between the R-locked P300 and the 
response differed significantly between treatments (F(2,16) = 5.5, p = 0.015). 
Lorazepam increased the interval (F(1,17) = 8.2, p = 0.011), while 
dexchlorpheniramine did not (F(1,17) < 1). Treatment did not interact with 
RC or SQ (Fs(2,16) < 1) (figure 2). 
 
R-locked and S-locked LRP 
Treatment had no main effect on the onset of the R-locked LRP (F(2,16) = 1.4, 
p = 0.283) and did not interact with RC (F(2,16) < 1) and with SQ (F(2,16) = 
1.04, p = 0.376) (figure 3). 
Treatment did affect S-locked LRP-onset latency significantly 
(F(2,16) = 6.2, p = 0.010). Lorazepam increased the latency (F(1,17) = 12.7, p = 
0.002), but overall dexchlorpheniramine did not (F(1,17) = 1.5, p = 0.239). 
However, RC tended to interact with Treatment (F(2,16) = 2.9, p = 0.080) and 
dexchlorpheniramine tended to decrease the S-locked LRP onset latency 
(F(1,17) = 3.7, p = 0.070) (figure 4). 
 
S-locked and R-locked P300 amplitude 
Treatment did not affect the S-locked P300 amplitude and did not interact 
with SQ (Fs(2,16) < 1) . However, Treatment did interact with RC (F(2,16) = 
4.8, p = 0.023). Lorazepam prevented a decrease of the amplitude of the P300 
in the complex response condition compared with placebo (F(1,17) = 10.2, p 
= 0.005).  
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Treatment also did not have a main effect on the R-locked P300 
amplitude (F(2,16) = 1.3, p = 0.298). In contrast to the results above, 
Treatment did not interact with RC (F(2,16) = 1.3, p = 0.296). 
 
Motor time  
Treatment marginally significantly affected MT (F(2,16) = 3.6, p = 0.052). 
Lorazepam significantly increased MT with 31.6 ms on average (F(1,17) = 7.2, 
p = 0.016), while dexchlorpheniramine had no significant effect (F(1,17) < 1). 
SQ had no significant effect on MT (F(1,17) < 1) and did not interact with 
Treatment (F(2,16) = 1.3, p = 0.296). 
 
Accuracy 
Statistical tests on the Log transformed accuracy data revealed a similar 
pattern of effects as was shown by the reaction time data. Treatment had a 
main effect (F(2,16) = 5.9, p = 0.012); lorazepam tended to reduce the 
accuracy (F(1,17) = 3.2, p = 0.093). Treatment significantly interacted with SQ 
(F(2,16) = 4.8, p = 0.023), but not with RC (F(2,16) < 1). The accuracy reducing 
effect of degraded SQ (F(1,17) = 45.0, p < 0.001) was enlarged by lorazepam 
(F(1,17) = 10.2, p = 0.005) and near significantly by dexchlorpheniramine 
(F(1,17) = 3.3, p = 0.085). 
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Figure 3: Effects of treatment and manipulations of stimulus quality and response complexity 
on the interval between the R-locked LRP and the response. Both treatments did not prolong 
the interval. Response complexity did increase the interval (p<0.01), but did not interact with 
treatment. 
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Figure 4: Effects of treatment and manipulations of stimulus quality and response complexity on 
the stimulus locked LRP onset latency. Lorazepam and degraded stimuli increased the onset 
latency (p’s < 0.01). Response complexity tended to interact with Treatment (p < 0.10) and 
dexchlorpheniramine tended to decrease the S-locked LRP onset when a complex response has to 
be given (p < 0.10). 
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Critical Tracking Task 
Treatment significantly impaired tracking performance (F(2,16) = 11.6, p = 
0.001); lorazepam decreased the critical frequency from an average (±SEM) 
lambda of 4.16 (±0.14) after placebo administration to an average (±SEM) 
lambda of 3.56  (±0.17)  (F(1,17) = 24.4, p = 0.001). Dexchlorpheniramine also 
decreased the critical frequency to an average lambda of 3.99 (±0.12), but not 
significantly (F(1,17) = 2.4, p = 0.141). 
 
Visual analogue scale 
Treatment significantly affected subjective drowsiness (F(2,16) = 7.8, p < 
0.004);  lorazepam and dexchlorpheniramine increased drowsiness scores 
from 34.5 (±5.0) to 51.7 (±4.3) (F(1,17) = 16.6, p = 0.001) and 59.4 (±4.5) (F(1,17) 
= 7.9, p = 0.012), respectively. 
 
DISCUSSION AND CONCLUSIONS 
 
This study aimed to determine the locus of effects of H1-blockade on 
sensorimotor processing in humans using the additive factor method and 
ERPs. Effects of the task manipulations in the placebo condition showed an 
additive pattern of effects of SQ and RC, confirming that the manipulations 
affected separate stages of information processing. Both treatments had 
significant sedative effects and impaired sensorimotor performance as 
measured by the CTT and CRT. The level of subjective drowsiness following 
dexchlorpheniramine administration was comparable to that in a former 
study (Van Ruitenbeek, et al., 2008). 
 
Dexchlorpheniramine 
In contrast to earlier studies, performance on the CTT was not significantly 
impaired by dexchlorpheniramine. A previous study by our group (Van 
Ruitenbeek, et al., 2008) used only female subjects, because they have been 
found to be more sensitive to the effects of antihistamines (Ramaekers & 
O'Hanlon, 1994; Robbe, 1990; Vermeeren, Ramaekers, & O'Hanlon, 2002; 
Vuurman, Uiterwijk, Rosenzweig, & O'Hanlon, 1994) whereas the present 
study used subjects of both sexes. Post-hoc analysis of Treatment effects in 
men and women in the present study revealed that in contrast to our 
expectations, the performance of women who received dexchlorpheniramine 
did not decrease, while the performance of men did. The interaction between 
Treatment and Gender was not significant, however. In contrast, lorazepam 
caused a marked decrease in performance in both sexes. Since lorazepam 
also increased MT in the CRT, the effects may partially be due to muscle 
relaxation (Olkkola & Ahonen, 2008). 
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Both treatments slowed reaction times in the CRT. The effect of 
dexchlorpheniramine on the stimulus-locked P300 latency was enlarged if 
stimuli were degraded, which indicates that the location of the effect was 
before the P300 peak latency. The effects on processes occurring before 300 
ms after stimulus presentation is supported by other studies in which 
antihistamines caused the P300 latencies to increase (Loring & Meador, 1989; 
Meador, Loring, Thompson, & Thompson, 1989; Seidl, et al., 1997). It needs 
some consideration that slowing of information processing may be related to 
impaired attention induced by antihistamines which has frequently been 
found [e.g. (Bower, et al., 2003; Fine, et al., 1994)]. Impaired attention 
processes are reflected by a decreased P300 amplitude (Polich, 2007). 
However, we did not observe an effect of dexchlorpheniramine on the P300 
amplitude. Therefore, an attention deficit does not explain the effects of 
dexchlorpheniramine in this study. 
To the best of our knowledge, there is no information on effects of 
antihistamines on response related processes. In the current study, 
dexchlorpheniramine did not have a main effect on the duration of the 
interval between the R-locked LRP-onset and the response nor did it interact 
with RC as measured by the duration of the interval. Taken together the 
results suggest that the effects of dexchlorpheniramine are located before the 
P300 peak amplitude and that it does not affect response related processes. 
However, in terms of reaction time data an interaction with SQ was 
not found, but was expected if dexchlorpheniramine would affect the feature 
extraction stage. To explain this, the subjects may have compensated for the 
effects on feature extraction by decreasing the duration of a different stage 
following the P300. The question is what stage this would be. The increase in 
reaction time with regard to complex responses tended to be less after the 
administration of dexchlorpheniramine as compared with placebo. In 
addition, the interval between the stimulus and the onset of the LRP 
decreased when subjects were required to give a complex response after 
administration of dexchlorpheniramine, which suggests that subjects began 
with their response sooner. Therefore, an increased P300 peak latency might 
have been compensated for by speeding up a process before response 
programming (e.g. response choice) so that the effect of SQ was not 
increased by dexchlorpheniramine as measured with reaction time. 
The Treatment by RC interaction as measured with the S-locked LRP 
is, however, problematic for the assumption of strictly serially ordered and 
discrete processing stages. Although not supported by some (de Jong, 
Wierda, Mulder, & Mulder, 1988), it has been suggested that information 
processing is not entirely serial and discrete (Miller & Hackley, 1992; Osman, 
Bashore, Coles, Donchin, & Meyer, 1992). Non-serial stages do not, however, 
invalidate the assumption of additivity (Miller, van der Ham, & Sanders, 
1995) and partial information of the stimulus is sufficient to start the 
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programming of the response. It is therefore possible that subjects started 
response programming before the stimulus had been identified. 
The effects on sensory processing are supported by the post-hoc 
analysis of the P150 peak amplitude, which was increased after 
dexchlorpheniramine intake (drug-placebo contrast: F(1,17) = 5.8, p = 0.028). 
An increase in amplitude has been interpreted as increased mapping of 
visual features on higher order representations (Chauncey, Grainger, & 
Holcomb, 2008). It is suggested that visual information processing is 
impaired and that the increased P150 amplitude possibly reflects a 
compensatory mechanism. 
This study has shown than histamine hypofunction impairs sensory 
information processing. This may be of relevance for the treatment of 
schizophrenic patients. Schizophrenia is characterized by changes in sensory 
processing and it has been found that the histamine system in these patients 
is affected  (Onodera, et al., 1994; Witkin & Nelson, 2004). Our findings 
suggest that the affected histamine system may be involved in the sensory 
deficits in schizophrenia. Histamine based drugs may, therefore be useful as 
a treatment in this disorder (Geyer, Krebs-Thomson, Braff, & Swerdlow, 
2001). 
 
Lorazepam 
Lorazepam increased the effect of SQ on reaction time and accuracy, which 
suggests that lorazepam affects the stage of feature extraction. In that case, 
however, lorazepam is expected to have a main effect on the S-locked P300 
peak latency and interact with SQ. We did not observe these temporal 
effects. In contrast to our results, other studies found increased P300 
latencies after the administration of lorazepam (Curran, et al., 1998; 
Pooviboonsuk, 1996). However, they all administered 2 mg orally which is 
twice the dose that was administered in this study. It is possible that only 
high dosages are able to increase the S-locked P300 latency and that a dose of 
1 mg only has subtle effects on stimulus driven stages of information 
processing. 
Similar to our results Pang & Fowler (1994) did not find triazolam to 
increase the effect of SQ on the S-locked P300 peak latency, while it did 
increase the effect of SQ on reaction time. Pang & Fowler (1994) argue that 
this dissociation between effects on the two measures may be due to the 
slowing of response related processes. This hypothesis is supported by the 
finding that lorazepam increased the interval between the R-locked P300 and 
the response. However, lorazepam did not affect the interval between R-
locked LRP-onset and the response, which should be observed when 
response related processes are affected. Similarly, Riba, et al. (2005) did not 
observe effects of 1 mg lorazepam on the R-locked LRP-onset latencies. 
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Therefore, it seems unlikely that response related processes within the 
central nervous system were affected. 
If the effect of lorazepam is neither located before the P300 peak 
latency nor after the start of response programming, it may be located in the 
transition between feature extraction and response programming. In 
support, lorazepam did increase the S-locked LRP onset latency, indicating a 
later onset of the response programming. Riba, et al. (2005) also found 
increased S-locked LRP-onset latencies after the administration of 1 mg 
alprazolam and Northoff, et al. (2000) found that 1 mg lorazepam increased 
the latencies of late readiness potentials. Our results also show that 
lorazepam increased the interval between the R-locked P300 and response. 
These results suggest that the temporal locus of the effect is before the 
response programming and after identification of the stimulus. 
To explain the difference between the temporal (ERP latency) and 
functional (functional stage) loci of effects, subjects may have shifted the 
speed-accuracy trade-off in favour of speed, such that subjects tended to 
guess the identity of the stimulus. If so, the effect on feature extraction is 
shifted such that subsequent stages of information processing (e.g. response 
choice) receive poor quality information on which the decision to respond 
left or right has to be based. Following such reasoning, the lorazepam 
induced delay in feature extraction may be located in central stages, i.e. in 
the interval between P300 and response onset. 
In conclusion, this paper shows that both drugs affect at least sensory 
stages of information processing. However, the effects of the treatments 
differ qualitatively as shown by the ERPs. Therefore, caution needs to be 
taken when interpreting the data. The effects of lorazepam on feature 
extraction resulted in a delayed onset of response programming and 
increased reaction times. Nevertheless, lorazepam can be used as an active 
control in studies investigating effects of drugs on sensory stages. Central 
H1-blockade leads to impaired sensory processing, but also to compensating 
response programming. Sensory disturbances in patients suffering from, for 
example schizophrenia, may be related to histamine dysfunction. Therefore, 
new histamine based drugs may be useful in treating sensory disturbances in 
such pathologies. 
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CHAPTER 6 
 
EFFECTS OF L-HISTIDINE DEPLETION AND 
L-TYROSINE/L-PHENYLALANINE 
DEPLETION ON SENSORY AND MOTOR 
PROCESSES IN HEALTHY VOLUNTEERS 
Van Ruitenbeek, P., Sambeth, A., Vermeeren, A., Young, S. N., Riedel, 
W. J. (In press). Effects of L-histidine depletion and 
tyrosine/phenylalanine depletion on sensory and motor processes in 
healthy volunteers. British Journal of Pharmacology. 
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INTRODUCTION 
 
Histamine has been associated with a number of clinical disorders in which 
cognitive performance is impaired (Onodera, Yamatodani, Watanabe, & 
Wada, 1994). Animal models for cognitive deficits in disorders like Attention 
Deficit Hyperactivity Disorder, Parkinson’s disease, schizophrenia and sleep 
disorders have been used to test the effects of histamine H3-receptor 
antagonists as possible therapeutic agents (Esbenshade, Fox, & Cowart, 2006; 
Leurs, Blandina, Tedford, & Timmerman, 1998; Vohora, 2004). H3-Receptor 
antagonists increase histamine function through presynaptic receptors. 
These studies have shown that performance on a plethora of tasks is 
improved and have therefore attracted the attention of many pharmaceutical 
companies (Esbenshade, et al., 2006; Leurs, et al., 1998; Wijtmans, Leurs, & 
de Esch, 2007). 
To study the role of histamine in cognition histamine functioning 
can be manipulated. The main observation in such studies is that increasing 
histamine activity leads to improved cognitive performance and prolonged 
wakefulness, while decreasing histamine activity leads to diminished 
performance and increased sleepiness. More specifically, the role of 
histamine in human cognition has mostly been studied by looking at the 
effects of histamine H1-receptor antagonists (i.e. antihistamines). The 
impairing effect of centrally active antihistamines in humans on 
sensorimotor performance has been well established and has often been 
attributed to its sedative effects (Hindmarch & Shamsi, 1999; Kay, 2000; 
O'Hanlon & Ramaekers, 1995; P. Van Ruitenbeek, Vermeeren, & Riedel, 
2008). These effects are believed to be representative of low level of 
histamine functioning in the brain. 
Next to histamine H1-receptor blockade another way to decrease 
histamine functioning is by depleting the precursor L-histidine from the 
brain. Histamine is synthesized by decarboxylation of the essential amino 
acid L-histidine (Cho, Anderson, Wixom, Hanson, & Krause, 1984).  
Analogous to the depletion of L-L-tyrosine/L-phenylalanine to decrease 
dopamine levels in the brain, depletion of L-histidine may cause a decrease 
in brain histamine. In rodents histamine metabolism can be altered more by 
changes in precursor availability as compared with any other 
neurotransmitter (e.g. serotonin, catecholamines and acetylcholine) (Young, 
1996). If the effects of low levels of histamine are H1-receptor mediated, L-
histidine depletion should exert the same effects as H1-antagonists. The 
effects of L-histidine depletion on sensorimotor performance have never 
been assessed before. Therefore, the aim of the present study is to assess the 
effects of L-histidine depletion on sensory and motor related cognitive 
processes in healthy volunteers using a behavioural and psychophysiological 
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approach as has been done before using an H1-antagonist (Van Ruitenbeek, 
Vermeeren, Smulders, Sambeth, Riedel, In press). 
The behavioural approach aims to find interactions between 
treatments and task manipulations in sensorimotor task performance. 
Sensorimotor functioning can be regarded as a result of information 
processing through serial stages from perception, through decision making 
to action. Treatments interacting with task manipulations specifically 
affecting individual stages consequently affect at least the same stage as the 
task manipulation (Sternberg, 1969). It has been shown that H1-blockade 
increases the effect of the visual degradation of stimuli and therefore affects 
sensory stages of information processing (Gaillard, Gruisen, & De Jong, 1988; 
Van Ruitenbeek, Vermeeren, Smulders, Sambeth, A., Riedel, In press). 
With the psychophysiological approach the effects of treatments on 
separate processes in cognitive functioning can be measured using Event 
Related Potentials (ERPs). The time interval between a peak and a stimulus 
or response is indicative of the duration of processes occurring during that 
interval. For example, the duration of the interval between a stimulus and 
the P300 peak latency is indicative of the duration of sensory processes 
(Polich, 2007; Riedel, Mehta, & Unema, 2006). The Lateralized Readiness 
Potential (LRP) is associated with motor programming and the interval 
between the onset of the LRP and the response is indicative for the duration 
of motor related processes (Hackley & Miller, 1995; Miller & Hackley, 1992). 
A former study has shown that H1-blockade increases the duration of the 
P300 peak latency, but does not affect the interval between the LRP onset 
and the response (Van Ruitenbeek, Vermeeren, Smulders, Sambeth, Riedel, 
In press). Thus, H1-blockade affects sensory, but not motor processes. L-
histidine depletion is expected to have similar effects. 
 Since the behavioural effects of L-histidine depletion have never 
been assessed before an active control treatment is needed to demonstrate 
sensitivity of the tests and procedures. A known way to deplete a 
neurotransmitter from the brain is L-L-tyrosine/L-phenylalanine depletion 
(McTavish, Cowen, & Sharp, 1999). L-L-tyrosine is the precursor of 
dopamine and is synthesized from L-phenylalanine. A decrease in dopamine 
levels has been observed after L-tyrosine/L-phenylalanine depletion 
(Montgomery, McTavish, Cowen, & Grasby, 2003) and has been shown to 
impair cognitive performance (Harmer, McTavish, Clark, Goodwin, & 
Cowen, 2001), especially in tasks assessing working memory (Harrison, et 
al., 2004). In addition, an increase in dopamine levels by administration of 
levodopa has shown to have selective effects on sensory stages of 
information processing as it interacted with stimulus intensity and not with 
stimulus-response mapping or stimulus foreperiod duration (Rihet, 
Possamai, Micallef-Roll, Blin, & Hasbroucq, 2002). Therefore, L-tyrosine/L-
phenylalanine depletion will act as an active control. 
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 In summary, if L-histidine depletion indeed causes brain histamine 
levels to decrease, and effects of H1-antagonists are representative for those 
of low levels of histamine, similar behavioural effects as seen after 
administering H1-antagonists are expected such as impaired psychomotor 
performance and increased sedation. Second, if L-histidine depletion affects 
sensorimotor performance the effects may be stage specific. This study 
shows that L-histidine depletion is effective in reducing L-histidine levels as 
measured in blood-plasma and that L-histidine depletion affects motor 
related processes, which is in contrast with the effects of H1-blockade. 
 
METHODS 
 
Subjects 
Twenty-two healthy volunteers (6 male) between 18 and 35 years (mean ± 
SD: 21 ± 2) were recruited by means of posters placed at Maastricht 
University locations. They were paid for their participation. Five subjects, all 
female, withdrew from the study due to side effects of the treatments i.e. 
nausea and vomiting after drinking the amino acid mixture. Data from 
another subject was lost due to a technical error. The remaining sixteen 
subjects out of the intended eighteen had a mean (± SD) age of 21 (± 2) years. 
Subjects’ health was screened using a medical history questionnaire. 
Exclusion criteria were a significant history or presence of any mental or 
physical disorder; gastrointestinal, hepatic, renal, cardiovascular or 
neurological. Also, drug abuse, a body-mass index outside the limits of 18.5 
and 30.0 kg m-2 and drinking more than 20 standard alcoholic consumptions 
per week or 5 beverages containing caffeine per day were regarded as 
exclusion criteria. For women, pregnancy and lactation were also regarded 
as exclusion criteria. No drugs or medication, except oral contraceptives, 
aspirin and acetaminophen, were allowed to be taken from a week before the 
first test-day until the end of the study. Smoking and the use of caffeine were 
prohibited on test-days, the use of alcohol from 24 hours before and during 
each test-day and the use of psychoactive drugs 2 weeks prior to the first 
test-day. On each test-day subjects received a low-protein, carbohydrate rich 
diet, which was similar to that given by Riedel, Klaassen, Deutz, van 
Someren, & van Praag (1999) and Sambeth et al. (2008) 
All subjects received written information about the study procedures 
and signed an informed consent form prior to enrolment. The study was 
approved by the ethics committee of Maastricht University and University 
Hospital Maastricht and carried out in accordance with the World Medical 
Association Declaration of Helsinki and its amendments (Edinburgh, 2000). 
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Study design and treatments 
 
The study was conducted according to a double blind, placebo controlled, 3-
way, cross-over design. Treatments were administration of L-histidine free 
(HID), L-tyrosine/L-phenylalanine free (TYD), or balanced (BAL) amino 
acid drinks (all treatments: Basic Pharma Manufacturing BV, Roermond, The 
Netherlands). L-histidine free treatment consisted of a mixture of 101.2 gram 
of amino acids mixed, but without the amino acid L-histidine. L-tyrosine/L-
phenylalanine depletion treatment consisted of a mixture of 91.8 gram of 
amino, but without the amino acids L-tyrosine and L-phenylalanine. The 
balanced drink contained the entire range of 104.4 gram of amino acids. All 
mixtures were mixed with 200 ml tab water. Female subjects received 85% of 
the drink male subjects received to adjust for differences in bodyweight. 
Treatment days were spaced apart by a washout period of at least 7 
days. The order of treatments and sequence of task conditions were 
counterbalanced between subjects, however not completely due to the drop 
out of six subjects. 
 
Table 1: Content of the amino acid mixtures (g). Histidine is lacking in the histidine depletion 
condition (HID), and L-tyrosine and L-phenylalanine are lacking in the L-tyrosine depletion 
condition (TPD). 
 Balanced drink 
(BAL) 
Histidine depletion 
(HID) 
L-tyrosine depletion 
(TYD) 
Isoleucine 8.0 8.0 8.0 
Leucine 13.5 13.5 13.5 
Lysine 11.0 11.0 11.0 
Methionine 3.0 3.0 3.0 
Valine 8.9 8.9 8.9 
Threonine 6.5 6.5 6.5 
Tryptophan 2.3 2.3 2.3 
Alanine 5.5 5.5 5.5 
Arginine 4.9 4.9 4.9 
Cysteine 2.7 2.7 2.7 
Glycine 3.2 3.2 3.2 
Serine 6.9 6.9 6.9 
Proline 12.2 12.2 12.2 
Histidine 3.2 x 3.2 
L-tyrosine 6.9 6.9 x 
L-phenylalanine 5.7 5.7 x 
 
Procedure 
All subjects were trained to perform the tasks at a plateau level within two 
weeks prior to the first test day. On treatment days subjects arrived well 
rested at the test facility at 9:00 a.m. after refraining from eating from 9:00 
p.m. the night before. One cup of tea or coffee (without milk or sugar) was 
allowed before 8:00 a.m. (6 hours before testing) to prevent possible caffeine 
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withdrawal effects. Consumption of tea of coffee was held constant over the 
treatments days within subjects. 
 After arrival subjects completed visual analogue scales measuring 
subjective mood. A catheter was inserted into the inner bend of the elbow to 
take blood samples before and at 2, 4, 6 and 7 hours after treatment (T0, T2, 
T4, T6 and T7, respectively). At 9:15 a.m., subjects received the amino acid 
drink, which had to be consumed within 15 minutes. Three hours after 
treatment subjects received a small low-protein meal. After treatment, 
subjects could watch television and play board games in a specially 
equipped room. EEG electrodes were attached to the head of the subject four 
hours after treatment and cognitive assessments started 5 hours after 
treatment (14:15 p.m.) and lasted for 45 minutes. Assessments included a 
baseline EEG recording (2 minutes eyes open and 2 minutes eyes closed), 
followed by a critical tracking task. Thereafter, a choice reaction time task 
and a cued simple reaction time task were performed during which EEG was 
recorded. Finally, subjects completed visual analogue scales assessing 
subjective alertness. 
 
Behavioural assessments 
 
Choice Reaction Time Task 
The choice reaction time task (CRT) used in this study was based on 
Smulders, Kok, Kenemans, & Bashore (1995) and was the same as to the task 
used by Van Ruitenbeek, Vermeeren, Smulders, Sambeth & Riedel (In press). 
The speed of information processing of the input and output stages are 
assessed by manipulating the quality of the visual stimuli and complexity of 
the motoric responses, respectively. Smulders et al. (1995) and Van 
Ruitenbeek, Vermeeren, Smulders, Sambeth & Riedel (In press) found 
selective effects of Stimulus Quality on the interval between the stimulus and 
P300 peak latency and selective effects of Response Complexity on the 
interval between the LRP-onset and the response. 
The task consisted of a repeated presentation of the numbers 2 and 5 
in random order on a computer screen. Stimuli consisted of small squares 
surrounded by a frame of squares. The squares consisted of grids of 6 by 6 
pixels. Stimulus presentation time was 200 ms, and the time between offset 
of a stimulus and the presentation of the next stimulus was varied between 
1500 and 2200 ms. Subjects had to respond as fast as possible by pressing a 
left or right hand button with their left or right index finger when a 2 or a 5 
appeared, respectively. The task consisted of four blocks of 112 trials, which 
each lasted approximately 4 minutes. In all blocks half of the stimuli were 
visually degraded and half of the stimuli were intact. Degradation was 
achieved by placing 20 dots (42%) from the frame at random positions in the 
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field within the frame not occupied by the 26 squares of the digit. There were 
7 degraded versions of each digit to prevent subjects from responding to 
learned features of the stimulus instead of recognizing the digit. 
In two blocks the complexity of the response was increased by 
asking the subjects to press three buttons instead of one in the following 
sequence; index, ring and middle finger. The pressing of the first button 
indicated the reaction time. The time between the first button press and the 
third was also recorded as ‘motor time’ (MT). Blocks requiring three button 
presses are indicated as complex (C) blocks and blocks requiring a single 
button press are indicated as simple (S) blocks. The blocks were presented in 
the orders SCCS and CSSC. Half of the subjects were presented with the 
SCCS order and the other halve with the CSSC order. 
 The primary performance variables in this task were the average 
reaction times (ms) of the correct responses for the four different task 
conditions, i.e. intact-simple, degraded-simple, intact-complex and 
degraded-complex. Accuracy scores (%) were logarithmically transformed 
due to the non-linear nature of a decrease in accuracy (Dickman & Meyer, 
1988). 
 
Critical Tracking Task 
The Critical Tracking Task (CTT) measures the ability to control an unstable 
error signal in a first-order compensatory tracking task (Jex, McDonnell, & 
Phatak, 1966). The task has been shown to be sensitive to effects of histamine 
manipulations (Van Ruitenbeek, et al., 2008). Error is displayed as a 
horizontal deviation of a yellow triangle from the midpoint on a horizontal 
scale. Compensatory movements null the error by returning the triangle to 
the centre. The frequency of the error gradually increases until the subject 
loses control. The frequency at which control is lost is the critical frequency 
or lambda-c (rad s-1). The CTT includes five trials of which the highest and 
lowest scores are removed. The average of the three remaining scores is the 
final score. 
 
Cued Simple Reaction Time Task 
A pre-cued simple reaction time task was used to assess treatment effects on 
the Contingent Negative Variation (CNV) (Walter, Cooper, Aldridge, 
McCallum, & Winter, 1964). The CNV is a motoric process related slow 
potential which develops when there is a clear temporal relationship 
between a warning and an imperative signal (Rizzo, et al., 1985). In this task 
subjects started by focusing on a fixation cross presented in the centre of the 
screen for one second. Then a warning signal (red circle) appeared in the 
centre of the screen, which was followed by the imperative stimulus (green 
circle) after exactly 2 seconds. Subjects were asked to respond as fast as 
possible by pressing a button on a response box with their right index finger. 
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The average amplitude (µV) of a 500 ms time window of the CNV is a 
measure of response preparation and was a dependent variable in this study. 
A decrease in average amplitude indicates a decreased supply of 
preparatory potentiality (Rockstroh, Elbert, Lutzenberger, & Altenmuller, 
1991). In addition, reaction time was measured as an indication of response 
slowing. 
 
Subjective alertness scale 
Subjects’ mood was assessed using a series of 16 analogue scales of 100 mm. 
These provide three factor analytically defined summary scores for 
‘alertness’, ‘contentedness’, and ‘calmness’ (Bond & Lader, 1974) of which 
alertness was of main interest. The scores on the 9 items associated with the 
factor drowsiness were added and taken as dependent measure. 
 
Baseline EEG 
Subjects sat still with their eyes open for a 2-minute period during which 
baseline EEG was recorded. Thereafter, baseline EEG was again recorded, 
but now subjects had their eyes closed. The power (µV2) of the delta (1-4 Hz), 
theta (4-8 Hz), alpha (8-12 Hz) and beta (12-30 Hz) frequency bands were 
taken as objective indicators of sedation and cortical activity. 
 
Plasma samples 
After taking a blood sample the catheter was cleaned in order to keep it open 
during the test day. The blood sample was centrifuged for five minutes at 
4ºC at 4000 rpm and Next, 1 ml plasma was frozen and stored at -80ºC until 
quantitative amino-acid analysis by high-performance liquid 
chromatography was performed (Van Eijk, Rooyakkers, & Deutz, 1993). 
 For the L-tyrosine/L-phenylalanine depletion we assessed changes 
in total L-tyrosine and L-phenylalanine levels from baseline at T7 (i.e. 
around testing). L-tyrosine and L-phenylalanine are transported across the 
blood-brain barrier by a transport system that is active towards all the large 
neutral amino acids (LNAA). As there is competition between the various 
LNAA for transport into the brain, the brain concentration is best 
approximated by the ratio of the plasma concentration of an amino acid to 
the sum of the plasma concentration of all other LNAA (ΣLNAA). Therefore, 
we also calculated the L-tyrosine and L-phenylalanine/ΣLNAA ratio for 
these time points. Although L-histidine is weakly basic it is transported into 
the brain by the same transport system as the LNAA (Oldendorf & Szabo, 
1976; Pardridge, 1983) Therefore, for the L-histidine depletion, we assessed 
the change from baseline in total L-histidine and in L-histidine/ ΣLNAA 
ratio for T2, T4, T6 and T7. The T2, T4 and T6 measurements were added due 
to the unknown decrease in L-histidine levels over time. 
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Event related potentials 
 
EEG recordings 
During performance on the cued simple reaction time task and choice 
reaction time task EEG was recorded to measure the P300, LRP and CNV 
ERPs. Dependent variables were the stimulus locked and response locked 
P300 amplitude and peak latencies, stimulus locked and response locked 
LRP onset and the surface under the CNV. EEG activity was recorded by 
means of an electrocap from an array of 32 electrodes from the standard 10-
20 system (Jasper, 1957). All electrodes were filled with electrode-gel and 
were line referenced to the right mastoid electrode. Offline they were 
referenced to both left and right mastoids. The FPz electrode was used as 
ground electrode. Horizontal EOG was recorded using electrodes attached to 
the outer canthi of the eyes and vertical EOG was recorded from electrodes 
attached above and below the left or right eye and in line with the pupil. 
All electrode impedances were kept below 5 kΩ. Signals were 
amplified using Neuroscan Synamps amplifiers and collected using 
Neuroscan software. All signals were sampled at a 1000 Hz and filtered 
online using a 100 Hz low-pass filter and a 0.05 Hz high-pass filter. 
 
Signal analysis 
Continuous signals obtained during the performance on the choice reaction 
time task were filtered off-line using a 1 Hz high-pass filter after which EEG 
was corrected for vertical and horizontal eye movements according to a 
procedure by (Semlitsch, Anderer, Schuster, & Presslich, 1986). Dependent 
variables from the choice reaction time task were duration of the interval 
(ms) between stimulus and P300 peak amplitude (S-locked P300) and 
between the response and the P300 peak amplitude (R-locked P300), and the 
interval between the stimulus onset and LRP onset (S-locked LRP) and the 
interval between the response and LRP onset (R-locked LRP). In addition, 
the amplitude of the S-locked and R-locked P300 was determined as a 
measure of resource availability for stimulus processing. The S-locked data 
were epoched in 1100 ms sweeps starting 100 ms before stimulus 
presentation and the interval between sweep onset and stimulus served as 
baseline. The R-locked data were epoched from 475 ms before to 625 ms after 
the response.  For the analysis of the P300 all sampled EEG and EOG epochs 
were low pass filtered using a 3.6 Hz low-pass filter (Smulders, et al., 1995) 
and for the analysis of the LRP the data were filtered using a 11.1 Hz low-
pass filter (Miller & Hackley, 1992). Sweeps containing artefacts exceeding 
+75 or -75 µV on the Fz, Cz, Pz, Oz, C3, or C4 electrodes were rejected. This 
resulted in an average acceptance of 93% of the epochs.  
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The length of the S-locked and R-locked intervals of the P300 were 
determined at the Cz electrode sites. The S-locked P300 latencies were 
determined as the time between onset of the stimulus and the latency of the 
largest local maximum using the Jackknife method (Miller, Patterson, & 
Ulrich, 1998; Ulrich & Miller, 2001). The amplitude was determined as the 
amplitude of that local maximum. The R-locked P300 intervals were 
determined as the time between the largest local maximum of the P300 
component and the given response, also using the Jackknife method. The 
amplitude was determined as the amplitude of that local maximum. 
LRPs were computed by subtracting C4 from C3, point by point, for 
right and left hand trials and subtracting left hand from right hand trials. 
The onset latencies of the S-locked and R-locked LRP waveforms were 
determined using the Jackknife scoring method with a 1 µV absolute 
criterium (Miller, et al., 1998; Ulrich & Miller, 2001). 
For the cued simple reaction time task, the CNV was determined in a 
window of 500 ms as a measure of response preparation. The data were first 
epoched and then low-pass filtered using a 30 Hz low-pass filter. The area 
report 500 ms before the beginning of the imperative stimulus was the 
dependent variable. 
The power of the delta (1-4 Hz), theta (4-8 Hz), alpha (8-12 Hz) and 
beta frequency (13-30 Hz) bands were calculated by means of a fast Fourier 
transformation of the means of the midline electrodes (Fz, Cz and Pz ). 
 
Statistical analysis 
All dependent variables were screened for normality of their distributions 
and no non-normalities were detected. 
 Baseline differences in blood-plasma levels of L-histidine, L-
histidine/ΣLNAA ratio, L-tyrosine/L-phenylalanine and L-tyrosine + L-
phenylalanine/ΣLNAA ratio were analysed using Analysis of Variance 
(ANOVA) for repeated measures with Treatment as within subject factor 
(BAL HID, TYD). The blood-plasma levels at T7 were further analysed as 
changes from baseline (∆T = T7–T0) with Treatment as within subject factor 
with 3 levels (BAL, HID, TYD). All significant (p<0.05) Treatment effects 
were followed by two treatment-placebo contrasts. Additionally, due to the 
unknown pattern of decrease in plasma levels over time, the L-histidine 
levels and the L-histidine/ΣLNAA ratio in the HID condition were analysed 
with Time as a within subject factor with 5 levels (T0, T2, T4, T6 and T7). 
Significant (p<0.05) effect of Time was followed by 4 simple contrasts with 
baseline (T0). 
Within subject factors in the CRT were Stimulus Quality (SQ: intact, 
degraded) and Response Complexity (RC: simple, complex). Performance 
and ERP data from the CRT were analysed for main effects of Treatment 
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(BAL, HID, TYD) and interactions of Treatment with SQ and RC using a 
3x2x2 within subjects factorial model. F-values for differences in S-locked 
and R-locked LRP onset latencies were divided by (n-1)2 to correct for the 
reduction of variance induced by the jackknife method (Ulrich & Miller, 
2001). If overall multivariate F-tests indicated a significant main effect or 
interaction (p<0.05), data were further analysed using two univariate drug-
placebo contrasts. 
Performance on the CTT, CNV surface area, subjective drowsiness 
scores and plasma levels were analysed for Treatment (3 levels) effects using 
repeated measures ANOVA. The power of each frequency band was 
analysed separately for effects of the treatments using a 3x3 within subject 
model with Treatment and Electrode (Fz, Cz and Pz) as factors when 
subjects held their eyes open and when they held their eyes closed. All data 
were analysed using SPSS for Windows (version 12.0.1). 
 
RESULTS 
 
Missing data 
One subject was removed from the CNV data set due to incomplete data 
collection. The analysis was done on complete data sets from 15 subjects. 
Due to difficulties during blood sample collection several blood samples 
could not be drawn, resulting in 14 complete data sets for the TYD condition. 
Therefore, Treatment effects were analysed using 14 data sets. Data sets for 
the BAL and HID conditions contained 16 subjects. The changes from 
baseline in the HID condition were analysed using 16 data sets. 
 
Blood-plasma levels 
Table 2 displays the average absolute values of L-histidine and L-tyrosine/L-
phenylalanine blood-plasma levels and L-histidine/ΣLNAA and L-
tyrosine+L-phenylalanine/ΣLNAA ratio over time and their changes from 
baseline. 
Blood-plasma levels of L-histidine, L-histidine/ΣLNAA ratio, L-
tyrosine/L-phenylalanine, L-tyrosine+L-phenylalanine/ΣLNAA ratio did 
not differ in the three conditions at baseline (F(2,12) = 2.0, p = 0.181 and Fs < 
1, respectively). 
Treatment had a marginally significant main effect on the change 
from baseline in absolute L-histidine levels (F(2,12) = 3.5, p = 0.063). 
Treatment-placebo contrasts showed that decrease from baseline of L-
histidine levels at T7 in the HID condition (20%) was larger as compared 
with the change in the BAL condition (F(1,13) = 7.6, p = 0.017). L-histidine 
levels did not decrease after treatment in the TYD condition (F<1) as 
compared with the BAL condition. Treatment also had a main effect on the 
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L-histidine/ΣLNAA ratio in blood (F(2,12) = 19.0, p < 0.001). The decrease 
from baseline in the HID condition (48%) was larger than the decrease in the 
BAL condition (12%) (F(1,13) = 33.3, p < 0.001). There was no significant 
difference in L-histidine/ΣLNAA ratio change from baseline between the 
TYD and BAL conditions (F<1). 
 
 
Table 2: Effects of treatments on amino acid levels (µmol/L). Means (±SEM) of absolute values of L-
histidine levels, L-histidine/ΣLNAA ratio, L-tyrosine/L-phenylalanine levels and L-tyrosine + L-
phenylalanine/ΣLNAA ratio at baseline (T0) and the change from baseline after 7 hours (∆T) after a 
balanced drink (BAL), L-histidine depletion (HID) and L-tyrosine/L-phenylalanine depletion (TYD) 
conditions. 1 Indicates significant (p<0.05) change from baseline as compared with placebo. 
 
A significant main effect of Time in the HID condition indicated 
successful reductions in plasma L-histidine levels (F(4,12) = 9.0, p<0.001). 
Levels were decreased at T4 (22%: F(1,15) = 15.1, p < 0.001), T6 (26%: F(1,15) 
= 21.5, p < 0.001) and T7 (20%: F(1,15) = 11.0, p < 0.005). L-histidine levels 
were not significantly reduced at T2 as compared to T0 (F(1,15) = 1.9, p = 
0.186). A main effect of Time also indicated a reduction of L-histidine / 
ΣLNAA ratio (F(4,12) = 45.0, p < 0.001). The ratio was reduced at T2 (58%: 
F(1,15) = 70.1, p < 0.001), at T4 (59%: F(1,15) = 62.0, p < 0.001), at T6 (46%: 
F(1,15) = 37.0, p < 0.001) and at T7 (36%: F(1,15) = 14.4, p = 0.002) (figure 1). 
Treatment Baseline 
(T0) 
  ∆T (T7-T0)   
 BAL HID TYD BAL HID TYD 
L-histidine  93.8 (7.1) 85.7 (7.8) 92.1 (8.0) 2.5 (5.2) -17.1 (5.5)1 8.6 (9.7) 
L-histidine/ 
ΣLNAA ratio 
0.18 
(0.009) 
0.17 
(0.014) 
0.18 
(0.016) 
-0.021 
(0.013) 
-0.083 
(0.011)1 
-0.003 
(0.021) 
L-tyrosine/L-
phenylalanine 
107.3 (6.0) 112.2 
(10.3) 
111.7 
(9.2) 
59.8 (12.7) 71.1 (10.6) -61.0 (5.3)1 
L-tyrosine+L-
phenylalanine/ 
ΣLNAA ratio 
0.28 
(0.018) 
0.28 
(0.008) 
0.27 
(0.013) 
0.120 
(0.021) 
0.088 
(0.019) 
-0.159 
(0.015)1 
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Figure 1: L-histidine/ ΣLNAA ratio in blood-plasma over time as a measure of L-histidine 
depletion. * indicates significant changes from baseline (T0). 
 
Treatment had a significant main effect on the change from baseline of 
absolute L-tyrosine/L-phenylalanine levels (F(2,12) = 62.4, p < 0.001). 
Treatment-placebo contrasts showed that L-tyrosine/L-phenylalanine levels 
decreased (55%) after treatment in the TYD condition as compared with the 
BAL condition (F(1,13) = 96.5, p < 0.001). The change from baseline in L-
tyrosine/L-phenylalanine levels did not differ between the HID and BAL 
conditions (F < 1). Treatment also affected the change from baseline in L-
tyrosine/L-phenylalanine/ΣLNAA ratio (F(2,12) = 58.7, p < 0.001). 
Treatment-placebo contrasts showed that there was a decrease of the ratio in 
the TYD condition (59%) at T7 as compared with the change BAL condition 
(F(1,13) = 125.6, p < 0.001). The change from baseline of the L-tyrosine/L-
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phenylalanine/ΣLNAA ration did not significantly differ between the HID 
and BAL conditions (F(1,13) = 2.2, p = 0.163). 
 
Choice Reaction Time Task  
Table 3 shows means and standard errors of performance measures and 
ERPs from the choice reaction time task. 
 
Behavioural performance 
Both SQ and RC affected response times (F(1,15) = 53.8, p < 0.001 and F(1,15) 
= 5.9, p = 0.028, respectively), but did not interact with each other (F < 1). 
Treatment did not affect reaction time and did not interact with SQ or RC (Fs 
< 1). 
Accuracy of the responses was significantly decreased by stimulus 
degradation (F(1,15) = 10.5, p = 0.006), but RC had no effect (F(1,15) = 1.6, p = 
0.230). Effects of SQ and RC did not interact (F(1, 16) = 2.6, p = 0.130). 
Treatment did not affect accuracy (F(2, 14) = 1.8, p = 0.189) and did not 
interact with SQ (F < 1) or RC (F(2, 14) = 1.7, p = 0.222). 
 
P300 
SQ significantly delayed the S-locked P300 peak latency (F(1,15) = 8.0, p = 
0.013), whereas it tended to be shortened by RC (F(1,15) = 4.1, p = 0.061). 
Treatment did not affect the P300 peak latency (F(2,14) = 1.7, p = 0.213.) and 
did not interact with SQ or RC (Fs < 1). SQ, RC and Treatment did not affect 
the R-locked P300 peak latency (F(1,15) = 2.3, p = 0.154, F(1,15) = 2.0, p = 
0.176 and F(2,14) = 1.9, p = 0.182, respectively). 
 
  
Table 3: Summary of the data derived from the Choice Reaction Time Task after L-histidine depletion (HID), L-tyrosine/L-phenylalanine depletion (TYD) or 
the balanced (BAL) drink administration. Significant or near significant main effects or interaction are indicated with bold p value. Significant (p < 0.05) 
differences in effects of Response Complexity (RC) after HID or TYD as compared with BAL are indicated with 1 
Choice Reaction Time    Treatment      
 Main 
effect  
Treatment 
SQ x 
Treatment 
RC x 
Treatment 
 
 
BAL  
Mean 
(±SEM) 
 HID 
Mean 
(±SEM) 
 TYD 
mean 
(±SEM) 
 
 p =  p =  p =  Intact  Degraded Intact  Degraded  Intact  Degraded  
Reaction time (ms) 0.786 0.953 0.395        
Simple      414 (9.4) 458 (13.2) 414 (9.8) 461 (12.9) 414 (9.0) 460 (13.5) 
Complex      443 (12.9) 488 (15.1) 448 (14.2) 489 (13.6) 439 (13.5) 483 (16.7) 
Accuracy (log%) 0.242 0.649 0.222        
Simple     -0.05 (0.025) -0.07 
(0.026) 
-0.01 
(0.002) 
-0.04 
(0.009) 
-0.01 
(0.002) 
-0.03 
(0.006) 
Complex     -0.02 (0.005) -0.04 
(0.008) 
-0.02 
(0.004) 
-0.04 
(0.008) 
-0.01 
(0.002) 
-0.06 
(0.006) 
S-locked P300           
latency (ms) 0.213 0.427 0.199        
Simple     382 (0.4) 394 (0.6) 391 (0.5) 400 (0.6) 391 (0.3) 402 (0.6) 
Complex     372 (0.4) 389 (0.6) 379 (0.5) 389 (0.7) 381 (0.4) 398 (0.5) 
amplitude (µV) 0.504 0.643 0.063        
Simple     6.7 (0.07) 5.8 (0.07) 6.8 (0.05) 6.3 (0.04) 6.2 (0.06) 6.0 (0.06) 
Complex     4.4 (0.08) 5.2 (0.07) 4.1 (0.06)1 3.7 (0.05)1 4.4 (0.06) 3.9 (0.05) 
R-locked P300            
  
latency (ms) 0.181 0.610 0.641        
Simple     -19 (0.7) -29 (0.6) -15 (0.8) -34 (0.9) -10 (0.7) -20 (0.7) 
Complex     -59 (-1.9) -61 (1.4) -42 (1.1) -73 (3.5) -34 (1.3) -43 (2.4) 
amplitude (µV) 0.965 0.025 0.8617        
Simple     5.0 (0.06) 4.5 (0.07) 5.2 (0.04) 3.9 (0.05) 4.6 (0.05) 4.8 (0.06) 
Complex     2.6 (0.06) 2.1 (0.06) 2.6 (0.06) 2.1 (0.05) 2.7 (0.06) 2.2 (0.06) 
S-locked LRP           
onset (ms) 0.336 0.218 0.286        
Simple     252 (0.5) 269 (0.8) 253 (1.0) 344 (3.5) 270 (0.5) 305 (2.0) 
Complex     247 (0.7) 303 (0.7) 279 (0.7) 309 (1.2) 271 (0.5) 272 (0.5) 
R-locked LRP           
onset (ms) 0.103 0.880 0.068        
Simple     -152 (0.9) -152 (1.5) -131 (0.7) -118 (0.8) -122 (0.7) -124 (0.5) 
Complex     -167 (1.2) -172 (1.0) -176 (1.2)1 -183 (1.6)1 -146 (0.5) -152 (0.8) 
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+
-
R-locked LRP after L-histidine depletion
Response
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Response
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Intact stimulus, Complex response
Degraded stimulus, Complex response
  
 
Figure 2: Effects of treatments of the R-locked LRP onset latency. L-tyrosine/L-
phenylalanine depletion decreased the interval between the R-locked LRP and 
response. L-histidine depletion interacted with RC and increased the interval 
prolonging effect. 
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S-locked P300 peak amplitude was significantly suppressed by RC 
(F(1,15) = 25.2, p < 0.001).  Treatment tended to interact with RC (F(2,14) = 
3.4, p < 0.063), which was due to an enhanced amplitude suppressing effect 
of RC after HID (F(1,15) = 6.8, p < 0.002) SQ and Treatment did not have 
main effects on the peak amplitude (F(1,15) = 1.7, p = 0.213. and F < 1, 
respectively) and did not interact (F < 1). The R-locked P300 amplitude was 
significantly suppressed by SQ and RC (F(1,15) = 4.7, p = 0.046 and F(1,15) = 
16.2, p < 0.001, respectively), but Treatment did not decrease the amplitude 
(F < 1). However, Treatment interacted with SQ (F(2,14) = 4.9, p = 0.025). 
Drug-placebo contrasts did not reveal any differences with BAL, however 
(HID: F(1,15) = 1.2, p = 0.285, TYD: F(1,15) = 1.7, p = 0.210). 
 
LRP 
The interval between the stimulus and onset of the LRP (i.e. S-locked LRP 
onset latency) was delayed by decreased SQ (F(2,14) = 7.9, p < 0.013). 
Treatment and RC had no effect (F(2,14) = 1.2, p = 0.336 and F < 1, 
respectively) and Treatment did not interact with SQ (F(2,14) = 1.7, p = 0.218) 
or RC (F(2,14) = 1.4, p = 0.286). SQ and RC also did not interact (F < 1). 
 The interval between the response and LRP onset (i.e. R-locked LRP 
onset) was increased by increased RC (F(1,15) = 13.8, p = 0.003),. Treatment 
tended to interacted with RC (F(2,14) = 3.3, p = 0.068), HID enhanced the 
effect of RC (F(1,15) = 6.8, p = 0.020) by increasing the interval between the 
LRP-onset and the response in case of a complex response (figure 2). 
Treatment (F(2,14) = 2.68, p = 0.106) did not have a main effect on the R-
locked LRP onset. Nevertheless, drug-placebo contrasts showed that TYD 
decreased the interval between the R-locked LRP-onset and the response 
(F(1,15) = 5.1, p = 0.039). SQ had no effect on the R-locked LRP onset and did 
not interact with Treatment (Fs < 1). 
 
Cued Simple Reaction Time Task 
Simple reaction time and associated area under the Contingent Negative 
Variation did not differ between treatments (F < 1 and F(2,13) = 1.3, p = 
0.314, respectively)(table 4).  
 
Critical Tracking Task 
Treatment had no significant main effect on the average tracking 
performance (F(2,14) = 2.5, p = 0.115) (table 4). 
 
Drowsiness 
 
Visual Analogue Scale 
Treatment had no significant effect on subjective alertness (F < 1) (table 4).  
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Table 4: Mean (±SEM) performance scores on electrophysiological and behavioural measures. 
Simple Reaction Time task and Critical Tracking Task performance, and subjective alertness 
after the balanced drink (BAL), L-histidine depletion (HID) and L-tyrosine/L-phenylalanine 
depletion (TYD). There were no significant differences between the treatments. 
 Treatment   
 BAL HID TYD 
Simple Reaction Time task    
CNV surface area (µV2) 4.4 (1.1) 3.3 (1.6) 5.2 (1.1) 
Reaction time (ms) 260 (13.6) 272 (68.3) 250 (42.6) 
Critical Tracking Task    
Lambda (rad/s) 3.7 (0.1) 3.8 (0.2) 3.6 (0.2) 
Visual Analogue Scale    
Alertness (mm) 608 (39) 593 (41) 610 (38) 
 
Frequency band power 
Treatment did not affect the power of the delta (F(2,14) = 1.9, p = 0.184), theta 
and alpha (Fs < 1) and beta (F(2,14) = 2.9, p = 0.091) frequency bands when 
subjects held their eyes open. When subjects held their eyes closed 
Treatment also did not affect the power of the delta, theta, alpha (Fs < 1) and 
beta (F(2,14) = 2.9, p = 0.092) frequency bands (table 5). 
 
Table 5: Mean (±SEM) frequency band power (µV2). Power for Delta (1-4 Hz), Theta (4-8 Hz), Alpha (8-12 
Hz) and Beta (12-30 Hz) frequency bands at the Fz, Cz and Pz electrodes in eyes open closed conditions 
were not affected by L-histidine depletion (HID) and L-tyrosine/L-phenylalanine depletion (TYD) as 
compared with the balanced drink (BAL). 
  Eyes open   Eyes closed   
Frequency  BAL HID TYD BAL HID TYD 
Delta power  Fz 12.2 (0.90) 12.3 (1.01) 14.1 (1.41) 18.6 (2.52) 17.0 (1.80) 20.3 (2.83) 
 Cz 12.2 (0.78) 12.8 (0.99) 13.9 (1.02) 17.2 (2.05) 16.8 (1.61) 19.0 (1.74) 
 Pz 12.0 (0.93) 12.8 (1.17) 13.6 (1.15) 15.9 (2.40) 14.7 (1.45) 16.6 (1.73) 
Theta power  Fz 10.6 (1.07) 9.8 (1.14) 10.7 (1.40) 12.4 (0.90) 11.1 (1.13) 11.8 (1.35) 
 Cz 9.5 (0.56) 9.8 (0.80) 10.0 (0.88) 12.9 (1.18) 11.8 (1.21) 12.7 (1.52) 
 Pz 7.7 (0.55) 7.8 (0.63) 7.9 (0.69) 11.1 (1.38) 10.2 (1.11) 10.8 (1.39) 
Alpha power  Fz 6.8 (0.95) 6.7 (1.22) 7.2 (1.29) 15.2 (2.66) 14.1 (2.99) 13.3 (2.40) 
 Cz 8.2 (1.50) 8.0 (1.52) 8.5 (1.73) 19.4 (3.94) 18.6 (4.09) 17.0 (3.20) 
 Pz 11.0 (2.14) 10.5 (2.48) 11.2 (2.56) 29.8 (6.71) 29.4 (7.51) 27.5 (5.88) 
Beta  power  Fz 1.3 (0.12) 1.2 (0.12) 1.4 (0.18) 1.7 (0.18) 1.5 (0.16) 1.7 (0.21) 
 Cz 1.3 (0.13) 1.3 (0.12) 1.5 (0.18) 1.8 (0.19) 1.7 (0.17) 2.0 (0.21) 
 Pz 1.5 (0.16) 1.3 (0.18) 1.5 (0.20) 2.3 (0.33) 2.1 (0.29) 2.2 (0.24) 
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DISCUSSION 
 
The aim of the present study was to decrease histamine levels in the brain by 
depleting subjects of its precursor L-histidine. In order to observe that, we 
determined if HID would exert effects that are comparable to those seen in 
other methods of reduced histamine activity (e.g. H1-blockade). To evaluate 
the hypothesised behavioural effects the neurophysiological consequences of 
precursor depletion needs to be considered. This can only be done based on 
observations concerning peripherally measured effects of the treatments. 
Results showed that, L-histidine levels in blood-plasma were successfully 
reduced by more than 20% from T4 to T7. The L-histidine/ΣLNAA ratio was 
maximally reduced by approximately 59% at T4 and by approximately 36% 
at T7. HID affected response related processes as shown with the significant 
interaction with RC as measured with the R-locked LRP onset latency and 
enhanced the amplitude suppressing effect of RC on the S-locked P300. 
However, L-histidine depletion did not significantly affect performance as 
measured with speed and accuracy in the CRT task, simple RT task or the 
CTT. In addition, HID did not significantly affect subjective and objective 
measures of alertness and arousal, such as mood and EEG power spectrum. 
HID increased the duration of the interval between the LRP onset 
and response indicating increased time needed for more complex response 
programming. In addition, HID increased the effects of complex responses 
on the P300 amplitude indicating that increased response demands reduces 
resources available for stimulus processing (Beauducel, Brocke, & Leue, 
2006; Kok, 1990). These effects were unexpected as a previous study (Van 
Ruitenbeek, Vermeeren, Smulders, Sambeth,  Riedel, In press) showed that 
the H1-antagonist dexchlorpheniramine enhanced the effect of stimulus 
degradation on S-locked P300 peak latency, whereas no effects on motor 
processes were found. The effects on processing of visual stimuli are in line 
with the observation that the visual cortex and other visual regions (e.g. 
LGN, superior colliculus) are densely innervated by histamine fibres 
(Manning, Wilson, & Uhlrich, 1996). In contrast, less H1-receptors are located 
in motor structures like the caudate putamen and globus pallidus of the 
basal ganglia of the guinea-pig brain (Bouthenet, Ruat, Sales, Garbarg, & 
Schwartz, 1988). However, we did not observe effects of HID on stimulus 
related processes in this study, suggesting that blocking the H1-receptor and 
decreasing histamine availability and hence histamine release may have 
qualitatively different effects. A possible explanation is that L-histidine 
depletion affects the action of histamine on H1, H2, H3 and H4 receptors as 
opposed to solely H1-blockade.  
The involvement of histamine in motor processes is supported by 
animal studies in which the histamine synthesizing enzyme histidine 
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decarboxylase (HDC) is depleted. For example, Brabant, et al. (2007) found 
that cocaine induced hyperactivity is reduced in HDC knock-out mice. In 
contrast, other authors found that the methamphetamine induced typical 
locomotor hyperactivity was facilitated in HDC knock-out mice (Iwabuchi, 
et al., 2004; Kubota, et al., 2002) and after administration of a H1-antagonist 
(Ito, Onodera, Watanabe, & Sato, 1997). As methamphetamine and cocaine 
increase dopamine activity it may be suggested that histamine interacts with 
dopamine. Several mechanisms of interaction have been suggested, like 
interactions with the GABA neurotransmitter system (Kubota, et al., 2002), 
and dopamine transporter (Matsunaga, et al., 1998). However, a study 
assessing the latter hypothesis could not confirm this (Theunissen, van 
Kroonenburgh, van Deursen, Blom-Coenjaerts, & Ramaekers, 2006). Taken 
together it is suggested that histamine in the brain plays a role in motor 
processes, which may be mediated by dopamine. However, the exact 
mechanism is not clear. 
The few significant effects on sensitive measures of psychomotor 
performance and sedation in this study call into question whether L-
histidine depletion has effectively decreased histamine levels in the brain in 
this study. The analyses of the blood samples taken between T4 and T7 
showed that L-histidine levels in the blood-plasma decreased by more than 
20%. In comparison, the effects of TYD on L-tyrosine/L-phenylalanine level 
were more pronounced as shown by a reduction of approximately 55%. 
However, brain concentration of L-histidine is best approximated by the L-
histidine/ΣLNAA ratio as various LNAA are competitively transported 
across the blood brain barrier. Analyses showed that the maximal reduction 
in L-histidine/ΣLNAA was 59%, which was similar to the maximal decrease 
in L-tyrosine + L-phenylalanine / ΣLNAA ratio. Compared with reductions 
in L-tyrosine/L-phenylalanine found in previous studies showing functional 
impairments (70-80%), reductions in L-histidine concentrations in the 
present study were only slightly lower (Leyton, et al., 2000; McTavish, et al., 
1999; Montgomery, et al., 2003). The relationship between the decreased L-
histidine availability in the brain and the decrease in histamine levels are yet 
unknown. It may be speculated that histamine stores were not yet fully 
depleted at time of testing and that the stored histamine was used during 
testing. Depletion of the stored histamine and the effect on behavioural 
measures may have occurred later. We suggest that in future studies 
behavioural performance should be assessed over a longer period of time to 
establish the time of maximal behavioural impairment. 
It may be argued that the effects found in this study are due to a 
non-specific effect of amino imbalance. This is unlikely, however. A similar 
issue was raised concerning tryptophan depletion. It was shown that acute 
lysine depletion has no effect on mood and cognition in humans, unlike 
tryptophan depletion (Klaassen, Riedel, Deutz, van Someren, & van Praag, 
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1999). In addition, in rodents histamine metabolism can be altered more by 
changes in precursor availability than can be done with any other 
neurotransmitter (Young, 1996). Therefore, the effects of HID found in this 
study might be attributed to small changes in histamine release. To account 
for the limited effect of HID that we found, it may be argued that a decrease 
in histamine release may not occur in all brain areas. Neurotransmitter 
release can be regulated differentially in different brain areas and small 
changes in histamine synthesis may lead to an inhomogeneous decrease of 
histamine release.  
Surprisingly, TYD decreased the interval between the LRP and the 
response, indicating increased motor processing capacity. However, TYD 
did not affect the CNV and performance on the CTT and the CRT as 
measured with reaction time. Studies applying the L-tyrosine/L-
phenylalanine depletion method are inconsistent regarding their results. 
Some studies showed impaired performance (Harmer, et al., 2001; Harrison, 
et al., 2004) and altered mood (Leyton, et al., 2000), while others did not 
observe such effects (Lythe, Anderson, Deakin, Elliott, & Strickland, 2005); 
(McLean, Rubinsztein, Robbins, & Sahakian, 2004). It has been suggested 
that the inconsistencies are due to large variability between subjects in brain 
dopamine availability. Mehta, Gumaste, Montgomery, McTavish, & Grasby 
(2005) showed that subjects who performed worse on a delayed response 
task and a planning task also showed the greatest reductions in dopamine 
levels in the striatum. It may be that there were many non-sensitive subjects 
in this study. 
To conclude, this was the first study that attempted to decrease 
histamine levels in the brain by L-histidine depletion in order to study the 
role of histamine in cognitive performance. The importance of using 
different methods to study the involvement of histamine in cognitive deficits 
needs to be stressed. Moreover, to study the involvement of histamine in 
cognition the effects of L-histidine depletion are at least as important as 
studying the effects of H1-blockade on cognitive performance. In this study, 
contrary to our expectations, HID had an impairing effect on motor related 
processes, suggesting that histamine is involved in more than sensory 
processing, which is affected by H1-blockade. However, HID did not impair 
psychomotor performance as measured by the CTT and reaction times and 
did not cause sedation as indicated by subjective and objective measures. 
The absence of effects may be explained by the small changes in histamine 
release. 
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GENERAL DISCUSSION 
 
The aim of the present dissertation was to gain knowledge about the role 
that the neurotransmitter histamine plays in human cognition. Studies 
described in this dissertation were done in order to discover which cognitive 
processes are affected when the histaminergic system is manipulated. The 
manipulations consisted of H1-blockade using first and second generation 
antihistamines and depletion of the histamine precursor L-histidine. In this 
final chapter, an attempt is made to provide a coherent view on the role of 
histamine in cognition. Second, an attempt is made to relate the effects of 
different histaminergic manipulations to symptoms seen in clinical disorders 
in which histamine has shown to be involved and the possibility to model 
these impairments. 
 
Histamine and cognition 
Up until now evidence for the role of histamine in cognition is mainly 
derived from animal studies in which histaminergic activity is decreased by 
H1-receptor blockade [e.g. (Kamei, Chung, & Tasaka, 1990)], H1-receptor 
knock-out [e.g. (Yanai, Son, Endou, Sakurai, & Watanabe, 1998)] or knock-
out for the histamine synthesizing enzyme histidine decarboxylase [e.g. 
(Brabant, et al., 2007; Iwabuchi, et al., 2004)]. Decrease in histaminergic 
activity leads to impaired performance on a plethora of cognitive tasks. In 
this dissertation, it is attempted to provide evidence for the role of histamine 
in human cognitive performance. 
In the review of the literature on the effects of central H1-receptor 
blockade on cognitive performance in humans is provided in chapter 1. It 
was concluded that alertness as measured either subjectively or objectively, 
psychomotor performance and driving performance were greatly affected by 
sedative first generation antihistamines. It seemed that tasks assessing more 
specific functions, or at least emphasizing specific functions, showed that 
both sensory and motor processes were affected after intake of the H1-
antagonist. Memory performance was also affected, but the effects seemed to 
be limited to those on working memory. Episodic and semantic memory 
functions were hardly affected by the drugs. The first experimental study 
described in this dissertation used a test battery to determine the pattern of 
the effects as described in the review. Indeed, it was established that 
psychomotor performance is impaired, alertness is decreased, but memory 
remained unaffected. 
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Memory 
From the review of the literature it was suggested that processing speed is 
decreased which leads to impaired working memory as measured using 
tasks like the N-back task and Sternberg’s memory scanning task. The 
dependent measures often rely on speed of responses, which may be a 
slowed due to impaired sensory and/or motor processes This type of slowed 
information processing does not necessarily affect the functional integrity of 
human memory performance i.e. correctly recalling words which may be 
irrespective of speed, and therefore effects on episodic memory and semantic 
memory may have been hardly found. In addition, the results from the study 
investigating the effects of cetirizine showed impaired performance on 
Sternberg’s memory scanning. The slope of the regression line of reaction 
time on memory load was increased after cetirizine administration. 
Therefore, cetirizine caused a slowing in mental scanning of digits held in 
memory, which does indicate impaired central processing speed. 
In the first experimental study, it was hypothesized that the H1-
antagonist dexchlorpheniramine would affect memory performance. 
However, results showed a lack of effects on memory. The active control 
drug scopolamine also failed to affect memory performance. Formally, the 
possibility remained that the study was unable to show drug induced 
memory impairments. Secondly, although the evidence for a lack of effects of 
H1-antagonists found on memory performance now seemed to pile up, there 
were still studies that reported such effects. Therefore, the presence of 
anthistaminergic effects on memory remained ambiguous. 
To finally test whether antihistamine induced memory impairments 
and the effects are independent of sedation the study described in chapter 4 
was conducted. In this study, the effects of H1-antagonism on objective and 
subject alertness and memory performance were measured. This study 
clearly showed that the antihistamine dexchlorpheniramine decreased 
alertness, while memory was not affected. At the same time, the 
benzodiazepine affected both alertness and memory. However, the effect of 
the benzodiazepine on alertness was much larger than that of 
dexchlorpheniramine. Therefore, effects sizes were calculated which showed 
that the difference between the effects on alertness was much smaller than 
the difference between the effects on memory. Therefore, it was finally 
concluded that histamine H1-antagonism does not affect memory. 
The lack of impairments after histamine H1-receptor blockade is in 
sharp contrast with the effects found of H3-antagonist in animal studies. 
Many studies have shown that memory performance improves when 
animals are treated with these drugs. In addition to its function as an 
autoreceptor the H3-receptor also functions as a heteroreceptor and blocking 
the receptor causes disinhibition of other monoamine transmitter release 
(Esbenshade et al., 2008). It has been suggest that there is a close interaction 
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between acetylcholine and the H3-receptor (Blandina 2004). Acetylcholine is 
known to be a very important mediator in memory functioning. 
Consequently, H3-antagonism and not H1-antagonism may lead to 
disinhibition of acetylcholine, which mediates the memory enhancing effects. 
Alternatively, animal models for cognitive deficits may not accurately 
predict impaired functioning in humans. The organisms are not functionally 
similar. For example, when modelling memory impairments in rodents, 
memory in these animals is highly dependent on the hippocampus, while 
humans are able to use more strategies (e.g. use of language) and, therefore, 
brain structures. Humans may, therefore compensate for their impairment. 
This may result in a higher sensitivity of rats for effects on memory. 
 
Sensory related processes 
Our studies and those of others consistently show that psychomotor 
functioning is impaired by antihistamine drugs. In the study described in 
chapter 6 we attempted to determine what underlying cognitive processes 
are impaired following H1-blockade. Using the additive factor method and 
psychophysiological measures, we found that the effects of visual 
degradation of a stimulus are enlarged by dexchlorpheniramine. This 
suggested that sensory, i.e. visual processes were affected by H1-blockade. 
These findings may be explained by the observation that the visual cortex 
and other visual regions (e.g. LGN, superior colliculus) are densely 
innervated by histaminergic fibres (Manning, Wilson, & Uhlrich, 1996). 
However, the study described in chapter 5 did not reveal effects on visual 
information processing as measured using a vigilance task. Using this task a 
stimulus discrimination index and response criterion were calculated. These 
measures are related to input and output processes, respectively. The 
previously observed effects on sensory processing suggested that the 
discrimination index would indicate impaired performance after H1-
blockade, while the response criterion would not. We did not observe any 
such effects, however. The lack of effects may be explained by the fact that a 
second generation antihistamine was used. Although these drugs have been 
shown to penetrate the blood brain barrier, they do so to a lesser extent than 
the first generation antihistamines and hence may only induce subtle effects. 
 
Motor related processes 
L-histidine depletion, described in chapter 7, caused the slowing of motor 
related processes. This effect was evidenced by the L-histidine depletion 
induced enlargement the response complexity effect as measured with the 
Lateralized Readiness Potential (LRP). The interval between this 
electrophysiological potential and the response indicates the duration of the 
processes needed for the preparation of the response. When subject are 
required to give a more complex response, i.e. pressing three buttons in a 
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predefined sequence, the interval between the pressing of the first button 
and the LRP increases. More time is needed to program the more complex 
response. Treatments affecting the programming, therefore, cause an 
increase in the response complexity effect on the LRP-response interval. The 
effect of L-histidine depletion suggests that low level of histamine affects the 
response preparation process. This effect in contrast with that of H1-
antagonism and was unexpected. Compared with other brain areas less H1-
receptors are located in motor related structures of the guinea-pig brain like 
the caudate putamen and globus pallidus of the basal ganglia (Bouthenet, 
Ruat, Sales, Garbarg, & Schwartz, 1988), which possibly explains the lack of 
effects of H1-blockade on motor related processes. A possible explanation for 
the effects of L-histidine depletion on motor related processes may be that 
the histaminergic system interacts with other transmitter systems. For 
example, the dopaminergic system is well known for its involvement in 
motor related functions. As the depletion of L-histidine likely affects more 
receptors than just the H1 receptor i.e. H3-receptor, it may be that dopamine 
is disinhibited by a decrease in H3 activation. 
 
Histamine based models 
As has been discussed in the introduction, histamine is suggested to be 
involved in the cognitive impairments seen in clinical disorders like 
Alzheimer’s disease [e.g. (Higuchi, 2000)], schizophrenia [e.g. (Nakai, et al., 
1991)], Attention Deficit Hyperactivity Disorder (Komater, et al., 2005; Peled, 
Carraso, Globman, & Yehuda, 1997), depression (Akhtar, Pillai, & Vohora, 
2005; Kano, et al., 2004), Parkinson’s disease [e.g.(Anichtchik, Rinne, Kalimo, 
& Panula, 2000; Rinne, et al., 2002)] and Wernicke-Korsakoff’s syndrome [for 
review see: (Onodera, Yamatodani, Watanabe, & Wada, 1994)]. Evidence for 
a possible treatment of these disorders comes from animal studies in which 
histamine functioning is increased using H3-antagonists. Many studies show 
that cognitive performance is improved in animal models for these clinical 
disorders after the administration of H3-antagonists [for reviews see: 
(Esbenshade, Fox, & Cowart, 2006; Leurs, Blandina, Tedford, & Timmerman, 
1998; Vohora, 2004; Wijtmans, Leurs, & de Esch, 2007; Witkin & Nelson, 
2004)]. It is therefore expected that increasing histaminergic activity in 
humans suffering from such disorders leads to improved cognitive 
functioning. In order to be able to quickly test the coming H3-antagonist 
drugs a model for cognitive impairments following histaminergic 
dysfunction is highly useful. 
 
Alzheimer’s disease 
Several studies have suggested that histamine plays an important role in 
Alzheimer’s disease [e.g.(Airaksinen, Paetau, et al., 1991; Airaksinen, 
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Reinikainen, Riekkinen, & Panula, 1991; Higuchi, 2000; Panula, et al., 1998) 
for a review see: (Onodera, et al., 1994)]. In addition, a large number of 
studies have shown that H3-receptor blockade in animals leads to improved 
memory performance [e.g. (Bernaerts, Lamberty, & Tirelli, 2004; Medhurst, 
Atkins, et al., 2007; Medhurst, Briggs, et al., 2007; Miyazaki, Imaizumi, & 
Onodera, 1995; Molinengo, Di Carlo, & Ghi, 1999) for reviews see: 
(Esbenshade, et al., 2006; Leurs, et al., 1998; Vohora, 2004; Witkin & Nelson, 
2004)]. Alzheimer’s disease is characterized by cognitive impairments of 
which impaired memory is the most prominent. However, in this 
dissertation we were unable to show that central H1-blockade affects 
memory performance. Therefore, H1-blockade is not suitable as model for 
memory impairments as present in Alzheimer’s disease. 
 
Schizophrenia 
Histamine has been suggested to be involved in the pathogenesis of 
schizophrenia (Onodera, et al., 1994). For example, Prell, et al. (1995) found 
increased levels of the histamine breakdown product, tele-methylhistamine, 
in the cerebrospinal fluid of schizophrenia patients suggesting increased 
histamine turn-over. They concluded that the increase could not be 
attributed to the medication taken, as patients who received antipsychotics 
and patients withdrawn from antipsychotic drugs displayed similar levels of 
the metabolite. Conventional antipsychotic medication has a high affinity for 
the H1 receptor and blocks this receptor (Buckley, 2007), whereby it 
decreases histaminergic activity, which possibly explains some therapeutic 
effects. In addition, Nakai et al. (1991) and Iwabuchi et al. (2005) found 
decreased binding to the histamine H1 receptor in the frontal cortex of 
schizophrenia patients, which indicates a decreased number of histamine H1 
receptors in these patients. Taken together, these findings suggest role for 
histamine in schizophrenia. 
Patients suffering from schizophrenia show impaired sensory gating 
which holds that irrelevant information is not filtered out causing a sensory 
overload (Geyer, Krebs-Thomson, Braff, & Swerdlow, 2001). Impaired 
sensory gating can be modelled using the pre-pulse inhibition of the startle 
response. Normally the startle response is inhibited when the stimulus is 
preceded by a pre-pulse stimulus. Patients suffering schizophrenia show no, 
or less, inhibition of the startle response. In animal models increasing 
histamine release using H3-antagonists attenuates the response to the same 
degree as antipsychotics (Browman, et al., 2004; Fox, et al., 2005; Ligneau, et 
al., 2007). In addition, H1-knock-out mice and mice treated with an H1-
antagonist also showed attenuated prepulse inhibition behaviour (Dai, et al., 
2005; Roegge, Perraut, Hao, & Levin, 2007), suggesting that histamine is 
involved in defective early sensory processing. The present dissertation has 
shown that histamine is involved in human sensory processing. More 
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specifically, H1-blockade leads to impaired feature extraction in sensory 
information processing. In the context of histamine possibly being involved 
in the sensory impairment as seen in schizophrenia, the effects of H1-
blockade and other histaminergic manipulations need to be tested in sensory 
gating paradigms like the pre-pulse inhibition paradigm. Nevertheless, the 
present results support the hypothesis that H1-antagonism may be involved 
in schizophrenic symptomatology.  
 
Parkinson’s disease 
Parkinson’s disease in characterized by a neurodegeneration of the 
dopaminergic cells in the substantia nigra. The loss of cells leads to impaired 
motor control and cognitive disturbances (Feinberg & Farah, 1997). The 
histaminergic system densely interacts with the affected dopaminergic 
system (Anichtchik, et al., 2000). It has also been shown that Parkinson’s 
disease patient exert high levels of histamine in the brain (Rinne, et al., 2002). 
In addition, the administration of L-histidine in rats (Maslinski, Lebrecht, 
Nowak, Pilc, & Wieczorek-Fila, 1973) and histamine in mice (Onodera, 1991) 
results in catalepsy like behaviour. Therefore, alterations in histamine lead to 
Parkinson’s disease like motoric disturbances. Results from the experiment 
in which the effects of L-histidine depletion were studied showed that the 
programming of the response was affected by the treatment i.e. slowed by L-
histidine depletion. The decreased levels of L-histidine presumably have 
lead to low levels of histamine in the brain and may have exerted effects that 
resemble the symptoms in Parkinson’s disease. It may be suggested that L-
histidine depletion is a model for motoric disturbances in Parkinson’s 
disease. However, the experiment described in chapter 7 was the first to 
apply this method and measure the effects on behaviour. Further studies 
need to confirm and elaborately study the effects of L-histidine depletion. 
 
CONCLUSION 
 
Taken together the histamine system appears to be involved in arousal 
regulating processes as evidenced by the effects of H1-antagonism on 
objective and subjective measures of sedation. These studies also show that 
the histamine system is involved in psychomotor performance. Deficits in 
clinical disorders in which psychomotor performance is impaired or in 
which a decrease in arousal occurs can be modelled using H1-antagonists. 
More specifically, H1-antagonism may be a suitable model for disorders in 
which impaired sensory processes occur, like schizophrenia. H1-antagonists 
do not affect memory performance. Therefore, H1-antagonists are not 
suitable to be used as a model for histamine based memory impairment. 
Decreasing histamine levels centrally by L-histidine depletion slows motor 
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related processes. Although further investigation is needed to study the 
effects of L-histidine depletion, it does appear to be promising as a model for 
disorders in which motor related processes are affected, like Parkinson’s 
disease. 
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SUMMARY 
 
Pharmacological treatments of cognitive deficits across several clinical 
disorders are largely unsuccessful. Therefore, the search for new drugs 
continues. It has been suggested that histamine may play a large role in 
cognitive deficits seen in disorders like Alzheimer’s disease, schizophrenia, 
Parkinson’s disease and Attention Deficit Hyperactivity Disorder. 
Histamine is a monoamine neurotransmitter, which functions through its 
action at H1, H2, H3 and H4 receptors. Activation of the H1-receptor leads to 
excitatory transmission, while activation of the H3-receptor is inhibits 
histaminergic activity. 
Results from animal studies show that blocking the H3-receptor 
improves performance on cognitive tasks, especially learning and memory. 
The so-called H3-antagonists may be used as new treatments for cognitive 
impairments seen in clinical disorders. Before long-term patient studies are 
done to test the efficacy of these treatments, screening in human subjects in 
earlier stages of development may be very useful. Such a screening could be 
done in healthy volunteers using models of cognitive impairments such as 
induced by histamine dysfunction. The aim of this dissertation is to 
determine what role histamine plays in cognition and to determine which 
histaminergic manipulations in human subjects are suitable as tools to 
probe cognitive function. 
An example of such a manipulation is pharmacological blocking of 
H1-receptors, which may be used in healthy volunteers as a model for 
histaminergic dysfunction seen in clinical disorders. Many studies have 
tested the effects of H1-antagonists on different cognitive domains. 
In chapter 1, the literature is reviewed of papers describing the 
effects of centrally active H1-antagonists. The review of 70 experimental 
studies on the performance effects of H1-antagonists revealed that 
psychomotor performance is the most likely domain to be impaired. The 
affected cognitive processes underlying these impairments are largely 
unexplored. However, results from tasks assessing perceptual functions 
show that these are impaired and may at least contribute to the 
performance impairments such as those seen in psychomotor performance. 
Performance on memory tasks after the administration of H1-
antagonists is frequently impaired when assessed using working memory 
tasks. However, results of such tasks may be confounded by slowed 
sensorimotor processing speed. Episodic memory relies less on 
sensorimotor speed and is less frequently impaired. However, episodic 
memory has only relatively scarcely been studied. 
It is concluded in chapter 1, that H1-antagonists may serve as a 
model for psychomotor impairment associated with reduced histaminergic 
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activity. The underlying affected cognitive subprocesses and memory 
functions need to be investigated further. 
In chapter 2, one of the main questions which emerged from the 
review discussed in chapter 1 was operationalized into an experiment in 
which H1-antagonists were administered to healthy volunteers while 
cognitive functions, in particular memory, were assessed. 
Twenty healthy young (aged 18-45 years) females participated as 
volunteers. Subjects received oral doses of the first generation antihistamine 
dexchlorpheniramine 2 mg, 4 mg, the muscarinic antagonist scopolamine 1 
mg and placebo according to a double-blind, placebo-controlled, 4-way 
cross-over design. Treatment effects on cognition were assessed using tasks 
probing learning and memory, psychomotor performance, attention and 
subjective alertness. These were measured before-, 2 and 4 hours after drug 
intake  
The centrally active antihistamine dexchlorpheniramine impaired 
performance on spatial learning, reaction time, tracking and divided 
attention but showed no effects on working memory, visual memory, word 
learning or memory scanning. However, scopolamine induced a similar 
pattern of effects, i.e. psychomotor impairment, but no effects on memory. 
As this was the active control drug a possible concern was that memory 
tasks were not sensitive in this study, even though the tasks shown to be 
sensitive to drug effects in other studies. 
It was concluded that both dexchlorpheniramine and scopolamine 
clearly impaired performance on psychomotor and attention tasks. In 
contrast, learning and memory remained unaffected. 
The question whether H1-antagonists affect memory performance 
in humans was again put to the test in chapter 3. Animal studies suggest a 
role of histamine in memory, but studies in humans are scarce and produce 
conflicting results. Studies that have found effects of H1-antagonists may 
have done so due to its sedative effects. Conversely, some studies that have 
not found effect on memory performance suffer from methodological 
issues. The aim of this study was to dissociate the effects of a centrally 
active antihistamine on memory performance and sedation. 
Oral doses of dexchlorpheniramine 4 mg, lorazepam 1 mg or 
placebo were administered to eighteen healthy volunteers (9 male, 9 female) 
aged 18-45 years, according to a double-blind, placebo-controlled, 3-way 
cross-over design. The effects of the treatments on memory performance 
were assessed between 1.5 and 2.5 hours after drug administration using a 
30-Words Learning Task, an N-Back task and Event Related Potentials 
(ERPs). Sedation was measured objectively and subjectively using visual 
analogue scales and electroencephalography (EEG). 
The active control drug clearly showed effects on memory 
performance as indicated by both behaviour and ERPs. In contrast, 
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dexchlorpheniramine did not affect memory performance, while both 
treatments clearly induced sedation. These results confirmed that H1-
blockade has a sedative effect, but does not affect memory in humans. 
Previous chapters used the so-called first generation H1-antagonists 
to investigate what role histamine plays in cognition. The drawback of these 
particular H1-antagonists is that they are mostly non-selective for the H1-
receptor. The second-generation antihistamines are far more selective, but a 
general claim is that they do not, or to a lesser extent, cross the blood brain 
barrier. However, cetirizine has been shown to induce cognitive 
impairments and, therefore, may be capable to cross the blood brain barrier. 
Cetirizine may be used as a tool drug to model cognitive deficits associated 
with histamine hypofunction. However, there is inconsistency regarding 
dose and time after administration after which the behavioural effects 
occur. 
In chapter 4, the effects of cetirizine on cognitive performance were 
measured by treating eighteen healthy volunteers (aged 18-45 years) with 
cetirizine 10 and 20 mg and placebo according to a double-blind, 3-way 
cross-over design. The effects of the treatments on word learning, memory 
scanning, vigilance, divided attention, tracking and visual information 
processing speed were assessed one hour and three hours after drug intake. 
The results indicated that cetirizine 10 mg impaired tracking 
performance and memory scanning speed 1 hour after treatment. The 20 mg 
dose impaired memory-scanning speed 3 hours after drug intake. The other 
measures did not show any impairments, which suggested that the effects 
of cetirizine were not very pronounced. Therefore, it may not be suitable as 
a tool drug to model cognitive deficits following histamine dysfunction in 
clinical disorders. 
A consistent finding regarding the effects of H1-antagonists is that 
they impair sensorimotor performance. It is not clear, however, which 
underlying processes are affected by the H1-antagonists, which results in 
the observed impairments. In chapter 5, a study is described which 
investigated the effects of H1-antagonists on subprocesses involved in 
sensorimotor performance. 
In order to gain more insight in which subprocesses are affected the 
interactions of dexchlorpheniramine with specific task manipulations in a 
choice reaction time task were studied. The task manipulations consisted of 
the visual degradation of stimuli and increased response complexity. The 
former affects stimulus processing and the latter affects the programming of 
the response. An interaction with these factors indicates which cognitive 
process is affected by the H1-antagonist. 
Healthy volunteers (9 female, 9 male) between 18 and 45 years of 
age were treated with single oral doses of 4 mg dexchlorpheniramine, 1 mg 
lorazepam as an active control drug and placebo according to a double-
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blind, placebo-controlled, 3-way cross-over design. Both behavioural 
measures (reaction times) and psychophysiological measures (ERPs) were 
used to assess the effects on cognitive processes between 1.5 hours and 3 
hours after drug administration. 
Dexchlorpheniramine significantly slowed reaction times, which 
indicated that the drug affected the performance. However, it did not 
significantly interact with task manipulations as measured with reaction 
times. Analyses of the ERP data showed that it did significantly interact 
with stimulus quality as measured by the prolonging effect of the 
antihistamine on the P300 component latency. Lorazepam also slowed 
reaction times and interacted with stimulus quality, but only shown by 
effects on reaction times. The results did not suggest any effects of the 
antihistamine on motor related processes. 
Taken together, this study suggested that the H1 receptor is 
involved in sensory information processing. In addition, this study showed 
that H1 blockade does not affect response programming. It was suggested 
that clinical disorders in which histamine dysfunction plays a role may 
suffer from impaired sensory processing and that H1-antagonists may 
suitable tools to model the deficit. 
Chapters 2 to 5 have all described studies in which cognitive 
deficits have been attempted to be modelled using H1 receptor blockade. 
However, this method may be limited as it mostly blocks just the H1 
receptor and, therefore, does not resemble low histamine levels. An 
alternative method to induce histamine hypofunction is to deplete the 
central nervous system from the histamine precursor, L-histidine. 
Histamine is synthesised from the essential amino acid L-histidine. 
Consumption of food containing other amino acids, but not L-histidine 
leads to a decrease in L-histidine levels in the body. Theoretically, histamine 
synthesis and, consequently, histamine levels in the central nervous system 
are lowered. In chapter 6, the method of L-histidine depletion was applied 
and the effects on cognitive measures were assessed. These effects were 
related to those of H1-antagonism as seen in chapter 5. 
Seventeen healthy volunteers (6 male, 11 female) aged between 18 
and 35 years were treated with amino acid drinks containing all large amino 
acids but L-histidine, L-tyrosine/L-phenylalanine (active control) and all 
large amino acids (placebo) according to a double-blind, placebo-controlled, 
3-way cross-over design. Similar as in chapter 5 the interactions with task 
manipulations in a choice reaction time task were studied. In addition, 
performance on a tracking task and subjective and objective sedation were 
measured. The effects were assessed 5 hours after drug administration 
Analyses of the data showed that measures of sedation and critical 
tracking task performance were not affected by L-histidine depletion and L-
tyrosine/L-phenylalanine depletion. In contrast to the effects of earlier 
SUMMARY 
 197 
studied H1-antagonists, L-histidine depletion enlarged the effect of 
Response Complexity as measured with the response locked Lateralized 
Readiness Potential onset latency. This suggests that histamine is also 
involved in response related processes. Therefore, L-histidine depletion 
may be suitable as a model for histamine based motor impairments. As this 
was only the first study to investigate the effects of L-histidine on cognitive 
functions, future studies need to confirm the effects. 
The final chapter provides an overview of the previous chapters 
and discusses the results and implications of the findings. The review of the 
literature from chapter 1 has shown that psychomotor performance is 
greatly sensitive to H1-receptor blockade. In contrast, performance on 
episodic memory tasks does not seem to be affected. However, there are 
only a few authors who have investigated the effects of H1-antagonism on 
episodic memory. Effects on working memory have been assessed 
frequently, but results may be confounded by effects of H1-antagonism on 
sensorimotor performance. Subsequent chapters also described experiments 
in which the effects of H1-antagonists on memory performance were 
assessed. These experiments all failed to find such effects. This is in sharp 
contrast with the effects of H3-antagonists on memory in animals. It is 
suggested that this may be due to the fact the H3-receptor also functions as a 
heteroreceptor, whereby it affects other transmitter systems. Alternatively, 
animal models of cognitive functions may not be generalized to human 
cognitive performance. 
A more consistent finding is that H1-antagonism impairs 
sensorimotor performance. It was shown that the impairment might be due 
to impaired sensory functioning, which is supported by anatomical data. 
Disorders like schizophrenia are also characterized by impaired sensory 
functioning. Although, further investigations are needed, H1-antagonism is 
suggested as a model for histamine based sensory impairment. 
In contrast to the effects of H1-antagonists, depletion of the 
histamine precursor L-histidine leads to an impairment of motor related 
processes. It is well known that dopamine plays a large role in motor 
related processes. As the histaminergic system closely interacts with the 
dopaminergic system, it is suggested that the effect of L-histidine is 
mediated by the dopaminergic system. 
Cognitive deficits as seen in Alzheimer’s disease are characterized 
by memory impairments. Our findings showed that these may not be 
modelled using H1-antagonists. In contrast, the effects of H1-antagonism 
appear to be functionally located at the sensory processes. Therefore, these 
impairments may be modelled using H1-antagonists. The effects of L-
histidine depletion on motor related processes suggest a role for histamine 
in disorders like Parkinson’s disease. 
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De farmacologische behandeling van cognitieve deficieten zoals die 
voorkomen in klinische stoornissen zijn in veel gevallen niet succesvol. 
Daarom gaat de zoektocht naar nieuwe medicatie onvermoeid door. De 
neurotransmitter histamine lijkt een belangrijke rol te spelen in de cognitieve 
deficieten zoals die te zien zijn in de ziekte van Alzheimer, schizofrenie, de 
ziekte van Parkinson en Attention Deficit Hyperactivity Disorder (ADHD). 
Histamine is een monoamine neurotransmitter en werkt in het brein door 
zich te binden aan de H1, H2, H3 en H4 receptoren. Activatie van de H1-
receptor leidt tot excitatoire neurotransmissie, terwijl de activatie van de H3-
receptor de activiteit van histamine remt. 
Onderzoek in dieren heeft laten zien dat prestaties op cognitieve 
taken verbetert als de H3-receptor wordt geblokkeerd, met name prestaties 
op taken die het geheugen meten. Deze zogenaamde H3-antagonisten 
zouden gebruikt kunnen worden als nieuw middel tegen cognitieve 
deficieten zoals die voorkomen in klinische stoornissen, bijvoorbeeld bij de 
ziekte van Alzheimer. Voordat deze middelen kunnen worden getest in 
patiënt populaties is het nuttig om een snelle vroege screening van de 
middelen toe te passen in gezonde vrijwilligers, om zo het onderzoek naar 
geneesmiddelen te versnellen. Een dergelijke screening kan worden gedaan 
met behulp van modellen van cognitieve deficieten, die zijn te induceren 
door middel van histaminerge disfunctie in gezonde vrijwilligers. Het doel 
van dit proefschrift is het achterhalen welke rol histamine speelt in cognitie 
en welke histaminerge manipulatie in gezonde vrijwilligers kan dienen voor 
het creëren van een model voor cognitieve deficieten die voorkomen bij 
verschillende klinische stoornissen. 
Een voorbeeld van een histaminerge manipulatie is het 
farmacologisch blokkeren van de H1-receptor in het centraal zenuwstelsel. 
Deze manipulatie zou kunnen worden gebruikt om cognitieve deficieten op 
te roepen. H1-antagonisten zijn middelen die de H1-receptor blokkeren en 
zijn daarom misschien te gebruiken om de cognitieve deficieten te 
modeleren. 
In het verleden is er al veelvuldig onderzoek gedaan naar de effecten 
van H1-antagonisten op verschillende cognitieve functies. In hoofdstuk 1 
worden 70 experimentele onderzoeken beschreven waarin H1-antagonisten 
zijn toegediend aan gezonde vrijwilligers en waarin de effecten op 
cognitieve functies zijn gemeten. In dit hoofdstuk komt naar voren dat het 
psychomotore functioneren het meest gevoelige cognitieve domein is voor 
de effecten van de H1-antagonist. De cognitieve processen die onderdeel zijn 
van het psychomotore functioneren kunnen zijn aangetast door de H1-
antagonist en zo de oorzaak zijn van het verminderd functioneren. Deze 
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onderliggende processen zijn helaas nog nauwelijks onderzocht. Tests die 
visuele processen meten, laten wel zien dat deze functie is aangetast. Dit 
suggereert dat de aangetaste visuele processen bijdragen aan de 
verslechterde prestaties op de psychomotore taken. 
De prestaties op taken die het werkgeheugen meten zijn veelvuldig 
slechter na het toedienen van een H1-antagonist. Desalniettemin kan het zijn 
dat de oorzaak van deze verslechterde prestatie te vinden is in het feit dat 
het sensor-motorisch functioneren is vertraagd. Prestaties op de zogenaamde 
werkgeheugen taken zijn vaak in grote mate afhankelijk van sensor-
motorisch functioneren. Het episodisch geheugen is, daarentegen, veel 
minder afhankelijk van deze functie en is dan ook minder vaak aangetast. Er 
dient wel te worden vermeld dat het episodisch geheugen niet vaak is 
gemeten na het toedienen van een H1-antagonist. 
Uit hoofdstuk 1 wordt geconcludeerd dat H1-antagonisme zou 
kunnen dienen als model voor psychomotore deficieten dat wordt 
geassocieerd met verminderde histaminerge activiteit. De onderliggende 
processen die zijn aangetast en de geheugen functies dienen nog verder 
onderzocht te worden.  
Eén van de vragen die voortkwam uit hoofdstuk 1 was de 
hoofdvraag van het in hoofdstuk 2 beschreven onderzoek, namelijk: zijn 
geheugen deficieten te modeleren met H1-antagonisten? In dit onderzoek 
werd daarom een H1-antagonist toegediend aan gezonde vrijwilligers 
waarna verschillende cognitieve functies werden gemeten, met name 
geheugen. Twintig gezonde vrijwilligers tussen de 18 en 45 jaar oud namen 
deel aan het onderzoek. De vrijwilligers kregen 2 of 4 mg van het eerste 
generatie antihistaminicum dexchloorfeniramine of 1 mg van de muscarine 
antagonist scopolamine of placebo oraal toegediend volgens een dubbel 
blind, 4-wegs, cross-over design. De effecten van de middelen werden 2 en 4 
uur na inname gemeten door gebruik te maken van taken die leren en 
geheugen, psychomotore functies, aandacht en subjectieve alertheid meten. 
Het antihistaminicum dexchloorfeniramine verslechterde de prestaties op 
spatieel geheugen, reactietijd, tracking en verdeelde aandacht taken, maar 
liet geen effect zien op werkgeheugen, visueel geheugen, woorden leren en 
geheugen scannen. De actieve controle scopolamine liet een soortgelijk 
patroon van effecten zien. Daardoor is een mogelijke verklaring dat de 
geheugentaken niet gevoelig genoeg waren om de effecten op te pikken, 
ondanks het feit dat vele andere onderzoeken hebben laten zien dat deze 
taken wel gevoelig zijn. Uit het onderzoek werd geconcludeerd dat 
dexchloorfeniramine een duidelijk effect had op psychomotore functies en 
niet op geheugen. 
Het vraagstuk of H1-antagonisten een effect hebben op geheugen 
komt in het in hoofdstuk 3 beschreven onderzoek opnieuw aan bod. 
Onderzoeken in dieren suggereren dat histamine een rol speelt in geheugen, 
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maar onderzoeken in mensen zijn schaars en laten tegenstrijdige resultaten 
zien. De effecten op geheugen functies die door sommige onderzoeken 
worden aangetoond, kunnen het gevolg zijn van de versuffende werking 
van de antihistaminica. In tegenstelling tot deze onderzoeken laten andere 
onderzoeken geen effecten zien, maar dat zou het gevolg kunnen zijn van 
eventuele methodologische tekortkomingen. Het doel van het onderzoek 
beschreven in hoofdstuk 3 was daarom het dissociëren van de effecten van 
een H1-antagonist op versuffing en geheugen. Achttien gezonde vrijwilligers 
tussen de 18 en 45 jaar oud kregen 4 mg dexchloorfeniramine, 1 mg 
lorazepam of een placebo oraal toegediend volgens een dubbel blind, 3-
wegs, cross-over design. De effecten op geheugen functies zijn gemeten 
tussen 1.5 en 2.5 uur na inname van het middel door gebruik te maken van 
een 30-woorden leertaak, N-back taak en Event Related Potentials (ERPs). 
Versuftheid werd objectief gemeten door gebruik te maken van een 
electroencefalogram (EEG). Lorazepam, de actieve controle, liet duidelijke 
effecten op geheugen zien, zoals gemeten met zowel gedragsmaten als 
electrofysiologische maten. In tegenstelling tot deze effecten liet 
dexchloorfeniramine geen effecten op geheugen zien, terwijl beide middelen 
de vrijwilligers versufte. De resultaten ondersteunen de hypothese dat H1-
antagonisten wel een versuffende werking hebben, maar het geheugen niet 
verslechteren. 
 De voorgaande hoofdstukken beschreven onderzoeken naar de rol 
van histamine in cognitie die gebruik maakten van eerste generatie 
antihistaminica. Een nadeel van dit soort middelen is dat ze meestal erg 
onselectief zijn voor de H1-receptor. Tweede generatie antihistaminica zijn 
veel selectiever, maar passeren in veel mindere mate de bloed-hersen-
barrière. Het middel cetirizine is van de tweede generatie, maar kan een 
uitzondering zijn door wel de bloed-hersen-barrière te passeren en zo 
effecten uit te oefenen op cognitieve functies. Enkele voorgaande 
onderzoeken hebben effecten van cetirizine op cognitieve functies 
aangetoond. Door de inconsistente bevindingen is het nog een vraag of 
cetirizine kan worden ingezet als middel om cognitieve deficieten te 
modeleren. In hoofdstuk 4 wordt een experiment beschreven waarin 
gezonde vrijwilligers tussen de 18 en 45 jaar een orale dosis van 10 of 20 mg 
cetirizine of een placebo toegediend kregen volgens een dubbel-blind, 3-
wegs, cross-over design. De effecten van cetirizine op het leren van woorden, 
geheugen scannen, vigilantie, verdeelde aandacht, tracking en visuele 
informatie verwerking werden 1 en 3 uur na inname gemeten. De resultaten 
lieten zien dat cetirizine 10 mg de prestatie op de tracking taak en de 
snelheid van geheugen scannen 1 uur na inname verminderde. De 20 mg 
dosering verminderde de snelheid van het geheugen scannen 3 uur na 
inname. Alle andere zeer gevoelige maten lieten geen effecten van cetirizine 
zien. Dit toont aan dat de effecten van cetirizine niet erg groot zijn. Hierdoor 
SAMENVATTING 
 204
is het op zijn minst twijfelachtig of cetirizine gebruikt kan worden om de 
cognitieve deficieten te modeleren.  
Een consistente bevinding in het onderzoek naar de effecten van H1-
antagonisten is dat deze middelen het psychomotore functioneren 
verslechteren. Het is echter nog niet duidelijk welke onderliggende 
processen worden aangetast die leiden tot de geobserveerde verslechterde 
prestaties. In hoofdstuk 5 wordt een onderzoek beschreven waarin de 
effecten van een H1-antagonist op cognitieve subprocessen zijn onderzocht. 
Om meer inzicht te krijgen in welke cognitieve subprocessen worden 
aangetast door H1-antagonisten, is er gebruik gemaakt van proces specifieke 
taak manipulaties in een keuze reactietijd taak. De manipulaties bestonden 
uit het visueel degraderen van de stimuli en het complexer maken van de 
respons. De eerste heeft invloed op de verwerking van de stimulus en de 
tweede beïnvloedt het programmeren van de respons. Een interactie-effect 
tussen de manipulatie en het antihistaminicum toont aan welke processen 
worden beïnvloed. Gezonde vrijwilligers (9 mannen en 9 vrouwen) tussen 
de 18 en 45 jaar kregen een orale dosis van 4 mg dexchloorfeniramine, 1 mg 
lorazepam of een placebo toegediend volgens een 3-wegs, dubbel-blind, 
cross-over design. Zowel maten van gedrag (reactietijd) als 
electrofysiologische maten (ERPs) zijn gebruikt om de effecten op cognitieve 
processen 1.5 en 3 uur na inname te bepalen. Dexchloorfeniramine 
vertraagde de reactietijd aanzienlijk, maar interacteerde niet met de taak 
manipulatie zoals gemeten met de reactietijd. Analyse van de ERP data liet 
zien dat dexchloorfeniramine interacteerde met stimulus kwaliteit zoals 
gemeten met de P300 latentie. Het middel bleek het effect van stimulus 
degradatie te vergroten. Lorazepam had hetzelfde effect, maar dan alleen 
zoals gemeten met reactietijd. De resultaten deden in geen enkel opzicht 
vermoeden dat de motorische processen door de middelen werden 
beïnvloed. Bij elkaar genomen kan worden geconcludeerd dat de H1-
receptor een rol speelt bij sensorische processen, maar niet bij motorische 
processen. Er kan nu worden gesuggereerd dat in stoornissen waarbij 
histamine een rol speelt vooral sensorische processen zijn aangetast en dat 
H1-antagonisten deze deficieten mogelijk kunnen modeleren.  
Hoofdstukken 2 tot en met 5 beschreven allemaal onderzoeken die 
H1-antagonisten gebruikten om cognitieve deficieten te modeleren. Het kan 
zijn dat deze methode een onvolledig beeld geeft van de effecten van een 
verlaging van histaminerge activiteit, omdat het alleen de H1-receptor direct 
beïnvloedt. Een alternatieve methode is om het lichaam te depleteren van de 
precursor van histamine, L-histidine, zodat de productie van histamine 
wordt verlaagd. Histamine wordt gesynthetiseerd door het omzetten van het 
essentiële aminozuur L-histidine. Consumptie van voedsel waar zich geen L-
histidine in bevindt, leidt theoretisch tot een verlaging van de synthese van 
histamine en een verlaging van histamine in het brein. In hoofdstuk 6 wordt 
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een experiment beschreven waarin deze methode werd toegepast en de 
effecten op cognitieve processen zijn gemeten. De effecten werden 
vervolgens vergeleken met die van H1-antagonisme zoals beschreven in 
hoofdstuk 5. Zeventeen gezonde vrijwilligers (6 mannen, 11 vrouwen) tussen 
de 18 en 35 jaar namen deel aan het onderzoek waarin ze één van de drie 
aminozuurdrankjes dienden te drinken volgens een dubbel-blind, 3-wegs, 
cross-over design. De drankjes bevatten alle grote aminozuren behalve L-
histidine of L-tyrosine/L-phenylalanine (actieve controle). De placebo-
conditie bestond uit een drankje met alle aminozuren. Zoals ook het geval 
was in hoofdstuk 5 werden de interacties tussen taakmanipulaties in een 
keuze reactietijd taak en de farmacologische behandeling gemeten. 
Daarnaast werden de prestaties op de tracking taak en de versuffende 
effecten subjectief en objectief gemeten. Alle effecten werden 5 uur na 
inname van het drankje gemeten. De analyse van de data liet geen effecten 
van L-histidine depletie en L-tyrosine/L-phenylalanine zien op tracking 
prestatie en versuftheid. In tegenstelling tot de resultaten uit eerder 
onderzoek naar de effecten van de een H1-antagonist, vergrootte L-histidine 
depletie het effect van respons complexiteit zoals gemeten met de lengte van 
het interval tussen de respons en de ‘Lateralized Readiness Potential’. Dit 
suggereert dat histamine ook een rol speelt bij respons gerelateerde 
processen. Dat zou kunnen betekenen dat L-histidine depletie een model kan 
vormen voor defecten van histamine gerelateerde motorische processen in 
het centraal zenuwstelsel. Echter, dit was het eerste onderzoek naar de 
effecten van L-histidine depletie op cognitieve processen. 
Vervolgonderzoeken dienen deze bevindingen te repliceren en uit te 
breiden. 
Hoofdstuk 7 bevat een overzicht van de voorgaande hoofdstukken 
en bespreekt de implicaties van de bevindingen. Een overzicht van de 
literatuur zoals beschreven in hoofdstuk 1 wijst uit dat psychomotore 
functies erg gevoelig zijn voor de effecten van H1-antagonisten. In 
tegenstelling, prestaties op een taak die episodisch geheugen meet lijkt niet 
te worden aangetast. Echter, er zijn niet veel auteurs geweest die dit effect 
hebben onderzocht. Effecten van H1-antagonisten op het werkgeheugen zijn 
veel vaker onderzocht, maar de gevonden effecten kunnen het gevolg zijn 
van verstoorde sensor-motorische functies. In de vervolg hoofdstukken 
werden de effecten van H1-antagonisten op geheugen gemeten. Helaas 
werden er geen effecten gevonden wat in tegenstelling is met de 
onderzoeken die in dieren gedaan zijn. In de onderzoeken met dieren wordt 
vaak de H3-receptor geblokkeerd wat leidt tot geheugen verbeterende 
effecten. Een verklaring voor de discrepantie kan zijn dat de H3-receptor ook 
functioneert als heteroreceptor waardoor de blokkade invloed heeft op 
andere neurotransmitter systemen. Een andere verklaring is dat 
diermodellen niet zomaar vertaald kunnen worden naar mensen. 
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Een consistentere bevinding is dat H1-antagonisten het 
psychomotore functioneren verslechteren. Het onderzoek beschreven in dit 
proefschrift toont aan dat het misschien de sensorische component is die 
wordt aangetast door H1-antagonisten. Deze bevindingen worden 
ondersteund door de anatomie van het histaminerge systeem. Klinische 
stoornissen zoals schizofrenie worden gekenmerkt door een verslechterd 
sensorisch functioneren. Daarom wordt gesuggereerd dat H1-antagonisme 
gebruikt kan worden voor het onderzoeken van enkele symptomen van deze 
stoornis. 
In tegenstelling tot bovenstaande bevindingen, leidt L-histidine 
depletie tot een verstoring van de motorische processen. Het is bekend dat 
dopamine een rol speelt bij motorische processen. Het histaminerge systeem 
en het dopaminerge systeem staan in nauw verband met elkaar. Daarom 
wordt geopperd dat de effecten van L-histidine depletie mogelijk verlopen 
via het dopaminerge systeem. 
Cognitieve deficieten in de ziekte van Alzheimer worden 
gekenmerkt door een verslechterd geheugen. Huidige bevindingen laten 
zien dat deze symptomen niet gemodelleerd kunnen worden door H1-
antagonisten. De effecten van deze middelen lijken te zijn gelokaliseerd in de 
sensorische processen, en dus zijn deze middelen mogelijk bruikbaar om 
defecten in sensorische processen te modelleren. De effecten van L-histidine 
depletie op motorisch gerelateerde processen suggereren een mogelijke rol 
voor histamine in onderzoek naar stoornissen waarin motorische 
symptomen een prominente rol spelen, bijvoorbeeld de ziekte van 
Parkinson. 
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